Notice of 2024 Annual Meeting of Shareholders and Proxy Statement
Dear Fellow Shareholders,

Thank you for your continued support of Eli Lilly and Company. As we reflect on our company’s progress in 2023, we are proud that we received approval for several life-changing medicines, served more patients around the world and advanced exciting new research into unmet medical needs. Our accomplishments included the regulatory approvals of Omvoh for patients with ulcerative colitis, Jaypirca for patients with MCL or CCL, and the approval and launch of Zepbound for obesity, an important medicine that has the potential to positively impact millions of lives. We released results from the landmark Trailblazer-ALZ 2 study that showed a slowing of cognitive and functional decline of early Alzheimer’s disease. We also worked hard to deliver value to you, posting strong total shareholder returns through December 31, 2023, in terms of both total share price appreciation and dividends.

We also invested in creating a stronger community and more positive world. In 2023, Lilly donated over $4 billion in medicines to charitable organizations that provide medicines for free to qualifying patients in the US. In addition, working with humanitarian organizations, Lilly and its affiliates provided more than $68 million in diabetes, cancer, and other therapies around the world to support disaster preparedness, disaster relief and humanitarian aid. These and other efforts contributed to Lilly’s 30x30 goal of improving quality health care for 30 million people living in resource limited settings, annually, by 2030. At the time of this letter, Lilly’s 30x30 reach is estimated to reach or exceed 15 million patients, halfway to our 2030 goal of 30 million patients. Lilly continues to work diligently to meet the needs of vulnerable communities around the world.

Since our 2023 annual meeting, we have spoken with many investors on an array of subjects, including drug pricing and global access to our products; key enterprise risks; and environmental, social and governance topics. We value this engagement and the constructive feedback we’ve received. As a result of ongoing input, and as in past years, the board is putting forward management proposals at the 2024 annual meeting of shareholders (the Annual Meeting) to eliminate the classified board structure and supermajority voting requirements in our articles of incorporation.

At Lilly we are committed to making medicines that make life better for people all over the world, and that commitment is not possible without your support. We look forward to welcoming you at the Annual Meeting.

Sincerely,

David A. Ricks  
Chair, President and CEO

Juan Luciano  
Lead Independent Director
# Table of Contents

Notice of 2024 Annual Meeting of Shareholders ............................................. 1
Proxy Statement Summary .......................................................... 2

## Governance

- Director Qualifications .......................................................... 11
- Director Nominations ........................................................... 26
- Director Compensation .......................................................... 28
- Item 1 - Election of Directors .................................................. 31
- Leadership Structure ............................................................. 31
- Board Structure ....................................................................... 34
- Governance Practices ............................................................. 37
- Board Alignment ..................................................................... 42
- Communication with the Board of Directors ............................... 43
- Shareholder Engagement on Governance Issues ......................... 44

Ownership of Company Stock ....................................................... 45

## Compensation

- Item 2 - Approval, on an Advisory Basis, of the Compensation Paid to the Company's Named Executive Officers ............................................. 46
- Talent and Compensation Committee Matters .............................. 47
- Compensation Discussion and Analysis ....................................... 48
- Executive Compensation Tables ............................................... 67
- CEO Pay Ratio ........................................................................ 76
- Pay versus Performance .......................................................... 77

Audit Matters .............................................................................. 81
- Item 3 - Ratification of the Appointment of the Independent Auditor 81

Management Proposals ............................................................... 84
- Item 4 - Proposal to Amend the Company's Articles of Incorporation to Eliminate the Classified Board Structure .................................. 84
- Item 5 - Proposal to Amend the Company’s Articles of Incorporation to Eliminate Supermajority Voting Provisions ................................ 85

Shareholder Proposals .................................................................. 86
- Item 6 through Item 9 ............................................................... 98

Other Information ........................................................................ 98
- Meeting and Voting Logistics .................................................. 98
- Other Matters ......................................................................... 102

Appendix A - Summary of Adjustments Related to the Annual Cash Bonus and Performance Award ....................................................... A-1

Appendix B - Proposed Amendments to the Company’s Articles of Incorporation ........................................................................ B-1

---

Frequently Referenced Topics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Director Diversity</td>
<td>12</td>
</tr>
<tr>
<td>Director Biographies</td>
<td>14</td>
</tr>
<tr>
<td>Director Skills Matrix</td>
<td>13</td>
</tr>
<tr>
<td>Lead Independent Director Duties</td>
<td>31</td>
</tr>
<tr>
<td>Board and Committee Oversight of:</td>
<td></td>
</tr>
<tr>
<td>- Sustainability</td>
<td>39</td>
</tr>
<tr>
<td>- Cybersecurity</td>
<td>39</td>
</tr>
<tr>
<td>- Human Capital Management</td>
<td>40</td>
</tr>
<tr>
<td>- Political Activities</td>
<td>40</td>
</tr>
<tr>
<td>- Transactions with Related Persons</td>
<td>42</td>
</tr>
<tr>
<td>- Share Ownership and Retention Guidelines</td>
<td>65</td>
</tr>
<tr>
<td>- Compensation Recovery Policy (Clawback)</td>
<td>66</td>
</tr>
</tbody>
</table>

## Cautionary Statements

This proxy statement contains forward-looking statements, including those regarding our strategies and financial performance; our development of new products and technologies; environmental, social and governance metrics, commitments and goals; and other statements that are not historical fact, and actual results could differ materially. Risks that could cause actual results to differ are set forth in the "Risk Factors" section of, and elsewhere in, our 2023 Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission (SEC). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on management estimates, projections, and assumptions, and we undertake no obligation to update any such statements.

Certain documents and information referenced in this proxy statement are available on our website. However, we are not including the information contained on our website, or any information that may be accessed by links on our website, as part of, or incorporating it by reference into, this proxy statement.

The information contained under the heading “Pay Versus Performance” shall not be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 (the Exchange Act) except to the extent that we specifically incorporate it by reference in any such filing.

Unless otherwise expressly stated or context requires otherwise, information in this proxy statement is as of March 22, 2024.
Notice of 2024 Annual Meeting of Shareholders

ITEMS OF BUSINESS

Item 1 Election of each of the four director nominees to serve three-year terms
Item 2 Approval, on an advisory basis, of the compensation paid to the company’s named executive officers
Item 3 Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2024
Item 4 Approval of amendments to the company’s articles of incorporation to eliminate the classified board structure
Item 5 Approval of amendments to the company’s articles of incorporation to eliminate supermajority voting provisions
Item 6 Shareholder proposal to publish an annual report disclosing lobbying activities
Item 7 Shareholder proposal to report on effectiveness of the company’s diversity, equity, and inclusion efforts
Item 8 Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents
Item 9 Shareholder proposal to adopt a comprehensive human rights policy

ADMISSION

The 2024 annual meeting of shareholders (the Annual Meeting) of Eli Lilly and Company will be held virtually via live webcast.

The webcast is designed to provide shareholders the opportunity to participate virtually to facilitate shareholder attendance and to provide a consistent experience to all shareholders, regardless of location. You will be able to attend the Annual Meeting, vote, and submit questions virtually via live webcast by visiting virtualshareholdersmeeting.com/LLY2024. To be admitted to the Annual Meeting webcast, you must enter the 16-digit control number found on the proxy card, voting instruction form, or notice you received. For further information on Annual Meeting logistics, see the section titled “Other Information—Meeting and Voting Logistics.”

This proxy statement is dated March 22, 2024. We mailed a notice of internet availability of proxy materials on or about that date to our shareholders of record as of February 28, 2024 (other than those who previously requested electronic or paper delivery of our proxy materials and certain participants in The Lilly Employee 401(k) plan (401(k) Plan)).

YOUR VOTE IS IMPORTANT

Every shareholder vote is important. Even if you plan to attend the Annual Meeting, we encourage you to vote promptly online, by telephone, or, if you received or requested paper copies of your proxy materials, by signing, dating, and returning your proxy card or voting instruction form by mail, so that a quorum may be represented at the meeting.

By order of the Board of Directors,

Anat Hakim
Executive Vice President, General Counsel and Secretary
March 22, 2024

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD MAY 6, 2024:

The annual report to shareholders and proxy statement are available at ProxyVote.com as well as on our website at lilly.com/policies-reports/annual-report.
Proxy Statement Summary

Powered by Purpose

Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. This purpose fuels every aspect of our business, as we aspire to:

Discover first or best-in-class molecules from internal and external sources that address significant unmet needs by integrating disease understanding with innovative scientific capabilities;

Develop molecules faster than competitors by executing clinical plans that maximize the human and economic value of the medicines we launch;

Reach people around the world by creating volume-driven uptake and broad access to a safe and reliable supply of life-changing medicines;

Scale our business by prioritizing investments into medicines that can deliver the greatest value for customers and can drive long-term sustainable growth; and

Reinvest profits into our next wave of innovation and generate value for our investors.

Highlights of 2023 Performance

We continued to progress our strategy in 2023, within operating performance, shareholder return (both absolute and relative), our innovation pipeline and other business development, and sustainability matters. See our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for more details on our financial performance.

Operating Performance

<table>
<thead>
<tr>
<th>2023 Revenue</th>
<th>2023 EPS</th>
<th>2023 EPS non-GAAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>$34.1 billion</td>
<td>$5.80</td>
<td>$6.32</td>
</tr>
</tbody>
</table>

Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. A reconciliation of EPS on a reported basis to EPS on a non-GAAP basis is included in Appendix A.

Shareholder Return

<table>
<thead>
<tr>
<th>2023 Total Shareholder Return (TSR)</th>
<th>Consistently Exceeded Compensation Peer Group and S&amp;P 500 in TSR in 2023 and the three- and five-year periods shown below</th>
</tr>
</thead>
<tbody>
<tr>
<td>61%</td>
<td>Total Shareholder Return</td>
</tr>
<tr>
<td>5-year</td>
<td>S&amp;P 500: 58% 107% Comp. Peer Group: -33% 31% 259% 446% Lilly: -1% 26% 61%</td>
</tr>
<tr>
<td>3-year</td>
<td>TSR takes into account both share price appreciation and dividends. Any dividends paid by a given company are assumed to be reinvested in the company’s stock on a quarterly basis.</td>
</tr>
<tr>
<td>1-year</td>
<td></td>
</tr>
</tbody>
</table>

-100% 0% 100% 200% 300% 400% 500%
## Innovation Pipeline and Other Business Development

### Highlights for New Products and Indications

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zepbound®</td>
<td>FDA approved Lilly's Zepbound® for adults with obesity or overweight with weight-related comorbidities</td>
</tr>
<tr>
<td>Jaypirca™</td>
<td>FDA approved Jaypirca™ for the treatment of adult patients with (i) chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, or (ii) relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy</td>
</tr>
<tr>
<td>Omvoh®</td>
<td>FDA approved Omvoh® for the treatment of adults with moderately to severely active ulcerative colitis</td>
</tr>
<tr>
<td>Verzenio®</td>
<td>FDA approved an expanded indication for Verzenio®, in combination with endocrine therapy, for the adjuvant treatment of adult patients with HR+, HER2-, node-positive early breast cancer at high risk of recurrence</td>
</tr>
</tbody>
</table>

### Key Data Readouts

- **Tirzepatide**: (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from the SURMOUNT-2 study. Those taking tirzepatide lost up to 15.7% (34.4 lb. or 15.6 kg) of body weight for the efficacy estimand. Two Phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo. Across SURMOUNT-3 and SURMOUNT-4, participants on tirzepatide following intensive lifestyle intervention or with continued tirzepatide treatment, achieved up to 26.6% mean weight loss, for the efficacy estimand.

- **Donanemab**: Positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.

- **Orforglipron**: Phase 2 results showed orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight. In additional Phase 2 data, orforglipron achieved a mean reduction in A1C of up to 2.1% at 26 weeks in adults with type 2 diabetes.

- **Retatrutide**: Phase 2 retatrutide results showed the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. In a secondary endpoint, retatrutide showed a mean weight reduction of up to 24.2% at 48 weeks.

- **Retevmo® (selpercatinib)**: was the first targeted therapy to demonstrate superior progression-free survival compared to a PD-1 inhibitor plus chemotherapy for adults with newly-diagnosed advanced or metastatic RET fusion-positive non-small cell lung cancer in the Phase 3 LIBRETTO-431 study.

- **Mirikizumab**: Mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn's disease.

### Other Business Development Activities

- Completed the global divestitures of Baqsimi and the olanzapine portfolio
- Acquired DICE Therapeutics, a biopharmaceutical company that develops novel oral therapeutic candidates to treat chronic diseases in immunology
- Acquired Sigilon Therapeutics, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases
- Acquired Versanis Bio, a clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases
- Acquired POINT Biopharma, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer
18 active global health partnerships focusing on noncommunicable diseases, strengthening health systems, and capacity building

2.1 megawatt (MW) solar array and battery storage system brought online at our site in Puerto Rico

$10 million investment announced for solar arrays at our campus in Indianapolis, Indiana

---

**Access and Affordability**

- **2019**
  - Introduction of a non-branded insulin at half the list price of branded Humalog

- **2020**
  - Announced the Lilly Insulin Value Program, a savings card allowing people with commercial insurance or those who are uninsured to buy their monthly prescription of Lilly insulin for $35

- **2021**
  - Participation in Medicare Part D Senior Savings Model, allowing enrolled seniors to purchase their monthly prescription of Lilly insulin for $35 during all phases of their Part D coverage
  - Automatic cap on out-of-pocket monthly cost to $35 for people with commercial insurance at participating retail pharmacies
  - Biosimilar basal insulin launched at a lower list price

- **2022**
  - Cut the price of Insulin Lispro vials to $25
  - Reduced the list price of our most commonly prescribed insulins by 70%

- **2023**
  - Highlights of Our Recent U.S. Insulin Access and Affordability Journey

Terms and conditions may apply to certain of these programs. Savings or caps may be automatically applied at the majority of retail pharmacies for those with commercial insurance. Government restrictions exclude people enrolled in federal government insurance programs from Lilly's $35 solutions. However, federal law provides that Medicare Part D beneficiaries also pay no more than $35 per month for insulin.

---

<table>
<thead>
<tr>
<th>Africa</th>
<th>Latin America, the Caribbean, Africa, and Southeast Asia</th>
<th>South Asia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovative collaboration to deliver high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries, most of which are in Africa</td>
<td>Cold-chain collaboration with Direct Relief to expand medical cold chain capacity in 20 countries, furthering access to medicines in low- and middle-income countries</td>
<td>Collaboration to provide our human insulin active pharmaceutical ingredient at reduced price to International Agencies (Bangladesh) Ltd. to support insulin production in Bangladesh</td>
</tr>
</tbody>
</table>
Board Leadership and Composition Highlights

Director Nominee Snapshot

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Director Since</th>
<th>Other Public Boards</th>
<th>Principal Occupation</th>
<th>Committee Membership</th>
</tr>
</thead>
</table>
| Katherine Baicker, Ph.D. | 52  | 2011           | 0                   | Provost, the Emmett Dedmon Professor, Harris School of Public Policy, University of Chicago | Ethics and Compliance (Chair)  
                         |     |                |                     |                                                                                        | Science and Technology |
| J. Erik Fyrwald       | 64  | 2005           | 1                   | Chief Executive Officer and board member, International Flavors & Fragrances Inc.       | Science and Technology  
                         |     |                |                     |                                                                                        | Talent and Compensation |
| Jamere Jackson        | 55  | 2016           | 0                   | Chief Financial Officer, AutoZone, Inc.                                                | Audit (Chair)          
                         |     |                |                     |                                                                                        | Directors and Corporate Governance |
| Gabrielle Sulzberger  | 63  | 2021           | 3                   | Chair of Global ESG Advisory, Teneo                                                     | Audit                 
                         |     |                |                     |                                                                                        | Directors and Corporate Governance |

Board Leadership and Structure Information

- **Lead Independent Director:** We have a strong lead independent director empowered with clearly defined responsibilities.

- **Independent Committees:** All standing board committees are composed solely of independent directors and led by independent committee chairs.

- **Executive Sessions:** Our board holds executive sessions of the independent directors that are presided over by the lead independent director at every regular board meeting.

- **Access to Management and Advisors:** Our independent directors actively engage in board meetings, have direct access to management, and, along with our board committees, have discretion to hire independent advisors at the company’s expense.

- **Conflict of Interest Management:** Our conflict of interest policy requires disclosures of potential conflicts to Lilly and clarifies when Lilly board service must be disclosed to others.

- **CEO Selection and Compensation:** Our independent directors lead the board’s process for selecting the CEO. Our Talent and Compensation Committee (and, in the case of our CEO, in consultation with other independent directors and our external compensation consultant) establishes the compensation for our CEO and other executive officers.

- **Refreshment:** We are committed to maintaining an active and insightful board and seek to balance continuity of experience with fresh perspectives. We also have robust board and committee education programs that cultivate the evolution of director skills as the company evolves.

- **Robust Annual Assessment:** Our board conducts a robust annual assessment of its performance led by the lead independent director, Directors and Corporate Governance Committee and board chair, including an annual assessment of each director. These assessments help provide the board with valuable perspectives to drive effectiveness and leadership.
Board Demographics Summary

- **92% Independent**
- **42% Female**
- **42% Diverse**

**Strategy and Risk Oversight**

- **Strategy**: Our board approves and actively oversees our corporate long-term strategy. Our board and committee meetings are structured to engage our directors in informed reviews of strategic and forward-looking issues, as well as in constructive challenges to management initiatives and programs.

- **Code of Conduct**: Our code of business conduct reflects principles that are consistent with our company values of integrity, excellence, and respect for people. This code applies to our board and all employees worldwide and is reviewed and approved annually by the board. We have a supplemental code of conduct for our CEO and all members of financial management, in recognition of their unique responsibilities to ensure proper accounting, financial reporting, internal controls, and financial stewardship.

- **Corporate Governance**: The charter of each of our board committees clearly establishes the committee’s roles and responsibilities.

- **Compliance Program and Enterprise Risk Reviews**: Our board reviews the overall state of our compliance program at least annually and reviews our enterprise-level risks on a regular basis and as matters arise. Our Audit Committee oversees the process by which we identify and create mitigation plans for enterprise-level risks. See “Governance Practices—Board Oversight” for additional information.
• Board Oversight of Certain Areas

<table>
<thead>
<tr>
<th>Cybersecurity</th>
<th>Political Activity</th>
<th>Sustainability</th>
<th>Talent Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Our Audit Committee is responsible for oversight of our programs, policies, procedures, and risk management activities related to information security and data protection. It meets regularly with management to discuss, among other things, threats, risks, and ongoing efforts to enhance cyber resiliency, and management promptly updates our board or the Audit Committee regarding significant threats and incidents as they arise.</td>
<td>Our board oversees our political expenditures and lobbying activities. Directors receive regular updates on public policy issues and on the company’s political corporate activity. The board also receives semi-annual updates on political engagement, including information on the contributions made by LillyPAC and the company, as well as trade association memberships.</td>
<td>Our board, including its Directors and Corporate Governance Committee, oversees and maintains ongoing engagement on key climate and sustainability matters.</td>
<td>Our board exercises active oversight of the overall talent management process, including human capital management strategies, corporate culture, and inclusion efforts. The board also oversees the work of its committees in connection with the board’s development of corporate policies and frameworks designed to attract, retain, engage, and develop a workforce that aligns with our values and mission.</td>
</tr>
</tbody>
</table>

---

**Exploring Responsible AI Use**

We see great potential in the advancements of artificial intelligence (AI) to help further our mission to create medicines that make life better for people around the world. As we explore the responsible development, management, and use of AI technologies, our board is focused on expanding its understanding and oversight of this emerging technology.

---

**Shareholder Access and Engagement**

**Engagement Response**

• In response to input from our shareholders and consistent with previous years, management is putting forth for consideration at the Annual Meeting proposals to amend our articles of incorporation to eliminate the classified board structure and to eliminate supermajority voting.

**Proxy Access**

• Our bylaws provide proxy access rights for shareholders holding at least three percent of our common stock for at least three years to nominate to the board the greater of two directors or 20 percent of our board seats.

**Board Accountability**

• We have a majority voting standard and a resignation policy for the election of directors in uncontested elections.
• Shareholders have the ability to amend our bylaws.
• We do not have a shareholder rights plan (known as a “poison pill”).
• We have meaningful stock ownership and retention guidelines for our directors and executive officers to foster alignment with shareholders.
• We have an annual cap on director compensation.
Compensation

Compensation Practices of Interest

Shareholders strongly support our compensation practices. For each of the last five years, greater than 94 percent of shares cast voted in favor of our executive compensation programs.

<table>
<thead>
<tr>
<th>Compensation Philosophy</th>
<th>What We Do</th>
<th>What We Don't Do</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Our compensation programs are designed to align executive pay with shareholder interests and link pay to performance through a blend of short- and long-term performance measures.</td>
<td>✓ We have robust stock ownership and retention guidelines for executive officers.</td>
<td>✕ We don’t enter into employment agreements with any of our executive officers.</td>
</tr>
<tr>
<td>✓ Our Talent and Compensation Committee annually reviews our compensation programs to help ensure our programs provide incentives to deliver long-term, sustainable business results while discouraging excessive risk-taking and other adverse behaviors.</td>
<td>✓ Executive officers are prohibited from hedging or pledging their company stock.</td>
<td>✕ We don’t provide tax gross-ups to executive officers (except for limited gross-ups related to international assignments).</td>
</tr>
<tr>
<td>✓ We have a compensation recovery or “clawback” policy that aligns with the requirements of Section 10 of the Exchange Act and also provides the ability to recover certain compensation upon a wide range of misconduct.</td>
<td>✓ We have a conservative approach on perquisites.</td>
<td></td>
</tr>
<tr>
<td>✓ We have double trigger change-in-control provisions in severance plans.</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

Executive Compensation Summary for 2023

In 2023, the average total target compensation for our named executive officers was comparable to the median of the company’s peer group. Bonus and equity payouts exceeded target, consistent with strong company performance over the respective performance periods.

Pay for Performance

As described in the Compensation Discussion and Analysis (CD&A), we link our incentive pay programs to a mix of measures on three dimensions of company performance: operating performance; progress with our innovation pipeline; and shareholder return (both absolute and relative). The Talent and Compensation Committee adjusts reported revenue and EPS results to eliminate the distorting effect of certain unusual items on incentive compensation performance measures.

The summary below highlights how our incentive pay programs are intended to align with company performance. Please also see Appendix A for adjustments made to revenue and EPS for incentive compensation programs.

- **Bonus Plan Result:** In 2023, the company exceeded its annual cash bonus targets for revenue and EPS. We also made significant pipeline advances. For purposes of the bonus, the Talent and Compensation Committee adjusted revenue and adjusted non-GAAP EPS to exclude the impact of transactions associated with the divestiture of certain legacy products, as well as acquired in-process research and development (IPR&D) charges, both of which were not included in 2023 bonus targets. See the CD&A for further discussion of the Eli Lilly and Company Bonus Plan (Bonus Plan).

  1.81

  **Bonus Plan Multiple**
• **2022-2024 Performance Award (PA) Result:** We exceeded the two-year EPS growth target set for our PA program. The PA target is based on expected EPS growth of peer companies over a two-year period. As a result of exceeding the EPS growth target set for our PA program, the PA payout was above target. See the CD&A for further discussion on the PA program.

128%

2022-2024 PA Payout

• **2021-2023 Shareholder Value Award (SVA) Result:** Our total stock price growth exceeded the target range in our SVA program, which is based on expected large-cap company returns over a three-year period. This performance resulted in a SVA payout above target. See the CD&A for further discussion on the SVA program.

175%

2021-2023 SVA Payout

• **2021-2023 Relative Value Award (RVA) Result:** The RVA measures Lilly’s relative total shareholder return (TSR) against its peers. Lilly’s TSR performance exceeded the peer median TSR for the 2021-2023 performance period resulting in a payout above target. See the CD&A for further discussion on the RVA program.

175%

2021-2023 RVA Payout

**Voting**

**How to Vote**

**ONLINE**
Visit the website listed on your notice, proxy card, or voting instruction form

**BY TELEPHONE**
Call 1-800-690-6903 and follow the instructions provided

**BY MAIL**
If you received or requested paper copies of your proxy materials, sign, date, and return your proxy card or voting instruction form

**AT THE MEETING**
Attend the Annual Meeting, online by live webcast at virtualshareholdermeeting.com/LLY2024 on Monday, May 6, 2024, at 8:30 a.m. EDT

**Vote Early:** Even if you plan to attend the Annual Meeting, we encourage you to vote prior to the meeting, either online, by telephone, or by mail.

**Beneficial Shareholders:** Shareholders who hold their shares beneficially through an institutional holder of record, such as a broker or bank (sometimes referred to as holding shares in street name), will receive voting instructions from that holder of record. If you do not provide voting instructions to the holder of record, your shares will not be voted on any proposal on which the broker does not have discretionary authority to vote. See “Other Information—Meeting and Voting Logistics—How to Vote” for more information.

**Voting Deadlines:** You may vote your shares prior to the Annual Meeting until 11:59 p.m. EDT on May 5, 2024, online, or by telephone. If you are voting by mail, your marked, signed, and dated proxy card must be received by May 5, 2024. Shareholders who hold their shares in the 401(k) Plan must vote by May 1, 2024, so the plan trustee can vote their shares accordingly. See “Other Information—Meeting and Voting Logistics—How to Vote” for more information.

**More Information:** Further information on how to vote, including if you hold voting shares in the 401(k) Plan, is provided under “Other Information—Meeting and Voting Logistics—How to Vote.”
<table>
<thead>
<tr>
<th>Voting Matter</th>
<th>Required Vote</th>
<th>Board Vote Recommendation</th>
<th>See Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 1</td>
<td>Election of four directors to serve three-year terms</td>
<td>Majority of votes cast (for each nominee)</td>
<td>FOR EACH NOMINEE</td>
</tr>
<tr>
<td>Item 2</td>
<td>Advisory vote on compensation paid to named executive officers</td>
<td>Majority of votes cast</td>
<td>FOR</td>
</tr>
<tr>
<td>Item 3</td>
<td>Ratification of the appointment of the independent auditor</td>
<td>Majority of votes cast</td>
<td>FOR</td>
</tr>
<tr>
<td>Item 4</td>
<td>Proposal to amend the company’s articles of incorporation to eliminate the classified board structure</td>
<td>80% of outstanding shares</td>
<td>FOR</td>
</tr>
<tr>
<td>Item 5</td>
<td>Proposal to eliminate supermajority voting provisions</td>
<td>80% of outstanding shares</td>
<td>FOR</td>
</tr>
<tr>
<td>Item 6</td>
<td>Shareholder proposal to publish an annual report disclosing lobbying activities</td>
<td>Majority of votes cast</td>
<td>AGAINST</td>
</tr>
<tr>
<td>Item 7</td>
<td>Shareholder proposal to report on effectiveness of the company’s diversity, equity, and inclusion efforts</td>
<td>Majority of votes cast</td>
<td>AGAINST</td>
</tr>
<tr>
<td>Item 8</td>
<td>Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents</td>
<td>Majority of votes cast</td>
<td>AGAINST</td>
</tr>
<tr>
<td>Item 9</td>
<td>Shareholder proposal to adopt a comprehensive human rights policy</td>
<td>Majority of votes cast</td>
<td>AGAINST</td>
</tr>
</tbody>
</table>
Governance

How We Build an Effective Board

Our directors are elected by the company's shareholders to oversee the actions and results of the company's management. The Directors and Corporate Governance Committee, which is chaired by the lead independent director, regularly assesses the effectiveness of the board to ensure that directors reflect the skill sets, experiences, diverse viewpoints and characteristics necessary to oversee our complex and evolving business. Execution of our robust assessment and refreshment process, guided by key governance guidelines, has resulted in a mix of directors that balances experienced institutional knowledge and fresh perspectives, and reflects a broad range of backgrounds and viewpoints.

Director Qualifications

Character: Our board members should possess the personal attributes necessary to be an effective director, including unquestioned integrity, sound judgment, a collaborative spirit, and commitment to our company, our shareholders, and other constituencies.

Independence: We believe there should always be a substantial majority (75 percent or more) of independent directors. The board annually determines the independence of directors based on a review and recommendation by the Directors and Corporate Governance Committee. No director is considered independent unless the board has affirmatively determined that he or she has no material relationship with the company, either directly or as a partner, shareholder, or officer of an organization that has a relationship with the company. In assessing whether a director has no material relationship with Lilly, the board of directors also considers any persons or organizations with which the director has an affiliation. Material relationships can include commercial, industrial, banking, consulting, legal, accounting, charitable, and familial relationships, among others. To evaluate the materiality of any such relationship, the board has adopted categorical independence standards consistent with the New York Stock Exchange (NYSE) listing standards.

Lilly’s process for determining director independence is set forth in our Standards for Director Independence, which can be found on our website at lilly.com/leadership/governance, along with our corporate governance guidelines.

On the recommendation of the Directors and Corporate Governance Committee, the board determined that each current non-employee director is independent and that the members of our Audit and Talent and Compensation Committees meet the heightened independence standards applicable to those committees. The board determined that none of the current non-employee directors has had during the last three years (i) any of the relationships identified in the company’s categorical independence standards or (ii) any other material relationship with the company that would compromise his or her independence.

In making its independence determinations, the board considered that Ms. Walker is affiliated with the Goldman Sachs Group, which the company may use for advisory, investment banking or similar services from time to time.

In addition, the board considered that some of the current non-employee directors are affiliated with companies or entities to which the company sold products or made payments, or from which the company purchased products or services during the year. Drs. Baicker, Kaelin, Hedley, and Runge are employed at medical or academic institutions with which the company engages in clinical research,
provides research grants, and/or engages in commercial transactions in the ordinary course of business. Mr. Luciano is employed by Archer-Daniels-Midland Company and Mr. Fyrwald is employed by International Flavors & Fragrances Inc. The company engages in routine business transactions with these organizations. Aggregate payments to or from each such organization, in each of the last three fiscal years, did not exceed the greater of $1 million or 2 percent of that organization’s consolidated gross revenues in a single fiscal year. In reviewing these relationships, the board considered all relevant factors, including:

• whether transactions were entered into at arm’s length in the normal course of business and, to the extent they were commercial relationships, had standard commercial terms; and
• whether any director had any direct business relationships with the company or received any direct personal benefit from any of these transactions, relationships, or arrangements.

Diversity: The board strives to achieve diversity in the broadest sense, including persons diverse in geography, gender, ethnicity, age, and experience. Although the board does not establish specific diversity goals or have a standalone diversity policy, the board’s overall diversity is an important consideration in the director selection and nomination process. The Directors and Corporate Governance Committee assesses the effectiveness of board diversity efforts in connection with the annual nomination process as well as in new director searches. The company’s current 12 directors range in age from 51 to 69 and include five women and five minority group members (MGM).

8 Years
Average Director Tenure

<table>
<thead>
<tr>
<th>Tenure</th>
<th>1</th>
<th>3</th>
<th>4</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>yrs.</td>
<td>&lt;3</td>
<td>3-5</td>
<td>6-10</td>
<td>&gt;10</td>
</tr>
</tbody>
</table>

Tenure: Our director composition reflects a mix of tenure on the board, which provides an effective balance of historical perspective and an understanding of the evolution of our business with fresh perspectives and insights.

Director Governance Spotlight

✔ Resignation Policy - In an uncontested election, directors are elected by a majority of votes cast. An incumbent nominee who fails to receive a greater number of votes “for” than “against” his or her election will tender his or her resignation from the board following the certification of the shareholder vote. The board, on recommendation of the Directors and Corporate Governance Committee, will decide whether to accept the resignation. The company will promptly disclose the board’s decision, including, if applicable, the reasons the board rejected the resignation.

✔ Director Retirement Policy - Non-employee directors must retire from the board no later than the date of the annual meeting that follows their seventy-second birthday, although the Directors and Corporate Governance Committee may recommend exceptions to this policy. The Directors and Corporate Governance Committee, with input from all board members, also considers the contributions of the individual directors annually, with a more robust assessment at least every three years when considering whether to nominate directors to new three-year terms. The company has not adopted term limits because the board believes that the company benefits from having a mix of longer- and shorter-tenured members of the board.

✔ Other Board Service Policy - To ensure proper engagement from our directors and effective functioning of our board, we have instituted certain limitations on service on the boards of other companies. In general, no director may serve on more than three other public company boards. No director that is an executive officer of a public company may serve on more than two public company boards (inclusive of Lilly). The Directors and Corporate Governance Committee may approve exceptions if it determines that the additional service will not impair the director’s effectiveness on the Lilly board. In addition, no director serving on the Audit Committee may serve simultaneously on the audit committee of more than two other public companies without the prior approval of the board.

✔ Confidentiality Policy - The board has adopted a Confidentiality Policy, applicable to all members of the board. The policy prohibits a director from sharing confidential information obtained in his or her role as a director with any third party except under limited circumstances where the director is seeking legal advice or is required by law to disclose information. The Confidentiality Policy can be viewed on the company’s website at: lilly.com/leadership/governance.
**Director Skills:**
Our directors are responsible for overseeing the company’s business consistent with their fiduciary duties. This significant responsibility requires highly skilled individuals with various qualities, attributes, and professional experiences. We believe the board is well-rounded, with a balance of relevant perspectives and experience, as illustrated in the following chart.

<table>
<thead>
<tr>
<th>Director Experience</th>
<th>Alvarez</th>
<th>Baicker</th>
<th>Fywald</th>
<th>Hedley</th>
<th>Jackson</th>
<th>Johnson</th>
<th>Kaelin</th>
<th>Luciano</th>
<th>Ricks</th>
<th>Runge</th>
<th>Sulzberger</th>
<th>Walker</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO Leadership. <strong>Chief Executive Officer experience at a large publicly traded or private company or other large organization.</strong></td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
</tr>
<tr>
<td>Finance / Accounting. <strong>Significant experience in positions requiring financial knowledge and analysis, including as chief financial officer and/or in accounting, corporate finance or treasury functions.</strong></td>
<td>●</td>
<td>● ● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>● ●</td>
<td>●</td>
<td>● ●</td>
<td>● ●</td>
<td>●</td>
<td>● ●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>International Business. <strong>Leadership position in an organization that operates internationally on a broad basis and/or in the geographic regions in which the company operates.</strong></td>
<td>●</td>
<td>● ●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Healthcare Industry. <strong>Medical professionals and those with significant experience in management-level positions in a company or industry involving healthcare products and/or services.</strong></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Science / Academia. <strong>Leadership or senior advisory position with a scientific, research and/or academic institution (including in an administrative or faculty role).</strong></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Government Relations / Public Policy. <strong>Experience in government relations or government affairs positions, public policy fields or at an organization operating in a complex regulatory environment.</strong></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Sales / Marketing. <strong>Strategic or management experience involving the marketing and branding of products.</strong></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Technology / Digital. <strong>Experience in the technology field, including related to digital technologies that facilitate business objectives (e.g., information technology).</strong></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Operations / Strategy. <strong>Significant experience in positions advising and overseeing strategic development and direction, including of an organization.</strong></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

**Director Experience:**
Set forth below is information, as of February 28, 2024, regarding our directors and director nominees. We have provided the most relevant experiences, qualifications, attributes, and skills that led to the conclusion that each director or director nominee should serve as a director in light of our business and operations.

No family relationship exists among any of our directors, director nominees, or executive officers. To the best of our knowledge, there are no pending material legal proceedings in which any of our directors or nominees for director, or any of their associates, is a party adverse to us or any of our affiliates, or has a material interest adverse to us or any of our affiliates. Additionally, to the best of our knowledge, there have been no events under any bankruptcy laws, no criminal proceedings and no judgments, sanctions, or injunctions during the past 10 years that are material to the evaluation of the ability or integrity of any of our directors or nominees for director. There is no arrangement or understanding between any director or director nominee and any other person...
pursuant to which he or she was or is to be selected as a director or director nominee.

Under our articles of incorporation, the board is divided into three classes with approximately one-third of the directors standing for election each year.

Class of 2024

KEY EXPERIENCE AND QUALIFICATIONS

Dr. Baicker’s experience in health economics research and policy at the highest levels, including as a former economic advisor to the White House and a current health advisor to the Congressional Budget Office, provides an invaluable perspective to the board. In addition to Dr. Baicker’s own high-impact research and educational institution gives her both insight into and influence over the future of health policy.

- Through Dr. Baicker’s decades of research and policy engagement, including with respect to the effects of health system reforms of public and private insurance coverage and payment policy, she brings to the board insight and context as it oversees the company’s navigation of the complex environment of government regulation, insurance reimbursement, and access to affordable care.
- Drawing on Dr. Baicker’s experience as an advisor to both the executive and legislative branches of the U.S. government, state governments, and numerous healthcare-related commissions and committees provides a keen understanding of government perspectives in our highly regulated industry.
- Dr. Baicker, with extensive involvement with medical and health system research organizations, adds valuable input on the research and development landscape within the pharmaceutical industry.

Katherine Baicker, Ph.D.

Age: 52
Director since: 2011

Board Committees:
- Ethics and Compliance (Chair)
- Science and Technology

Other Public Boards:
- None

Recent Prior Public Boards:
- HMS Holdings Corp.

Key Skills:

CAREER HIGHLIGHTS

- University of Chicago
  - Provost (2023 - present)
  - Emmett Dedmon Professor, Harris School of Public Policy (2017 - present)
  - Dean of the Harris School of Public Policy (2017 - 2023)

- Harvard University
  - C. Boyden Gray Professor of Health Economics (2014 - 2017)
  - Department of Health Policy and Management, chair (2014 - 2016)
  - Harvard T.H. Chan School of Public Health (primary)
  - Harvard Kennedy School of Government (secondary)

- National Bureau of Economic Research
  - Research Associate, Health Care and Public Economics Programs (2007 - present)
  - Faculty Research Fellow, Public Economics Program (2001 - 2005)

- Council of Economic Advisers, Executive Office of the President
  - Member, confirmed by U.S. Senate (2005 - 2007)

OTHER HIGHLIGHTS

- Panel of Health Advisers to the Congressional Budget Office
- Advisory Board of the National Institute for Health Care Management
- Editorial Board of Health Affairs, JAMA Health Forum
- Trustee of the Mayo Clinic
- Member of the National Academy of Medicine, the National Academy of Social Insurance, the Council on Foreign Relations, and the American Academy of Arts and Sciences
Mr. Fyrwald brings to the board a deep understanding of operational and strategic leadership and international business.

- Mr. Fyrwald’s substantial experience in leading international companies provides valuable perspectives relating to international operations, manufacturing, logistics, and sustainability.
- Mr. Fyrwald has a demonstrated focus on technology and a deep understanding of the challenges of developing and commercializing the results of innovation, as he worked to align Syngenta to digital innovation and new agricultural technologies in the fight against climate change.
- Mr. Fyrwald has also developed significant corporate governance experience through his current and prior service on the boards of directors of international companies and not-for-profit entities.

**CAREER HIGHLIGHTS**

- **International Flavors & Fragrances Inc.**, creator and manufacturer of food, beverage, health and biosciences, scent and pharma solutions
  - Chief Executive Officer (2024 - present)
  - Member of the board of directors (2024 - present)
- **Syngenta Group**, a global Swiss-based agriculture technology company that produces agrochemicals and seeds
  - President and Chief Executive Officer (2016 - 2023)
  - Member of the board of directors (present)
  - Member of the sustainability committee (present)
- **Univar, Inc.**, a leading distributor of chemicals and provider of related services
  - President and Chief Executive Officer (2012 - 2016)
- **Ecolab, Inc.**, a leading provider of cleaning, sanitation and water products and services
  - President (2011 - 2012)
- **Nalco Company**, a leading provider of water treatment products and services
  - Chairman and Chief Executive Officer (2008 - 2011)
- **E.I. du Pont de Nemours and Company**, a global chemical company
  - Various management positions from 1980 to 2008 in production, sales, and marketing, including most recently Group vice president, agriculture and nutrition (2003 - 2008)
KEY EXPERIENCE AND QUALIFICATIONS

Mr. Jackson brings to the board significant global financial experience and a strong background in strategic planning.

- Mr. Jackson's global finance experience, including as chief financial officer at multiple Fortune 500 companies, provides extensive knowledge of international business operations and their associated financial complexities.
- Mr. Jackson brings a valuable perspective on the management of complex financial risks and wide-ranging knowledge of finance and accounting matters to his role as Audit Committee Chair.
- Mr. Jackson has also held roles in strategic planning and mergers and acquisitions, including responsibility for driving financial rigor, developing strategy and implementing change.

CAREER HIGHLIGHTS

- **AutoZone, Inc.**, a leading retailer and distributor of automotive replacement parts and accessories in the United States, Mexico and Brazil
  - Chief Financial Officer (2020 - present)
- **Hertz Global Holdings, Inc.**, a global vehicle rental, leasing and fleet management business
  - Chief Financial Officer (2018 - 2020)
- **Nielsen Holdings plc**, a global measurement and data analytics company
  - Chief Financial Officer (2014 - 2018)
- **General Electric Corporation**, an American multinational company and leader in the power renewable energy, aviation and healthcare industries
  - Vice President and Chief Financial Officer, General Electric Oil and Gas, drilling and surface division (2013 - 2014)
  - Senior Executive, Finance, General Electric Aviation (2007 - 2013)

OTHER HIGHLIGHTS

- Certified Public Accountant
- Not-for-profit boards of directors:
  - Youth Villages
KEY EXPERIENCE AND QUALIFICATIONS

Ms. Sulzberger brings over 30 years of experience advising public and privately held companies in consumer products, retail, financial services, and life sciences.

- Ms. Sulzberger provides global perspective as the chair of global ESG advisory at Teneo, supporting Lilly and the board’s commitment to continuous progress and improving our positive impact on people, the planet and society.
- Ms. Sulzberger developed deep corporate governance experience through her work with corporate boards, both as a board member and as a governance committee chair.
- Ms. Sulzberger’s career in private equity has given her valuable experience in helping companies navigate disruption and transformation, engage with shareholders, and position businesses for growth and success.
- Ms. Sulzberger also draws on experiences from her prior service as chief financial officer of several publicly and privately held companies and audit committee chair of several public companies, providing leadership as an Audit Committee Financial Expert.

CAREER HIGHLIGHTS

- **Teneo**, a global CEO advisory firm
  - Chair of Global ESG Advisory (2021 - present)
- **Two Sigma Impact**, a private equity firm based in New York, New York
  - Senior Advisor (2021 - 2023)
- **Centerbridge Partners**, a multidisciplinary investment firm
  - Senior Advisor (2021 - present)
- **Rustic Canyon/Fontis Partners L.P.**, a private equity firm based in California
  - General Partner (2005 - 2018)

OTHER HIGHLIGHTS

- Director or trustee of the following not-for-profit organizations:
  - Metropolitan Museum of Art
  - Ford Foundation
  - Trinity Church Wall Street
  - Sesame Street Workshop
- Former director, board chair and audit committee chair, Whole Foods Market, Inc.
Mr. Alvarez brings to the board more than 40 years of experience in consumer marketing, global operations, international business, and strategic planning, as well as extensive executive leadership experience in managing some of the world’s best-known brands. Mr. Alvarez is a leader of people and brings to the board a strong perspective on how to motivate and engage diverse talent.

- As a senior executive of a leading global foodservice retailer and other global restaurant businesses, Mr. Alvarez developed in-depth knowledge of consumer marketing, talent and brand management and strategic planning.
- Mr. Alvarez also contributes an understanding of international markets and operations, including a special focus on Japan and emerging markets.
- Mr. Alvarez has acquired wide-ranging corporate governance experience from his service on other publicly and privately held company boards.
- Mr. Alvarez is an Audit Committee Financial Expert based on his public company experience, including his prior audit committee service on Lowe’s board of directors.

CAREER HIGHLIGHTS

- **Advent International Corporation**, a leading global private equity firm
  - Operating Partner (2017 - present)
- **Skylark Co., Ltd.**, a leading restaurant operator in Japan
  - Chairman of the board (2013 - 2018)
- **McDonald’s Corporation**, a leading food service retailer
  - President and Chief Operating Officer (2006 - 2009)

OTHER HIGHLIGHTS

- Member, University of Miami President’s Council
KEY EXPERIENCE AND QUALIFICATIONS

Dr. Hedley’s career has uniquely combined discovery, translational and clinical research and commercialization, bringing to the board extensive business leadership and scientific investigation experiences in the biotechnology industry.

- Having served as co-founder, chief executive officer, president, chief scientific officer or chief operating officer of several biotechnology companies, Dr. Hedley has experience leading and overseeing the complex operations and risks of these businesses, including building C-suite teams, raising capital, and managing research and development, commercial development, manufacturing and supply chains, quality, regulatory affairs, and corporate strategy.

- Dr. Hedley contributes a wide-ranging perspective on the life science business, acquired through her roles at multiple successful companies and her industry-spanning work advising chief executive officers, venture and life science companies in addition to academic scientists advancing therapeutic drug development while at the Broad Institute.

- Dr. Hedley has substantial experience with developing and commercializing oncology therapeutics, one of Lilly’s core therapeutics areas.

- Dr. Hedley’s service on the boards of directors and board committees of other public companies and not-for-profit entities, and, in particular, as chair or former chair of the nominating and corporate governance committees at each of Veeva Systems and Millendo Therapeutics and the audit committee of Centessa Pharmaceuticals, provides a multifaceted governance perspective.

CAREER HIGHLIGHTS

- **Broad Institute of Harvard and MIT**
  - Senior Scientific Fellow (2021 - present)

- **Third Rock Ventures**, a leading healthcare venture capital firm
  - Venture Partner (2023 - present)

- **GlaxoSmithKline plc**, a leading global pharmaceutical company
  - Member of executive research and development team; led integration efforts for TESARO acquisition (2019 - 2020)

- **TESARO, Inc.**, a company focused on the development and global commercialization of oncology therapeutics (acquired by GlaxoSmithKline plc in 2019)
  - President and Chief Operating Officer (2010 - 2019)

- **Abraxis BioScience, Inc.**, a biotechnology company (acquired by Celgene Corporation in 2010)
  - Executive Vice President and Chief Science Officer (2009 - 2010)

OTHER HIGHLIGHTS

- Member, American Association of Immunologists; American Association for Advancement of Science; American Society of Clinical Oncology; American Association of Cancer Research

- Advisory board, Boston Museum of Science and chair, Life Science Committee
KEY EXPERIENCE AND QUALIFICATIONS

Ms. Johnson brings to the board considerable financial experience and a strong background in technology, governance, talent management and strategy for global risk management.

- Ms. Johnson’s wide-ranging operational experience at two complex financial institutions has included leadership over various departments focused on cybersecurity, technology, operations, account services, enterprise change, data modeling, analytics, information security, resiliency, innovation, and corporate strategy.
- Ms. Johnson also brings deep understanding of enterprise risk management, having served as chief risk officer of Fannie Mae and currently overseeing enterprise risk as part of her role at T. Rowe Price.
- Ms. Johnson also brings to the board knowledge of technology operations, having led Fannie Mae’s digital transformation, establishing a four-year enterprise modernization plan and an operational roadmap for redesigning business processes and reengineering core technology.

CAREER HIGHLIGHTS

- **T. Rowe Price Group, Inc.,** a global leader in asset management
  - Vice President and Chief Operating Officer (2022 - present)
- **Federal National Mortgage Association (Fannie Mae),** a provider of affordable mortgage financing in the United States
  - Executive Vice President and Chief Operating Officer (2018 - 2022)
  - Executive Vice President and Chief Risk Officer (2017 - 2018)
  - Senior Vice President and Chief Risk Officer (2015 - 2017)
  - Senior Vice President and Deputy Chief Risk Officer (2013 - 2015)
- **Credit Suisse AG,** a global wealth manager, investment bank, and financial firm founded and based in Switzerland
  - Director, Interest Rate Derivative Products (2005 - 2006)
  - Vice President (2002 - 2004)

OTHER HIGHLIGHTS

- Trustee, Princeton University
Mr. Luciano’s decades of experience, including as chairman and chief executive officer of Archer-Daniels-Midland Company, in leading large organizations, international business, strategy, and operations bring to the board valuable insights into the complexities of operating in a rapidly changing global market. Mr. Luciano has robust leadership qualities that enable him to act as a strong lead independent leader for the board.

- As chairman and chief executive officer of a major global enterprise, Mr. Luciano contributes extensive knowledge of international business and the development and execution of strategy, such as the increased use of innovative technologies to meet customer needs.
- Mr. Luciano’s experience as a chief operating officer and line executive in several product areas also bring a thorough understanding of operations, especially in highly regulated sectors.
- Mr. Luciano’s results-oriented perspective and his experience in leading a major multinational company are particularly valuable to the board and make him a strong and engaged lead independent director.
- Mr. Luciano is a well-respected leader of the board, with the willingness and ability to provide direct, candid feedback to the chief executive officer while acting as a facilitator of discussion and progress.

**CAREER HIGHLIGHTS**

- **Archer-Daniels-Midland Company**, a global food processing and commodities-trading company
  - Chairman (2016 - present)
  - Chief Executive Officer and President (2015 - present)
  - President and Chief Operating Officer (2014 - 2015)
- **The Dow Chemical Company**, a multinational chemical company
  - Executive Vice President and President, Performance Division (2010 - 2011)

**OTHER HIGHLIGHTS**

- Alternate director, Wilmar International
- Director, Intersect Illinois
- Director, Rush University Medical Center
- Member, The Business Roundtable
- Member, Civic Committee at the Commercial Club of Chicago
- Member, Economic Club of Chicago
William G. Kaelin, Jr., M.D.

Age: 66
Director since: 2012
Board Committees:
- Directors and Corporate Governance
- Science and Technology (Chair)
Other Public Boards:
- None
Recent Prior Public Boards:
- None
Key Skills:

KEY EXPERIENCE AND QUALIFICATIONS

Dr. Kaelin is a world-renowned Nobel Laureate, scientist, academician, and physician who provides valuable leadership to the board’s oversight of Lilly’s discovery and development programs. His groundbreaking research and discovery talents provide an important resource to management, including in his role as the chair of the board’s Science and Technology Committee.

- With decades of preeminent medical research experience, particularly within oncology, Dr. Kaelin offers a valuable perspective to the board and management in pharmaceutical research and discovery in key therapeutic areas.
- Dr. Kaelin has extensive experience as a professor and mentor to medical professionals who are key constituents for Lilly’s business and workforce.
- As an investigator at Howard Hughes Medical Institute, Dr. Kaelin has a deep understanding of the challenges, perspectives, and opportunities for medical researchers.
- Dr. Kaelin also brings commercialization experience to the board through his work with venture capital funds and biotech companies.
- Dr. Kaelin’s passion for improving the lives of patients drives his ongoing research and is core to Lilly’s mission.

CAREER HIGHLIGHTS

- Harvard Medical School
  - Sidney Farber Professor of Medicine (2018 - present)
  - Professor of Medicine (2002 - 2018)
- Dana-Farber Cancer Institute and Brigham and Women’s Hospital
  - Professor (2002 - present)
- Howard Hughes Medical Institute
  - Investigator (2002 - present)

OTHER HIGHLIGHTS

- Recipient of numerous prizes and honors, including:
  - Nobel Prize in Physiology or Medicine
  - Albert Lasker Basic Medical Research Award
  - Canada Gairdner International Award
  - Wiley Prize in Biomedical Sciences from the Rockefeller University
  - Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center
- Member, National Academy of Medicine; National Academy of Sciences; American College of Physicians; Association of American Physicians; American Society of Clinical Investigation; American Academy of Arts and Sciences

CEO Leadership
Finance / Accounting
International Business
Healthcare Industry
Science / Academia

Government Relations / Public Policy
Sales / Marketing
Technology / Digital
Operations / Strategy
Mr. Ricks has 25 years of experience at Lilly, leading and shaping large-scale operations across the world. He has overseen some of the most transformative growth in the company’s history; since assuming the role as Chief Executive Officer, Lilly has (i) experienced revenue growth of approximately 61%, (ii) experienced a five-year total shareholder return of 446%, and (iii) taken important steps to increase the affordability and accessibility of our products around the globe.

- Mr. Ricks embodies the “tone at the top” that strengthens Lilly’s culture, including through his commitment to compliance, talent development, and the expansion of our diverse workforce.
- Mr. Ricks has combined his company-specific and industry knowledge to grow, articulate and implement Lilly’s strategic plan, as reflected by the growth in revenue, robust pipeline, and progressive approach on leveraging technology into the business.
- As the primary face of Lilly, Mr. Ricks is able to draw on his extensive interactions with various stakeholders to apprise the board of significant developments in our business and industry, as well as to communicate feedback to the board and offer insights.
- Mr. Ricks’ multi-faceted leadership approach is derived from his experience in marketing, sales, drug development, and international operations, as well as his significant experience in public policy.

**CAREER HIGHLIGHTS**

- **Eli Lilly and Company**
  - Chair, President, and Chief Executive Officer (2017 - present)
  - Senior Vice President and President, Lilly Bio-Medicines (2012 - 2016)
  - President, Lilly USA (2009 - 2012)
  - Served in various marketing, sales and international leadership roles (1996 - 2009), including:
    - As President and General Manager of Lilly China
    - As General Manager of Lilly Canada

**OTHER HIGHLIGHTS**

- Director, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
- Director and former chair, Pharmaceutical Research and Manufacturers of America (PhRMA)
- Member, U.S. Patent and Trademark Office Council for Inclusive Innovation
- Director and executive committee member, Central Indiana Corporate Partnership
- Director, The Business Roundtable
KEY EXPERIENCE AND QUALIFICATIONS

Dr. Runge’s extensive experience as a physician and scientist contributes a unique depth of understanding to the board’s risk oversight and advice on scientific matters involving Lilly’s discovery and development programs, including a strong understanding of healthcare facility systems, biomedical research and training, innovation, clinical trial design and patient safety.

- As CEO of one of the largest hospitals in Michigan that is committed to high-quality care to under-resourced communities and is also a premier academic medical center, Dr. Runge brings to the board first-hand knowledge of healthcare services delivery, including hospital procurement and in-patient experiences with pharmaceuticals. Dr. Runge is committed to providing high-quality, low-cost healthcare for underserved populations – locally and across the state.
- With over three decades of academic experience across the United States, Dr. Runge provides a distinctive perspective on how future healthcare professionals are trained.
- Dr. Runge’s service as a principal investigator and director of an institution that was part of a national consortium to improve the way biomedical research is conducted across the country, as well as his own research efforts, provide valuable insights into the medical research process.
- Dr. Runge’s practical experience obtained at some of the nation’s renowned medical institutions offers a valuable perspective on diabetes and obesity treatment.

CAREER HIGHLIGHTS

- **University of Michigan**
  - Chief Executive Officer, Michigan Medicine (2015 - present)
  - Executive Vice President for Medical Affairs (2015 - present)
  - Dean, Medical School (2015 - present)
  - Board of Regents (2015 - present)

- **University of North Carolina School of Medicine**
  - Executive Dean (2010 - 2015)
  - Chair of the Department of Medicine (2000 - 2015)
  - Principal Investigator and Director of the North Carolina Translational and Clinical Sciences Institute (2010 - 2015)

OTHER HIGHLIGHTS

- Vice Chair, the University of Michigan Health Board
- Chair, the Michigan Health Corp. Board (the governing board for business partnerships)
- Member, American Association of Medical Colleges, American College of Cardiology, and American Medical Association
- Cardiology Fellow and Faculty Member, Harvard’s Massachusetts General Hospital
- Associate Professor of Medicine, Emory University
- John Sealy Distinguished Centennial Chair in Internal Medicine and Director of the Division of Cardiology and the Sealy Center for Molecular Cardiology, University of Texas Medical Branch at Galveston
KEY EXPERIENCE AND QUALIFICATIONS

Ms. Walker brings to the board extensive experience in building and strengthening brands, cultivating opportunities in new and existing markets, scaling organizations, and demonstrating accountability for results. She has an acute understanding of technology’s importance in organizational success.

- Ms. Walker has spent more than three decades in the information technology industry, building strong technology acumen and strategic insight through business and consumer leadership positions.
- Ms. Walker has been a key leader in international organizations applying new strategies to achieve transformative change, including transforming the Intel brand, and an award-winning integrated marketing and communications approach using digital and social media to engage customers and partners on their purchase journey.
- During her career at Cisco, Ms. Walker led a complete transformation of the company’s marketing function to become a leader in real-time marketing and communications while also spearheading transformation to a hybrid business model selling hardware, services, software as a service (SaaS) and software.

CAREER HIGHLIGHTS

- **The Goldman Sachs Group, Inc.**, a leading global financial institution that delivers a broad range of financial services
  - Operating Partner (2023 – present)
- **Boston Consulting Group**, a leading management consulting firm
  - Senior Advisor (2023 - present)
- **Intel Corporation**, a leader in the semiconductor industry
  - Senior Vice President and Chief Marketing Officer (2019 - 2022)
- **Cisco Systems, Inc.**, a provider of communications technologies and services to commercial and governmental customers
  - Senior Vice President and Chief Marketing Officer (2015 - 2019)
  - Senior Vice President, Marketing (2013 - 2015)
  - Senior Vice President of Segment, Services and Marketing Partner (2012 - 2013)
- **Hewlett-Packard Company**, a manufacturer of software and computer services
  - Various marketing, strategy and operations roles in Europe, North America and Asia-Pacific (1984 - 2009)

OTHER HIGHLIGHTS

- Advisory board member, Salvation Army of Silicon Valley
- Forbes Top 10 Most Influential CMOs in the World (2017 and 2019)
**Director Nominations**

Each year, the board proposes a slate of director nominees for election by shareholders at the Annual Meeting. The board has delegated the process of screening potential director candidates to the Directors and Corporate Governance Committee, which receives input from other board members.

**Candidate Identification:** Director candidates can be identified from several sources, including incumbent directors, shareholders, executive search firms retained by the committee, and management.

The Directors and Corporate Governance Committee employs the same process to evaluate all candidates, including those submitted by shareholders, in accordance with our bylaws and corporate governance guidelines.

1. **Evaluate director qualifications.** The committee initially evaluates a candidate based on publicly available information and additional information supplied by the party recommending the candidate. The committee, assisted by management or a search firm, may gather additional data as needed, including on the candidate’s qualifications, relationships or transactions with related party, availability, probable level of interest, and any potential conflicts of interest.

   *Incumbent Directors* - For incumbent directors being considered for re-nomination, the Directors and Corporate Governance Committee has the additional benefit of (i) feedback from the annual board and committee evaluations and related individual discussions between each director and the chair and/or the lead independent director; (ii) knowledge of attendance and participation at, and preparation for, prior board and committee meetings; and (iii) shareholder feedback, if such nominee has been elected at a prior annual meeting.

2. **Meetings with Select Directors.** If the committee’s subsequent evaluation continues to be favorable, the candidate is contacted by the chair of the board and one or more of the independent directors, including the lead independent director, for direct discussions to determine the mutual level of interest in pursuing the candidacy.

3. **Recommendation for Election.** If these discussions are favorable, the committee recommends that the board nominate the candidate for election by the shareholders (or for the board to elect the candidate to fill a vacancy, as applicable).
Shareholder Director Candidates

✓ **Shareholder Recommendations of Director Candidates** - A shareholder who wishes to recommend a director candidate for evaluation should forward the candidate’s name and information about the candidate’s qualifications by delivery and email to:

Chair of the Directors and Corporate Governance Committee
c/o General Counsel and Secretary
Lilly Corporate Center
Indianapolis, IN 46285
Email: shareholderproposals@lilly.com

The candidate must meet the selection criteria described above under “Governance—How We Build an Effective Board—Director Qualifications” and must be willing and expressly interested in serving on the board.

✓ **Shareholder Nominations for Director Candidates for Inclusion in the Proxy Statement (“Proxy Access”)** - If a shareholder or group of shareholders wishes to nominate one or more director candidates to be included in the proxy statement for the 2025 annual meeting pursuant to the “proxy access” provisions of the company’s bylaws, such shareholder or group of shareholders must deliver to the company’s Secretary, and the company’s Secretary must receive, written notice no later than November 22, 2024, and no earlier than October 23, 2024. However, if the date of the 2025 annual meeting is changed by more than 30 days from May 5, 2025 (the date contemplated for the 2025 annual meeting as set forth in this proxy statement), a shareholder must give the company written notice no earlier than 150 days in advance of the date of the 2025 meeting and no later than the close of business on the later of 120 days in advance of the 2025 annual meeting or 10 days following the date we first publicly announce the date of 2025 annual meeting. Any such notice must also comply with the timing, disclosure, procedural, and other requirements as set forth in the bylaws.

✓ **Other Shareholder Nominations for Director Candidates** - In addition, under Section 1.9 of the company’s bylaws, any shareholder of record wishing to directly nominate a director candidate at the 2025 annual meeting of shareholders (i.e., to propose a candidate for election who is not otherwise nominated by the board through the recommendation process described above and not pursuant to the “proxy access” provisions described above) must deliver to the company’s Secretary, and the company’s Secretary must receive, written notice no later than the close of business on November 22, 2024, and no earlier than the close of business on September 23, 2024. However, if the date of the 2025 annual meeting is changed by more than 30 days from May 5, 2025 (the date contemplated for the 2025 annual meeting as set forth in this proxy statement), a shareholder must give the company written notice no later than the close of business on the later of 120 days in advance of the 2025 annual meeting or 10 days following the date we first publicly announce the date of 2025 annual meeting. Any such notice must also comply with the timing, disclosure, procedural and other requirements as set forth in the bylaws. A copy of the bylaws is available online at lilly.com/leadership/governance.

✓ **Universal Proxy for Shareholder Nominations** - In addition to satisfying the requirements under our bylaws, if a shareholder intends to comply with the SEC’s universal proxy rules and to solicit proxies in support of director nominees other than the company’s nominees, the shareholder must provide notice that sets forth the information required by Rule 14a-19 under the Securities Exchange Act of 1934 which notice must be postmarked or transmitted electronically to us at the address stated above for shareholder recommendations no later than 60 calendar days prior to the one-year anniversary date of the Annual Meeting (for the 2025 annual meeting of shareholders, no later than March 7, 2025). If the date of the 2025 annual meeting of shareholders is changed by more than 30 calendar days from such anniversary date, however, then the shareholder must provide notice by the later of 60 calendar days prior to the date of the 2025 annual meeting of shareholders and the 10th calendar day following the date on which public announcement of the date of the 2025 annual meeting of shareholders is first made by the company.
**Director Compensation**

Directors who are employees receive no additional compensation for serving on the board. Non-employee director compensation is reviewed and approved by the board, on the recommendation of the Directors and Corporate Governance Committee.

- **65%** board service annual retainer amounts linked to the long-term performance of Lilly stock
- **5x** annual board retainer share ownership requirement for non-employee directors
- **CAPPED** total annual compensation for non-employee directors

**Director Compensation Governance**

The Directors and Corporate Governance Committee performs an annual in-depth review of non-employee director compensation, including considerations such as:

- General industry and pharmaceutical company peer group analysis conducted with the assistance of an outside compensation consultant,
- The desire to have non-employee director compensation positioned near the market median when compared against the general industry peer group,
- The desire to avoid excess compensation, and
- A focus to link a significant portion of compensation to the long-term performance of Lilly stock.

If the Directors and Corporate Governance Committee determine adjustments to non-employee director compensation are warranted, it will make recommendations to the full board for consideration.

**Compensation Elements**

The following table shows the compensation elements in effect for all non-employee directors in 2023:

<table>
<thead>
<tr>
<th>Compensation Element</th>
<th>Payment or Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Board Service</strong>¹</td>
<td></td>
</tr>
<tr>
<td>Annual board retainer</td>
<td>$110,000</td>
</tr>
<tr>
<td>Annual equity grant³</td>
<td>$200,000 in deferred stock units</td>
</tr>
<tr>
<td>Lead independent director</td>
<td>$40,000</td>
</tr>
<tr>
<td><strong>Committee Service</strong>¹</td>
<td></td>
</tr>
<tr>
<td>Annual Committee Retainer²</td>
<td>Chair</td>
</tr>
<tr>
<td>Audit Committee</td>
<td>$26,000</td>
</tr>
<tr>
<td>Science and Technology Committee</td>
<td>$18,000</td>
</tr>
<tr>
<td>Talent and Compensation Committee</td>
<td>$17,000</td>
</tr>
<tr>
<td>Ethics and Compliance Committee</td>
<td>$17,000</td>
</tr>
<tr>
<td>Directors and Corporate Governance</td>
<td>Member</td>
</tr>
<tr>
<td>Committee</td>
<td>$6,000</td>
</tr>
<tr>
<td></td>
<td>$6,000</td>
</tr>
<tr>
<td></td>
<td>$3,000</td>
</tr>
<tr>
<td></td>
<td>$3,000</td>
</tr>
<tr>
<td></td>
<td>$3,000</td>
</tr>
<tr>
<td><strong>Total Compensation Value Cap of $800,000</strong>⁴</td>
<td></td>
</tr>
</tbody>
</table>

¹ **Expenses and Ad Hoc Committees.** Directors are reimbursed for customary and usual travel expenses in connection with their travel to and from board meetings and other company events. Non-employee directors may also receive additional cash compensation for serving on ad hoc board committees that may be formed by the board from time to time. Committee chair retainers are in addition to member retainers.

² **Changes for 2024.** Following the Directors and Corporate Governance Committee’s in-depth review of 2024 non-employee director compensation (as further described above), the board approved increases to (i) the annual equity grant (to $220,000 in deferred stock units) and (ii) the chair retainers for the Science and Technology committee (to $23,000), and the Talent and Compensation committee, Ethics and Compliance committee, and Directors and Corporate Governance committee (each to $22,000), effective January 1, 2024.
Stock Compensation. Non-employee directors received an annual equity-based award that was credited to each non-employee director’s deferred stock account established under the Lilly Directors’ Deferral Plan as a number of units calculated by dividing $200,000 by the closing stock price on a pre-set annual date (approximately 335 units). When applicable, the annual equity-based award is prorated for time served. See “Lilly Directors’ Deferral Plan—Deferred Stock Account”.

Annual Compensation Cap for Directors. The board approved an annual cap to the total annual compensation (cash and equity compensation) for non-employee directors of $800,000. The cap is intended to avoid excessive director compensation and is included in both the Lilly Directors’ Deferral Plan and in the Amended and Restated 2002 Lilly Stock Plan approved by shareholders at the 2018 annual meeting of shareholders.

Share Ownership Guidelines
Non-employee directors are required to hold Lilly stock, directly or through units representing the right to receive shares of Lilly stock under the Lilly Directors’ Deferral Plan, valued at not less than five times their annual board retainer. New non-employee directors are allowed five years to reach the required ownership level. All non-employee directors serving at least five years have satisfied these guidelines. All other non-employee directors are, or in the case of recently elected directors, are expected to begin making progress toward these requirements.

Lilly Directors’ Deferral Plan
In addition to the annual equity-based grants credited to each non-employee director’s deferred stock account as described above, the Lilly Directors’ Deferral Plan allows non-employee directors to defer receipt of all or part of their cash compensation until after their service on the board has ended. Each director can choose to invest any amounts deferred in one or both of the following two accounts:

• Deferred Stock Account. This account allows the non-employee director, in effect, to invest his or her deferred cash compensation in company stock. Funds in this account are credited as units representing the right to receive shares of company stock based on the closing stock price on pre-set monthly dates. Hypothetical dividends are deemed “reinvested” in additional units based on the market price of the stock on the date dividends are paid. The units become issuable to the non-employee director as shares of company stock commencing in the second January following the director’s departure from board service (either in a lump sum or installments as described below). The deferral stock account is the same account where the annual equity awards for board service are credited using the same conversion timing and procedure.

• Deferred Compensation Account. Deferred cash compensation in this account earns interest each year at a rate of 120 percent of the applicable federal long-term rate, compounded monthly, as established the preceding December by the U.S. Treasury Department under Section 1274(d) of the Internal Revenue Code of 1986 (the Internal Revenue Code). The aggregate amount of interest that accrued in 2023 for the participating directors was $210,349, at a rate of 5.1 percent. The rate for 2024 is 5.89 percent.

Both accounts may be paid out in a lump sum or in annual installments for up to 10 years based on individual director annual elections. All payments begin the second January following the director’s departure from board service. Amounts in the deferred stock account are paid in shares of company stock.
## 2023 Compensation for Non-Employee Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Fees Earned or Paid in Cash ($)</th>
<th>Stock Awards ($)</th>
<th>All Other Compensation and Payments ($)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Alvarez</td>
<td>$136,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$336,000</td>
</tr>
<tr>
<td>Dr. Baicker</td>
<td>$136,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$336,000</td>
</tr>
<tr>
<td>Mr. Fyrwald</td>
<td>$119,000</td>
<td>$200,000</td>
<td>$25,884</td>
<td>$344,884</td>
</tr>
<tr>
<td>Dr. Hedley</td>
<td>$119,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$319,000</td>
</tr>
<tr>
<td>Mr. Jackson</td>
<td>$145,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$345,000</td>
</tr>
<tr>
<td>Ms. Johnson</td>
<td>$116,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$316,000</td>
</tr>
<tr>
<td>Dr. Kaelin</td>
<td>$137,000</td>
<td>$200,000</td>
<td>$12,150</td>
<td>$349,150</td>
</tr>
<tr>
<td>Mr. Luciano</td>
<td>$173,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$373,000</td>
</tr>
<tr>
<td>Dr. Runge</td>
<td>$119,000</td>
<td>$200,000</td>
<td>$0</td>
<td>$319,000</td>
</tr>
<tr>
<td>Ms. Sulzberger</td>
<td>$119,000</td>
<td>$200,000</td>
<td>$16,500</td>
<td>$335,500</td>
</tr>
<tr>
<td>Ms. Walker</td>
<td>$119,000</td>
<td>$200,000</td>
<td>$40,000</td>
<td>$359,000</td>
</tr>
</tbody>
</table>

**Former Director:**

| Mr. Tai       | $39,987                         | $83,333          | $70,000                                 | $193,320  |

1. Each non-employee director received an equity-based award of units valued at $200,000 (approximately 335 units) except Mr. Tai who received a pro-rated award for a partial year of service valued at $83,333 (approximately 139 shares). These units, and all prior awards of such units, are fully vested; however, the shares subject to such awards of units are not issued until the second January following the director’s departure from board service when, as described above under “Lilly Directors’ Deferral Plan,” the units are converted into shares of company stock and distributed to the former director. The column shows the grant date fair value for each director’s equity-based award computed in accordance with FASB ASC Topic 718, based on the closing stock price on the grant date. See Note 12 of the consolidated financial statements in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for additional detail regarding assumptions underlying the valuation of equity awards. Aggregate outstanding stock awards are shown in the “Common Stock Ownership by Directors and Executive Officers” table in the “Stock Units Not Distributable Within 60 Days” column.

2. This column includes amounts donated by the Eli Lilly and Company Foundation, Inc. (the Foundation) under its matching gift program, which is generally available to U.S. employees as well as non-employee directors. Under this program, the Foundation matched 100 percent of charitable donations over $25 made to eligible charities in a calendar year, up to a maximum of $30,000 per year for each individual. However, donations made by an eligible individual at the end of a calendar year may not be matched by the Foundation until the beginning of the next calendar year, in which case the match will be included in the table in the calendar year in which the match is actually paid by the Foundation. The Foundation matched these donations via payments made directly to the recipient charity. The expected payments in 2024 related to matching contributions for donations made by non-employee directors at the end of 2023 include for Mr. Fyrwald - $22,356; Mr. Kaelin - $1,000 and Ms. Sulzberger - $27,750. The amount for Mr. Tai includes a $10,000 donation by the Foundation to a charity of Mr. Tai’s choosing in honor of his retirement from the board, consistent with the company’s traditional practice for retiring directors.

3. Non-employee directors do not participate in a company pension plan or non-equity incentive plan.

4. Mr. Tai retired following the 2023 annual meeting.
Item 1. Election of Directors

Under our articles of incorporation, the board is divided into three classes with approximately one-third of the directors standing for election each year. The Directors and Corporate Governance Committee has recommended that each of the following four nominees be elected at the Annual Meeting. Each of the director nominees is currently serving as a director.

### 2024 Nominees

<table>
<thead>
<tr>
<th>Nominee</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katherine Baicker</td>
<td>Independent Director</td>
</tr>
<tr>
<td>J. Erik Fyrwald</td>
<td>Independent Director</td>
</tr>
<tr>
<td>Jamere Jackson</td>
<td>Independent Director</td>
</tr>
<tr>
<td>Gabrielle Sulzberger</td>
<td>Independent Director</td>
</tr>
</tbody>
</table>

The term for directors to be elected this year will expire at the annual meeting of shareholders held in 2027. Each of the director nominees above has agreed to serve for that term. Nominees are elected to serve until his or her successor is duly elected and qualified. If a nominee set forth in this proxy statement is unable to serve or for good cause will not serve, proxy holders may vote for another nominee proposed by the board or, as an alternative, the board may reduce the number of directors to be elected at the Annual Meeting.

For more information about each of the nominees and the other directors serving on our board, please see “Director Experience” in this proxy statement.

**RECOMMENDATION FOR**

The board recommends that you vote FOR the election of each of the board’s nominees, Katherine Baicker, J. Erik Fyrwald, Jamere Jackson, and Gabrielle Sulzberger to serve as directors until our 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified, or until their earlier death, resignation, or removal.

How We Operate an Effective Board

We believe that high board effectiveness promotes the long-term interests of our shareholders, strengthens the accountability of the board of directors and management, and improves our standing as a trusted member of the communities we serve. In addition to having the right mix of directors, there are many factors involved in operating an effective board.

**Working Dynamics**

**Leadership Structure**

**Approach.** Under our bylaws, the positions of chair of the board and chief executive officer are separate positions that may be occupied by the same person at the discretion of the board. This gives the board flexibility to choose its optimal leadership structure that will best serve the interests of the company and its shareholders as they evolve over time. The board currently combines the role of chair of the board with the role of chief executive officer, and designates a strong independent and clearly defined lead independent director to further strengthen...
the company’s governance structure. The board periodically reviews its leadership structure to ensure that the chosen leadership structure continues to strike the appropriate balance for the company and our stakeholders and enables us to promote the long-term interests of our shareholders.

**Why our board leadership structure is appropriate at this time.** After thoughtful consideration of our business, long-term strategy, related risks, and other factors described below, the board believes that the combination of the chair and CEO roles, combined with a strong lead independent director, continues to be in the best interest of the company and our shareholders. Combining the chair and CEO roles fosters clear accountability, effective decision making, and alignment on corporate strategy.

The board has also implemented governance practices that facilitate effective independent oversight, including:

- **Executive sessions of the independent directors:** Held at each regularly scheduled board meeting and presided over by the lead independent director.

- **Annual performance evaluation of the chair and CEO:** Conducted by the independent directors, the results of which are reviewed with the CEO and considered by the Talent and Compensation Committee and independent directors in establishing the CEO’s compensation for the following year.

- **Lead independent director assessment:** The lead independent director is elected by and from among the independent directors of the board, and the board annually conducts an assessment of the lead independent director’s performance as part of the annual board assessment process.

- **Director access to independent advisors:** The independent directors and all committees have the ability to retain their own independent advisors, at the company’s expense, whenever they deem it desirable to do so.

- **Director access to management:** Independent directors have direct access to members of management whenever they deem it necessary, and certain of the company’s executive officers attend part of each regularly scheduled board meeting.

- **Independent board (other than Mr. Ricks):** The board is independent (other than Mr. Ricks) and has fully independent board committees with independent chairs.

The board believes that this structure provides the company and the board with strong leadership, appropriate independent oversight of management, and the ability to communicate the company’s strategy to regulators and stakeholders in a single voice.

Mr. Ricks’ extensive knowledge of, and experience in, the pharmaceutical industry enables him to effectively drive the long-term strategic direction of the company and provide diligent, long-term leadership and direction for management and our board. This is vital to our innovative research and development business with prolonged product development cycles and a challenging regulatory environment.

**How we select a Lead Independent Director.** Each year the Directors and Corporate Governance Committee reviews the qualifications and attributes of a strong lead independent director and makes a recommendation to the independent directors of one from among them to be appointed as lead independent director.

Mr. Luciano serves as the current lead independent director and fulfills the duties below. As the CEO and president of Archer-Daniels-Midland Company, he brings valuable and diverse experience and outside perspective to his lead independent director role, which permits him to serve as a trusted adviser to the independent directors as well as Mr. Ricks and ensure effective board management and risk oversight.
Lead Independent Director Responsibilities. The lead independent director is empowered with and exercises, robust, well-defined duties. Including the following:

- **Lead**
  - Lead the board’s processes for selecting the CEO
  - Oversee the independent directors’ annual performance evaluation of the chair and CEO
  - Call meetings of the independent directors, as appropriate

- **Facilitate**
  - Preside at executive sessions of the independent directors
  - Preside at all meetings of the board at which the chair is not present
  - Approve meeting agendas and schedules and review information to be provided to the board

- **Advocate**
  - Be available for consultation and direct communication with shareholders, as appropriate
  - Serve as a liaison between the chair and the independent directors
  - Retain advisors for the independent directors, as appropriate

- **Shape**
  - Conduct the annual board assessment process with the Directors and Corporate Governance Committee and chair
  - Lead the director succession planning process

In 2023, the independent directors, led by Mr. Luciano, met at each regularly scheduled board meeting in executive session to discuss various matters related to the oversight of the company, the management of the board’s affairs, and the CEO’s performance. We believe Mr. Luciano fosters an open and constructive dialogue during these sessions as well as during individual discussions with independent directors. As appropriate, Mr. Luciano informs Mr. Ricks of the independent directors’ discussions, including providing performance feedback.

### Board Assessment

**Reexamine Evaluation Process**
- Directors provided written feedback on an unattributed basis.

**Questionnaire**
- Each director had one-on-one discussions with the lead independent director and/or with the board chair.

**One-On-One Discussions**
- A summary of board and committee evaluations results was provided to the board and its committees.

**Evaluation Summary**
- Closed session evaluation discussions of the board and committees were led by our lead independent director and independent committee chairs.

**Closed Session Discussions**
- Incorporated feedback into nomination process and the 2024 board and committee planning process, as applicable.

**Follow Through**
- Every year, the Directors and Corporate Governance Committee, together with the chair and the lead independent director, conducts a robust assessment of the performance of the board and board committees, and of all board processes, based on input from all directors. We also conduct an annual assessment of each director’s performance, and every three years we conduct a detailed review of individual director performance when considering whether to nominate the director to a new three-year term.

The results of these assessments inform the board’s recommendations on nominations for directors at the annual meeting of shareholders each year and help provide us with insight on the types of experiences, skills, perspectives, and other characteristics we should be seeking for future director candidates. Together with our lead independent director, the Directors and Corporate Governance Committee performs periodic assessments of the overall composition and skills of the board to ensure that the board is actively engaged in succession planning for directors, and that our board reflects the diversity of viewpoints and expertise necessary to support our complex and evolving business.

### Board Education

Periodic briefing sessions are provided to members of the board and committees on subjects that would assist them in discharging their duties. Directors also attend regular continuing education sessions on areas of relevance or importance to our company, and we hold regular mandatory training sessions for the Audit Committee.
Beyond the Boardroom

Director Orientation
Each new director participates in an orientation program upon joining the board. The program includes presentations by senior management to familiarize new directors with, among other things, Lilly’s ethics, compliance and governance programs, business units, financial position, strategic plans, and human capital management programs.

Business Deep Dive and Site Visits
Periodically, directors are invited to or may request to visit the company’s manufacturing or other operating sites, and management prepares educational sessions for directors relevant to the location’s business and culture.

Additionally, directors are invited to or may request “deep dive” educational sessions with respect to a particular business unit or other aspect of our business. In 2023, these included sessions on product launches, field sales, medical conferences, and affordability initiatives.

Employee Events
Directors have the opportunity to participate in a variety of Lilly events, both as presenters and as participants. This offers a chance for directors to connect with Lilly employees, show their support for these activities and see our inclusion strategies in action.

Shareholder Engagement
The board receives periodic updates on shareholder engagement led by management, and is directly involved in responding to and participating in communications where appropriate. From time to time, including in 2023, directors participate in direct engagement with shareholders to discuss specific matters of mutual importance.

Board Structure
The board has established five standing committees: Audit, Talent and Compensation, Directors and Corporate Governance, Science and Technology, and Ethics and Compliance. Our independent directors are appointed to committees to take advantage of their diverse skill sets and enable deep focus on a specific scope of matters. The board annually reviews committee memberships and chair positions, seeking the best blend of continuity and innovative perspectives on the committees.

Each of our committees:
• operates pursuant to a written charter (available on our website at lilly.com/leadership/governance),
• evaluates its performance annually, and
• reviews its charter annually.

The chair of each committee determines the frequency and agenda of committee meetings, subject to any minimums specified in the relevant committee charter, and the committees meet alone in executive session on a regular basis.

Meetings of the Board and Its Committees
In 2023, our board met seven times, and each director attended at least 75 percent of the total number of meetings of the board and the committees on which he or she served during his or her tenure as a board or committee member. In addition, all board members are expected to attend the Annual Meeting. All directors then serving on the board attended the 2023 annual meeting of shareholders with the exception of Mr. Tai, who retired following the 2023 annual meeting. Key responsibilities, current committee membership and the number of meetings of each committee held in 2023 are shown below.
Committees of the Board

Audit Committee

Members:
- Mr. Alvarez*
- Mr. Jackson* (Chair)
- Ms. Sulzberger*
- Ms. Walker

* Financial Experts

Meetings in 2023: 6

Key responsibilities and areas of risk oversight:
- oversees integrity of financial information provided to our shareholders and others
- oversees management’s systems of internal controls and disclosure controls
- oversees performance of internal and independent audit functions
- establishes qualifications and determines independence of the company’s independent auditor
- has sole authority to appoint or replace the independent auditor
- oversees compliance with legal and regulatory requirements
- oversees processes and procedures related to identifying and mitigating enterprise-level risks
- oversees the company’s programs, policies, procedures, and risk management activities related to information security and data protection
- together with the ethics and compliance committee, oversees the company’s compliance with the company’s code of ethics

Talent and Compensation Committee

Members:
- Mr. Alvarez (Chair)
- Mr. Fyrwald
- Ms. Johnson
- Mr. Luciano
- Ms. Walker

Meetings in 2023: 6

Key responsibilities and areas of risk oversight:
- establishes the compensation of the CEO (in consultation with independent directors and external compensation consultant) and other executive officers
- oversees global compensation philosophy and human capital management efforts, including diversity, equity, and inclusion efforts
- has authority to appoint or replace the compensation consultant
- acts as the oversight committee with respect to the company’s deferred compensation plans, management stock plans, and other management incentive and benefit programs
- reviews succession plans for the CEO and other key senior leadership positions, including a broad review of our succession management
- advises management and the board regarding other human capital management, diversity, equity, and inclusion efforts, and employee compensation and benefits matters
- reviews, monitors, and oversees stock ownership guidelines for executive officers
- oversees the company’s executive compensation recovery policy
- oversees the company’s engagement with shareholders regarding executive compensation matters, including reviewing and evaluating the results of advisory votes on executive compensation
Directors and Corporate Governance Committee

Members:
- Mr. Jackson
- Dr. Kaelin
- Mr. Luciano (Chair)
- Ms. Sulzberger

Meetings in 2023: 3

Key responsibilities and areas of risk oversight:
- reviews and recommends to the board the size and composition of the board and its committees
- leads the process for director recruitment, together with the lead independent director
- reviews recommendations for nominees for the board of directors
- oversees matters of corporate governance, including board performance, non-employee director independence and compensation, corporate governance guidelines, and shareholder engagement on governance matters
- identifies and brings to the attention of the board as appropriate current and emerging environmental, social, political, and governance trends and public policy issues that may affect the business operations, performance, or reputation of the company
- annually assesses the performance of the board, board committees and board processes, and reviews such findings with the board

Ethics and Compliance Committee

Members:
- Dr. Baicker (Chair)
- Dr. Hedley
- Ms. Johnson
- Dr. Runge

Meetings in 2023: 3

Key responsibilities and areas of risk oversight:
- reviews, identifies and, when appropriate, brings to the attention of the board legal and regulatory trends and issues, and compliance and quality matters that may have an impact on the business operations, financial performance, or reputation of the company
- reviews, monitors, and makes recommendations to the board on corporate policies and practices related to compliance, including those related to employee health and safety
- together with the audit committee, assists the board in its oversight of legal and regulatory compliance and oversees the company’s compliance with its code of ethics

Science and Technology Committee

Members:
- Dr. Baicker
- Mr. Fyrwald
- Dr. Hedley
- Dr. Kaelin (Chair)
- Dr. Runge

Meetings in 2023: 6

Key responsibilities and areas of risk oversight:
- reviews and advises the board regarding the company’s long-term strategic goals and objectives and the quality and direction of the company’s research and development programs
- reviews and advises the board and management on the company’s major technology positions and strategies relative to emerging technologies, emerging concepts of therapy and health care, and changing market requirements
- monitors and evaluates developments, technologies, and trends in pharmaceutical research and development
- regularly reviews the company’s product pipeline
- assists the board with its oversight responsibility for enterprise risk management in areas affecting the company’s research and development
Compensation Committee Interlocks and Insider Participation
During the year ended December 31, 2023, Mr. Alvarez, Mr. Fyrwald, Ms. Johnson, Mr. Luciano, and Ms. Walker served on the Talent and Compensation Committee.

None of the Talent and Compensation Committee members:
- has ever been an officer or employee of the company,
- is or has been a participant in a related person transaction with the company (see “Governance—How We Operate an Effective Board—Board Alignment—Conflicts of Interest and Transactions with Related Persons—Review and Approval of Transactions with Related Persons” for a description of our policy on related person transactions), or
- has any other interlocking relationships requiring disclosure under applicable SEC rules.

Governance Practices
We are committed to good corporate governance, which promotes the long-term interests of shareholders and other company stakeholders, builds confidence in our leadership, and strengthens accountability by the board and management.

Board Oversight
The board exercises oversight over a broad range of areas, but the board’s key responsibilities include the following (certain of which are carried out through the board’s committees):
- providing general oversight of the business,
- approving corporate strategy,
- approving major management initiatives,
- overseeing significant capital allocation,
- selecting, compensating, evaluating, and, when necessary, replacing the CEO, and compensating other senior executives,
- ensuring that an effective succession plan is in place for all key senior leadership positions and reviewing our broader talent management process, including human capital management strategies, overall corporate culture, and diversity, equity, and inclusion programs,
- overseeing the company’s ethics and compliance program and management of significant business risks,
- selecting, compensating, and evaluating directors, and evaluating board processes and performance,
- overseeing the company’s enterprise risk management program, including receiving regular briefings on cybersecurity, technology, and information risks,
- overseeing the company’s approach to current and emerging environmental, social, political, and governance trends and public policy issues that may affect the business operations, performance or reputation of the company, and
- overseeing the company’s political expenditures and lobbying activities.

Key Areas of Oversight by the Board and Its Committees

Strategy

The board takes an active role in overseeing the development and execution of the company’s business strategy. Each year, the board and executive management conduct an extended review and discussion of the company’s strategy, goals, external environment, and key risks. Board meetings include discussions of company performance relative to its strategy. The board also reviews strategic focus areas for the company, such as innovation, information security, cybersecurity, and human capital management. Decisions reached in this session are reevaluated throughout the year, including as the board discusses the company’s financial performance, the performance of our business units, and progress in our product pipeline.
Compliance

The board, together with its committees, oversees the processes by which the company conducts its business to ensure the company operates in a manner that complies with laws and regulations and reflects the highest standards of integrity. The Ethics and Compliance Committee meets at least four times per year, including semi-annual private sessions to discuss compliance with the company’s chief ethics and compliance officer, the general auditor, and the executive vice president, global quality. On an annual basis, the full board reviews the company’s overall state of compliance and the Ethics and Compliance Committee receives an update on compliance at each committee meeting. The chief ethics and compliance officer and the executive vice president, global quality report directly to the CEO.

Risk Management

Our board, as a whole, is responsible for broad oversight of all existing and emerging enterprise risk (over the short-, mid- and long-term) and of management's development and execution of mitigation strategies designed to address those risks. In this capacity, the board has designated committees to assist in its oversight of particular key risks as described in Board Structure—Committee Descriptions. Oversight of additional matters of potential risk not delegated remain the responsibility of the full board.

While the board and its committees oversee risk management, the company’s senior management is responsible for identifying, assessing and mitigating risk on a day-to-day basis. Each committee of our board meets regularly with key management personnel and, as desired by the applicable committee, outside advisors (including outside counsel, consultants and experts) to oversee risks associated with their respective principal areas of focus. In turn, each committee reports to the board regularly, fostering awareness and communication of significant matters among all directors, and promoting a coordinated and cohesive approach to enterprise risk oversight.

The company’s enterprise risk management program, which is overseen by the Audit Committee, is directed by its chief ethics and compliance officer. Enterprise risks are identified and prioritized by management through both top-down and bottom-up processes. Management uses robust internal processes and controls to manage risk. The enterprise-level risks are reviewed annually at a full board meeting, and relevant enterprise risks are also addressed in periodic business function reviews and at the annual board and senior management strategy session. Management frequently collaborates throughout the year to keep an open dialogue on emerging risks identified from a variety of internal and external sources.

Governance

Corporate Governance Guidelines - The board has adopted corporate governance guidelines that set forth the company’s key principles of corporate governance and are available at lilly.com/leadership/governance.

Code of Ethics - The board approves the company’s code of ethics, which are available at lilly.com/operating-responsibly/ethics-compliance and lilly.com/operating-responsibly/ethics-compliance/financial-management-ethical-conduct. These written standards include:

The Red Book: A code of ethical and legal business conduct applicable to all employees worldwide and to our board. The Red Book is reviewed and approved annually by the board.

Code of Ethical Conduct for Lilly Financial Management: A supplemental code for our CEO and all members of financial management in recognition of their unique responsibilities to ensure proper accounting, financial reporting, internal controls, and financial stewardship.

In the event of any amendments to, or waivers from, a provision of the code affecting the CEO, chief financial officer, chief accounting officer, controller, or persons performing similar functions, we intend to post on the above website, within four business days after the event, a description of the amendment or waiver as required under applicable SEC rules. We will maintain that information on our website for at least 12 months.
CEOs Succession Planning

At least annually, the Talent and Compensation Committee, board, and CEO review the company’s succession plans for the CEO and other key senior leadership positions. The independent directors also meet without the CEO to discuss CEO succession planning.

During these reviews, the CEO and directors discuss:
- future candidates for the CEO and other senior leadership positions;
- succession timing; and
- development plans for potential candidates.

The independent directors and the CEO maintain a confidential plan for the timely and efficient transfer of the CEO’s responsibilities in the event of an emergency or his sudden departure, incapacitation, or death.

The company ensures that the directors have multiple opportunities to interact with the company’s top leadership talent in both formal and informal settings to allow them to most effectively assess the candidates’ qualifications and capabilities.

Cybersecurity

The Audit Committee is responsible for oversight of our programs, policies, procedures, and risk management activities related to information security and data protection. It meets regularly with management to discuss threats, risks, and ongoing efforts to enhance cyber resiliency, as well as changes to the broader cybersecurity landscape. In addition, the Ethics and Compliance Committee supports the Audit Committee and board in oversight of legal and regulatory compliance. Our board also regularly participates in presentations on cybersecurity and information technology. In addition to regular presentations, management promptly updates the board or the Audit Committee regarding significant threats and incidents as they arise.

Sustainability

Our approach to sustainability includes board oversight, management accountability, corporate policies and management systems, and stated public policies and positions on key topics. Our full board is engaged in strategic sustainability oversight, receives regular updates on these matters, reviews our long-term environmental goals, and weighs in on significant strategic investments, including those related to our overall sustainability priorities. The Directors and Corporate Governance Committee is also responsible for identifying and bringing to the attention of the board, as appropriate, current and emerging environmental, social, political, and governance trends and public policy issues that may affect our business operations, performance, or reputation.

In addition, we have formed an internal governance committee that includes senior leaders across many of our business functions to provide internal oversight of environmental, social, and governance matters. The committee reports to our senior leadership Executive Committee.

Our approach to sustainability efforts incorporates internal and external input to better determine the issues that matter most to our company and stakeholders. We set ambitious, measurable goals that are integrated into our business strategy and operations to directly support Lilly’s purpose.

We are striving to improve access to medicines, improve healthcare for people with limited resources, strengthen communities and address social issues that impact health, empower a diverse workforce, minimize our environmental impact, and operate ethically and responsibly.

For example, we offer a variety of affordability solutions through patient support programs and copay assistance across our major products, including medicines for diabetes, migraine, immunology diseases and cancer. Beyond our medicines, we work with global health systems and organizations to extend our reach by seeking to be part of the solution for complex global health challenges that disproportionately affect people living in settings with limited resources. As a global company, we are particularly aware of the social and economic circumstances in many
developing countries that may make access to medicines difficult. In response, Lilly is researching and implementing alternative business models, recognizing particular access challenges in lower-income countries.

Through investments in people, medicines and health systems, we aim to improve access to quality health care for 30 million people living in settings with limited resources annually by 2030. This global effort is intended to advance health equity across three areas of impact: our pipeline and external pipelines we help support, programs to increase access to Lilly medicines, and donations. In each of these areas, we are working to develop high-impact, scalable solutions.

While making medicines requires the use of valuable resources, including energy, water, and raw materials, we remain committed to improving our environmental impact across our product life cycles and supply chain. We have set 2030 sustainability goals to reduce our emissions and waste and to continue using water responsibly and efficiently.

Our Environmental, Social, and Governance Report provides a central location for information about goals, efforts and progress on these initiatives.

**Political Activities**

We believe that as a biopharmaceutical company that develops treatments for serious diseases, we are in a position to help promote access to needed medications through engagement with policymakers. Through public policy engagement, we provide a way to offer Lilly’s perspective on the political environment in a manner that supports access to innovative medicines and a way to engage on issues specific to local business environments.

Our board exercises governance oversight of our political expenditures and lobbying activities, ensuring our commitment to stewardship of corporate funds and risk minimization with respect to such activities. The Directors and Corporate Governance Committee is responsible for identifying current and emerging environmental, social, political, and governance trends and public policy issues that may affect the business operations, performance, or reputation of the company. In addition, the board receives regular updates at board meetings from management, which include updates on public policy issues and the company’s political corporate activity, as needed. The board also receives semi-annual updates on political engagement, including information on the contributions made by our employee political action committee (LillyPAC) and the company, as well as trade association memberships.

We provide information on our website related to direct company contributions and LillyPAC contributions to support candidates for political office, political parties, officials, or committees in the United States, as well as information regarding our trade association memberships and the company’s oversight of these activities. In response to input from our stakeholders, over time we have reviewed and enhanced the information available on our website.

**Human Capital Management**

The board exercises active oversight of our overall human capital strategy, including our talent management process, corporate culture, and inclusion efforts. The board also oversees the work of its committees in developing corporate policies and frameworks designed to attract, retain, engage, and develop a workforce that aligns with our values and mission. The Talent and Compensation Committee advises the board and management on oversight of human capital management, inclusion efforts, and employee compensation and benefits matters, and annually reviews our leadership development and succession planning practices.

The board also oversees human capital management by regularly engaging with management and facilitating a system of reporting that highlights the importance of inclusion to Lilly. Our board also oversees the activities of our CEO and executive committee in setting expectations for inclusivity in our workforce. Our chief diversity, equity, and inclusion officer is a senior vice president who also has responsibility for all aspects of talent management in the company, which enables full integration of these efforts into our talent systems. The senior vice president of diversity, equity and inclusion and talent management reports to the executive vice president for human resources and diversity, who is a member of our executive committee that reports to our CEO. We believe this system of oversight and reporting by the board and our key executives is critical to our success in fostering an inclusive, supportive, and rewarding workplace.
Talent Management Approach

Our comprehensive approach to human capital management is grounded in our core values of integrity, excellence, and respect for people, which reflect our commitment to creating a safe, supportive, ethical, and rewarding work environment. We are committed to fairness and nondiscrimination in our employment practices, and we deeply value diverse backgrounds, skills, and global perspectives. To fulfill our purpose, we believe we must look at challenges from multiple viewpoints and understand the diverse experiences of the patients who depend on us. In short, we believe that diverse representation at all levels makes Lilly a stronger and more innovative company.

Workforce Diversity

From the end of 2019 through the end of 2023, we have seen positive changes in representation across all levels of our workforce.

Workforce Diversity

Data as of year-end for each given year. Includes Regular and Fixed Term Employees only, excluding Temporary Employees and Contingent Workers.

MGM means minority group members.

Empowering a global culture of inclusion also extends into our physical spaces and the accessibility of our workplace. One of our recent initiatives to increase equity and inclusion is our platform for supporting employees with disabilities, and it covers multiple categories, including learning and development, facilities, and information systems. We have grown our ability to provide guidance, tools, and resources to help employees with disabilities thrive.

Employee Development

Recruiting: We believe attracting and retaining the best talent begins with the recruiting process. Our recruitment strategy focuses on opportunities to reach more candidates across a variety of dimensions, including but not limited to race, religion, sexual orientation, gender identity, national origin, veteran status, disability status, education, and experience. We strive to include a diverse pool of candidates and to provide a diverse panel of interviewers for open positions. We believe that recruiting in this way helps ensure that everyone will have an equal opportunity to advance their careers.

Onboarding and Continuing Education: Beginning with our 12-month new employee onboarding program with multiple touchpoints, we offer training to enable our employees to perform their duties in our highly regulated industry. We also strive to cultivate a culture that promotes ongoing learning by encouraging employees to seek further education and growth experiences, helping them build rewarding careers and creating connections to further a sense of belonging. We have introduced online programming to facilitate access to our learning and
development offerings in addition to our in-person programs. Across Lilly, we are continuously working to design learning experiences to be more inclusive and effective, including by improving accessibility for people with disabilities and other unique needs. In addition, we have implemented development tools and resources for all employees, improved our talent programs and processes to provide broader access to information, implemented an 18-month leadership curriculum focused on developing five essential skills for new leaders, and increased transparency regarding career development and advancement at Lilly.

Compensation, Benefits, and Pay Equity

While our rewards programs vary around the world, we take a holistic approach to employee benefits. These may include flexible work arrangements, on-site conveniences, such as cafes, fitness centers and child development centers, competitive time-off programs, retirement benefits, and health and disability programs that are available to eligible employees when they need support.

We are committed to ensuring pay is administered equitably across our workforce. For more than 20 years, we have regularly conducted pay equity studies of our workforce in the United States and have more recently started conducting studies of our workforce outside of the United States. Where appropriate, we have made pay adjustments as warranted.

Employee Health and Safety

We strive to foster a healthy, vibrant work environment, which includes keeping our employees safe. We seek to create a companywide culture where best-in-class safety practices are consistently followed. To do this, we assess and continuously attempt to improve our companywide safety performance to promote the well-being of employees and to help safeguard communities where we operate. We believe a holistic approach and dedication to safety helps us be our best as we deliver on our company purpose to improve lives around the world.

Our Environmental, Social, and Governance Report provides additional information about programs, recognitions, and progress on our talent management efforts.

Board Alignment

Conflicts of Interest and Transactions with Related Persons

Conflicts of Interest

Occasionally, a director’s business or personal relationships may give rise to an interest that conflicts, or appears to conflict, with the interests of the company. As outlined in the company’s corporate governance guidelines, directors must disclose to the company all relationships that could create a conflict or an appearance of a conflict. The board, after consultation with counsel, takes appropriate steps to identify actual or apparent conflicts and ensure that all directors voting on an issue are disinterested with respect to that issue. A director may be excused from board discussions and decisions on an issue related to an actual or apparent conflict, as appropriate.

In addition, a director’s relationship with Lilly may give rise to an interest that conflicts, or appears to conflict, with the interests of another company, institution, or other stakeholder. A director must disclose his or her relationship with Lilly in connection with any scientific publication, using the International Committee of Medical Journal Editors (ICMJE) conflict of interest form for this purpose when possible. Each director must disclose his or her service on the board to his or her employer and any other organization with which the director has a relationship of trust and where the relationship with Lilly is relevant. In addition, directors must follow the internal conflict of interest policies and procedures of each such organization.

Review and Approval of Transactions with Related Persons

The board has adopted a written policy and procedures for review, approval, and monitoring of transactions involving the company and related persons (including current executive officers, directors, or director nominees and persons who served in those roles at any time since the beginning of our last fiscal year, greater than five percent shareholders of the company, immediate family members of such persons, and related entities of such persons, including entities in which any of such persons is employed, is a general partner or principal or in which such person has a 10 percent or greater beneficial ownership interest). The policy covers any related person transaction that meets the minimum threshold for disclosure in this proxy statement under relevant SEC rules (generally, transactions involving amounts exceeding $120,000 in which a related person has a direct or indirect
Policy:

Related person transactions must be preapproved by the Directors and Corporate Governance Committee of the board or another independent body of the board, who will approve the transaction only if the Directors and Corporate Governance Committee or such independent body determines it to be consistent with the interests of the company and its shareholders. In considering the transaction, the Directors and Corporate Governance Committee or such independent body will consider all relevant factors, including:

- the company’s business rationale for entering into the transaction;
- the purpose of, and potential benefits to the company of, the transaction;
- the alternatives to entering into a related person transaction;
- whether the transaction is on terms comparable to those available to third parties, or in the case of employment relationships, to employees generally;
- the potential for the transaction to lead to an actual or apparent conflict of interest and any safeguards imposed to prevent such actual or apparent conflicts;
- the overall fairness of the transaction to the company;
- the approximate dollar value of the amount involved in the transaction, particularly as it relates to the related person;
- the related person’s interest in the transaction; and
- any other information regarding the transaction or the related person that would be material to the company’s shareholders in light of the circumstances of the particular transaction.

Procedures:

- Prior to entering into a transaction that may be a related person transaction, the related person (or the appropriate executive officer or director, in the case of immediate family members) is required to bring the matter to the attention of the chair of the board or the lead independent director, or alternatively, the General Counsel and Secretary.

- The chair of the board and the lead independent director jointly determine (or, if either is involved in the transaction, the other determines in consultation with the chair of the Directors and Corporate Governance Committee) whether the matter should be considered by the Directors and Corporate Governance Committee or another independent body of the board.

- If a director is involved in the transaction, he or she will be recused from all discussions and decisions relating to the transaction.

- The Directors and Corporate Governance Committee or such other independent body may approve the related person transaction only if the Directors and Corporate Governance Committee or such other independent body determines in good faith that, under all of the circumstances, the transaction is consistent with the interests of the company and its shareholders.

- The Directors and Corporate Governance Committee or such other independent body may impose such conditions as it deems appropriate on the company or the related person in connection with the approval of the related person transaction.

- If the transaction is recurring and is approved, the Directors and Corporate Governance Committee or such other independent body will review the related person transaction annually to determine whether it continues to be consistent with the interests of the company and its shareholders.

The Directors and Corporate Governance Committee or another independent body of the board retains the right to review and ratify related person transactions. In addition, the Directors and Corporate Governance Committee or such other independent body may take or cause to be taken additional actions including, but not limited to, immediate discontinuation or rescission of the transaction, or modification of the transaction.
In 2023, there were no related party transactions required to be reported pursuant to relevant SEC rules in this proxy statement.

Communication with the Board of Directors
You may send written communications to members of the board, including independent directors, addressed to:

Board of Directors
Eli Lilly and Company
c/o General Counsel and Secretary
Lilly Corporate Center
Indianapolis, IN 46285

Shareholder Engagement on Governance Issues
To ensure that a variety of perspectives are thoughtfully considered on key issues, each year the company engages large shareholders and other key constituents to discuss areas of interest or concern related to corporate governance, as well as any specific issues for the coming proxy season. Since our 2023 annual meeting of shareholders, we have spoken with a number of investors on an array of subjects, including board leadership; environmental, social and governance matters; drug pricing transparency and global access to our products; product quality and safety; key enterprise risks; executive compensation; and human capital management. We appreciate the thoughtful and constructive feedback that we receive from our stakeholders. While a few shareholders communicated differing views on some of our governance practices, the investors with whom we spoke were generally supportive of our performance and overall compensation and governance policies. This feedback has been discussed with our chair and CEO, the lead independent director, our Talent and Compensation Committee, and our Directors and Corporate Governance Committee, and it was a key input into board discussions on corporate governance topics. As a result of these discussions and its own deliberations, the board decided to recommend in favor of the two management proposals described below. We are committed to continuing to engage with our investors to ensure that their diverse perspectives on corporate governance and other issues are thoughtfully considered.

Management Proposals to Eliminate Classified Board and Supermajority Voting Requirements
Each year between 2007 and 2012, and again from 2018 through 2023, our management put forward proposals to eliminate the company’s classified board structure. The proposals have not passed because they failed to receive a “supermajority vote” of 80 percent of the outstanding shares of our common stock, as required in the company’s articles of incorporation. In addition, each year from 2011 through 2013, and again from 2019 through 2023, we submitted management proposals to eliminate the supermajority voting requirements. Those proposals also did not receive the required 80 percent vote. In the last five years, the vote in support was approximately 70 percent of our outstanding shares.

After considering the interests of the company and our shareholders, we have resubmitted for consideration at the Annual Meeting management proposals to eliminate the classified board structure and supermajority voting requirements (see Items 4 and 5).

We will continue to engage with our shareholders on these and other topics to ensure that we continue to demonstrate strong corporate governance and accountability to shareholders.

Shareholder Proposals

Shareholder Proposals under Rule 14a-8
Shareholders interested in submitting a proposal considered for inclusion in the proxy statement for the 2024 annual meeting must follow the procedures set forth in Rule 14a-8 under the Securities Exchange Act of 1934. Proposals should be addressed to the General Counsel and Secretary and mailed to Lilly Corporate Center, Indianapolis, IN 46285. For convenience, emailed copies may also be sent to shareholderproposals@lilly.com. In general, to be eligible for inclusion in the proxy statement for the 2025 annual meeting, shareholder proposals must be received no later than November 22, 2024.

Other Shareholder Proposals
In addition, under section 1.8 of the company’s bylaws, any shareholder of record wishing to propose business (other than pursuant to Rule 14a-8 or related to the nomination of directors) at the 2025 annual meeting of
shareholders, must give the company written notice no later than the close of business on November 22, 2024, and no earlier than the close of business on September 23, 2024. However, if the date of the 2025 annual meeting is changed by more than 30 days from May 5, 2025 (the date contemplated for the 2025 annual meeting as set forth in this proxy statement), a shareholder must give the company written notice no later than the close of business on the later of 120 days in advance of the 2025 annual meeting or 10 days following the date we first publicly announce the date of the 2025 annual meeting. Any such notice must also comply with the timing, disclosure, procedural and other requirements as set forth in the bylaws. A copy of the bylaws is available online at lilly.com/leadership/governance.

Ownership of Company Stock

Common Stock Ownership by Directors and Executive Officers

The following table sets forth the number of shares of company common stock beneficially owned by directors, named executive officers, and all directors and executive officers as a group, as of February 28, 2024. On February 28, 2024, there were 950,766,100 shares of the company’s common stock outstanding. None of the stock or stock units owned by any of the listed individuals has been pledged as collateral for a loan or other obligation.

<table>
<thead>
<tr>
<th>Beneficial Owners</th>
<th>Shares Owned</th>
<th>Stock Units Distributable Within 60 Days</th>
<th>Percent of Class</th>
<th>Stock Units Not Distributable Within 60 Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ralph Alvarez</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>53,906</td>
</tr>
<tr>
<td>Anat Ashkenazi</td>
<td>42,521</td>
<td>—</td>
<td>*</td>
<td>18,203</td>
</tr>
<tr>
<td>Katherine Baicker, Ph.D.</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>22,710</td>
</tr>
<tr>
<td>J. Erik Frywald</td>
<td>100</td>
<td>—</td>
<td>*</td>
<td>71,786</td>
</tr>
<tr>
<td>Anat Hakim</td>
<td>30,479</td>
<td>—</td>
<td>*</td>
<td>6,704</td>
</tr>
<tr>
<td>Mary Lynne Hedley</td>
<td>346</td>
<td>—</td>
<td>*</td>
<td>1,201</td>
</tr>
<tr>
<td>Jamere Jackson</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>8,810</td>
</tr>
<tr>
<td>Kimberly H. Johnson</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>2,597</td>
</tr>
<tr>
<td>William G. Kaelin, Jr., M.D.</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>21,064</td>
</tr>
<tr>
<td>Juan R. Luciano</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>15,612</td>
</tr>
<tr>
<td>David A. Ricks</td>
<td>687,161</td>
<td>—</td>
<td>*</td>
<td>36,314</td>
</tr>
<tr>
<td>Marschall S. Runge, M.D., Ph.D.</td>
<td>202</td>
<td>—</td>
<td>*</td>
<td>16,421</td>
</tr>
<tr>
<td>Daniel Skovronsky, M.D., Ph.D.</td>
<td>193,738</td>
<td>—</td>
<td>*</td>
<td>12,290</td>
</tr>
<tr>
<td>Gabrielle Sulzberger</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>2,098</td>
</tr>
<tr>
<td>Jake Van Naarden</td>
<td>20,489</td>
<td>—</td>
<td>*</td>
<td>4,134</td>
</tr>
<tr>
<td>Karen Walker</td>
<td>—</td>
<td>—</td>
<td>*</td>
<td>5,919</td>
</tr>
<tr>
<td><strong>All directors and current executive officers as a group (24 people):</strong></td>
<td><strong>1,194,105</strong></td>
<td>—</td>
<td>*</td>
<td><strong>350,050</strong></td>
</tr>
</tbody>
</table>

* Less than 1.0 percent of the outstanding common stock of the company.

1 The sum of the “Shares Owned” and “Stock Units Distributable Within 60 Days” columns represents the shares considered “beneficially owned” for purposes of disclosure in this proxy statement. Unless otherwise indicated in a footnote, each person listed in the table possesses sole voting and sole investment power with respect to their shares.

2 This column includes the number of shares of common stock held directly or indirectly, including the number of 401(k) Plan shares held by the beneficial owners indirectly through the 401(k) Plan.

3 This column sets forth restricted stock units that vest within 60 days of February 28, 2024.

4 For the executive officers, this column reflects restricted stock units that will not vest within 60 days of February 28, 2024. For the non-employee directors, this column reflects the number of units representing the right to receive shares of company stock credited to the directors’ accounts in the Lilly Directors’ Deferral Plan.

5 The shares shown for Mr. Ricks include 68,216 shares that are owned by a family foundation for which he is a director. Mr. Ricks has shared
Common Stock Ownership of Certain Beneficial Holders

The following table sets forth the number of shares of company common stock beneficially owned as of December 31, 2023, unless otherwise indicated, by each person known to the company to beneficially own more than 5 percent of the outstanding shares of the company’s common stock:

<table>
<thead>
<tr>
<th>Name and Address</th>
<th>Number of Shares Beneficially Owned</th>
<th>Percent of Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lilly Endowment Inc. (the Endowment) 2801 North Meridian Street Indianapolis, IN 46208</td>
<td>99,768,810</td>
<td>10.5%</td>
</tr>
<tr>
<td>The Vanguard Group 100 Vanguard Blvd. Malvern, PA 19355</td>
<td>71,604,696</td>
<td>7.5%</td>
</tr>
<tr>
<td>BlackRock, Inc. 55 East 52nd Street New York, NY 10055</td>
<td>64,376,027</td>
<td>6.8%</td>
</tr>
<tr>
<td>The PNC Financial Services Group, Inc. 300 Fifth Avenue Pittsburgh, PA 15222</td>
<td>51,540,105</td>
<td>5.4%</td>
</tr>
</tbody>
</table>

* Percent of class is calculated based on the shares of our common stock outstanding as of February 28, 2024.

1 Based on information provided to Lilly by the Endowment as of January 16, 2024, and a Schedule 13G/A filed by the Endowment with the SEC on January 26, 2024, the Endowment has sole voting and sole dispositive power with respect to all of its shares.

2 Based solely on the Schedule 13G/A filed with the SEC on February 13, 2024, by The Vanguard Group, it beneficially owns 71,604,696 shares altogether.

3 Based solely on the Schedule 13G/A filed with the SEC on February January 29, 2024, by BlackRock, Inc., it has sole voting power with respect to 58,375,051 of its shares and sole dispositive power with respect to 64,376,027 of its shares.

4 Based solely on the Schedule 13G/A filed with the SEC on February 9, 2024, by The PNC Financial Services Group, Inc.; PNC Bank, National Association; PNC Delaware Trust Company; PNC Ohio Trust Company; and PNC Investments LLC (collectively, PNC), PNC beneficially owns 51,540,105 shares in total. PNC has sole voting power with respect to 1,508,279 of its shares and shared voting power with respect to 50,005,466 of its shares. PNC has sole dispositive power with respect to 1,227,861 of its shares and shared dispositive power with respect to 50,267,100 of its shares. Of the total shares of common stock reported for PNC above, 50,000,000 shares are held in the Eli Lilly and Company Compensation Trust account for which PNC Bank serves as directed trustee. As directed trustee, PNC Bank is deemed to share both voting power and investment discretion with respect to those 50,000,000 shares.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our directors and executive officers and persons who own more than 10% of a registered class of our equity securities to file reports of ownership of, and transactions in, our equity securities with the SEC. Based on a review of the copies of these reports, and on written representations from our reporting persons, we believe that all such reports were timely filed, except that certain shares that are held in trust by Ms. Hedley for the benefit of her family members, were inadvertently omitted from her original, timely Form 3.

Compensation

Item 2. Advisory Vote on Compensation Paid to Named Executive Officers

Section 14A of the Securities Exchange Act of 1934 provides the company’s shareholders with the opportunity to approve, on an advisory basis, the compensation of the company’s named executive officers as disclosed in this proxy statement. Our compensation philosophy is designed to attract, engage, and retain highly talented individuals from a variety of backgrounds and motivate them to create long-term shareholder value by achieving
top-tier corporate performance while embracing the company’s core values of integrity, excellence, and respect for people.

The Talent and Compensation Committee and the board believe that our executive compensation aligns well with our philosophy and with corporate performance. Executive compensation is an important matter for our shareholders. We routinely review our compensation practices and engage in ongoing dialogue with our shareholders to ensure our practices are aligned with stakeholder interests and reflect best practices.

We request shareholder approval, on an advisory basis, of the compensation of the company's named executive officers as disclosed in this proxy statement. As an advisory vote, this proposal is not binding on the company. However, the Talent and Compensation Committee values input from shareholders and will consider the outcome of the vote when making future executive compensation decisions.

RECOMMENDATION FOR

The board recommends that you vote FOR the approval, on an advisory basis, of the compensation paid to the named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the CD&A, the compensation tables, and related narratives provided below in this proxy statement.

Talent and Compensation Committee Matters

Background

Role of the Independent Consultant in Assessing Executive Compensation

The Talent and Compensation Committee has retained Frederic W. Cook & Co., Inc. (FW Cook) as its independent compensation consultant. FW Cook reports directly to the Talent and Compensation Committee, and it is not permitted to have any business or personal relationship with management or members of the Talent and Compensation Committee. FW Cook’s responsibilities are to:

• review the company’s total compensation philosophy, peer group, and target competitive positioning for reasonableness and appropriateness;
• review the company’s executive compensation program and advise the Talent and Compensation Committee of evolving best practices;
• provide independent analyses and recommendations to the Talent and Compensation Committee on the CEO’s pay;
• review the CD&A and related tables for the proxy statement;
• proactively advise the Talent and Compensation Committee on best practices for board governance of executive compensation; and
• undertake special projects at the request of the Talent and Compensation Committee or its chair.

FW Cook interacts directly with members of company management only on matters under the Talent and Compensation Committee’s oversight and with the knowledge and permission of the Talent and Compensation Committee chair.

Role of Executive Officers and Management in Assessing Executive Compensation

With the oversight of the CEO and the executive vice president of human resources and diversity, the company’s global compensation group formulates recommendations on compensation philosophy, plan design, and compensation for executive officers (other than the CEO, as noted below). The CEO provides the Talent and Compensation Committee with a performance assessment and compensation recommendation for each of the other executive officers. The Talent and Compensation Committee considers those recommendations with the assistance of its compensation consultant FW Cook. The CEO and the executive vice president of human resources and diversity attend Talent and Compensation Committee meetings; however, they are not present for executive sessions or any discussion of their own compensation. Only non-employee directors and the Talent and Compensation Committee’s consultant attend executive sessions.

The CEO does not participate in the formulation or discussion of his pay recommendations. He has no prior knowledge of the recommendations that FW Cook makes to the Talent and Compensation Committee.
Risk Assessment Process

As part of the company’s overall enterprise risk management program, in 2023, with consultation from the independent compensation consultant, the Talent and Compensation Committee reviewed the company’s compensation policies and practices and concluded that the programs and practices are not reasonably likely to have a material adverse effect on the company. The Talent and Compensation Committee noted numerous policy and design features of the company’s compensation programs and governance structure that reduce the likelihood of inappropriate or excessive risk-taking, including, but not limited to:

- Only independent directors serve on the Talent and Compensation Committee.
- The Talent and Compensation Committee engages its own independent compensation consultant.
- The Talent and Compensation Committee has downward discretion to lower compensation plan payouts.
- The Talent and Compensation Committee approves all adjustments to financial results that affect compensation calculations.
- Different measures and metrics are used across multiple incentive plans that appropriately balance cash/stock, fixed/variable pay, and short-term/long-term incentives.
- Incentive plans have predetermined maximum payouts.
- Performance objectives are challenging but achievable.
- Programs with operational metrics have a continuum of payout multiples based upon achievement of performance milestones, rather than “cliffs” that might encourage suboptimal or improper behavior.
- A compensation recovery policy is in place that complies with applicable NYSE listing standards, and additionally provides for discretionary recoupment in the event of misconduct.
- Meaningful share ownership and retention requirements are in place for all members of senior management and the board.

Talent and Compensation Committee Report

The Talent and Compensation Committee evaluates and establishes compensation for executive officers and oversees the deferred compensation plan, management stock plans, and other management incentive and benefit programs. Management has the primary responsibility for the company’s financial statements and reporting process, including the disclosure of executive compensation in the CD&A. With this in mind, the Talent and Compensation Committee has reviewed and discussed the CD&A with management. Based on this discussion, the Talent and Compensation Committee recommended to the board that the CD&A be included in this proxy statement and incorporated by reference into the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for filing with the SEC.

Talent and Compensation Committee

Ralph Alvarez, Chair
J. Erik Fyrwald
Kimberly H. Johnson
Juan R. Luciano
Karen Walker

Compensation Discussion and Analysis

This CD&A describes our executive compensation philosophy, the Talent and Compensation Committee’s process for setting executive compensation, the elements of our compensation program, the factors the Talent and Compensation Committee considered when setting executive compensation for 2023, and how the company’s results affected incentive payouts. This CD&A provides compensation information for our chief executive officer, David Ricks, our chief financial officer, Anat Ashkenazi, and our next three most highly compensated executive officers who were serving as executive officers on December 31, 2023, Daniel Skovronsky, Anat Hakim, and Jake Van Naarden.
Our Philosophy on Compensation

At Lilly, our purpose is to unite caring with discovery to create medicines that make life better for people around the world. To do this, we must attract, engage, and retain highly talented individuals from a variety of backgrounds and motivate them to create long-term shareholder value by achieving top-tier corporate performance while embracing the company’s core values of integrity, excellence, and respect for people. Our compensation programs are designed to help us achieve these goals while balancing the long-term interests of our shareholders and customers.

Objectives

Our compensation and benefits programs are based on the following objectives:

- **Reflect individual and company performance:** We reinforce a high-performance culture by linking pay with individual and company performance. As employees assume greater responsibilities, the proportion of total compensation based on absolute company performance, relative company performance, and shareholder returns increases. We perform annual reviews to ensure our programs provide an incentive to deliver long-term, sustainable business results while discouraging excessive risk-taking or other adverse behaviors.

- **Attract and retain talented employees:** Compensation opportunity is market competitive and reflects the level of job impact and responsibilities. Retention of talent is an important factor in the design of our compensation and benefit programs.

- **Implement broad-based programs:** While the amount of compensation paid to employees varies, the overall structure of our compensation and benefit programs is broadly similar across the organization to encourage and reward all employees who contribute to our success.

- **Consider shareholder input:** Management and the Talent and Compensation Committee consider the results of our annual say-on-pay vote and other sources of shareholder feedback when designing executive compensation and benefit programs.
Say-on-Pay Results
At our 2023 annual meeting of shareholders, greater than 95 percent of the votes cast were in favor of the company’s say-on-pay proposal on executive compensation. Management and the Talent and Compensation Committee view this vote as supportive of the company’s overall approach toward executive compensation.

Talent and Compensation Committee’s Processes and Analyses

Setting Compensation
The Talent and Compensation Committee considers individual performance assessments, compensation recommendations from the CEO (with respect to each of the other executive officers), company performance, peer group data, input from its compensation consultant, feedback from shareholders, and its own judgment when determining compensation for the company’s executive officers.

- **Individual performance:**
  - **CEO:** The independent directors, under the direction of the lead independent director, meet with the CEO at the beginning of each year to establish the CEO’s performance objectives. At the end of the year, the independent directors meet to assess the CEO’s achievement of those objectives along with other factors, including contribution to the company’s performance, environmental, social and governance matters, ethics, and integrity. This evaluation is used in setting the CEO’s total direct compensation target.
  - **Other Executives:** The Talent and Compensation Committee receives individual performance assessments and target compensation recommendations from the CEO for each of the remaining executive officers. Each executive officer’s performance assessment is based on the achievement of objectives established at the start of the year, as well as other factors, including contribution to the company’s performance, environmental, social and governance matters, ethics, and integrity. The Talent and Compensation Committee considers these inputs, its knowledge of and interactions with each executive officer, and its judgment to develop a final individual performance assessment. For new executive officers, target compensation is set by the Talent and Compensation Committee at the time of appointment.

- **Company performance:** Lilly performance is considered in multiple ways:
  - Overall prior year performance is a factor in setting target compensation for the upcoming year.
  - At the beginning of each calendar year, annual performance goals are established and approved by the Talent and Compensation Committee. Performance against these annual goals is used to determine the short-term cash incentive payout.
  - Prior to the annual equity grant, multi-year performance goals are established and approved by the Talent and Compensation Committee. Performance against these multi-year objectives is used to determine the long-term incentive equity payout.

- **Peer group analysis:** The Talent and Compensation Committee uses data from the peer group described below as a market check for compensation decisions but does not use these data as the sole basis for its compensation targets and does not target a specific position within that range of market data.

- **Input from independent compensation consultant:** The Talent and Compensation Committee considers the advice of its independent compensation consultant, FW Cook, when setting executive officer compensation.

Competitive Pay Assessment
Lilly’s peer group is composed of companies that directly compete with Lilly, use a similar business model, and employ people with the unique skills required to operate an established biopharmaceutical company. The Talent and Compensation Committee selects a peer group whose median market cap and revenue are broadly like Lilly’s. The Talent and Compensation Committee reviews and approves the peer group at least every three years, and the Chair and independent compensation consultant review the peer group annually. The Talent and Compensation Committee approved the following peer group in May 2021 for purposes of assessing competitive pay:
At the time of the review, all peer companies were no greater than two times our revenue or market cap except Johnson & Johnson and Roche. The Talent and Compensation Committee included these two companies despite their size because they compete directly with Lilly, have similar business models, and seek to hire from the same pool of management and scientific talent.

When determining pay levels for target compensation, the Talent and Compensation Committee considers an analysis of market competitive pay for each executive officer position, along with internal factors such as the performance and experience of each executive officer, and the CEO’s recommendations for executives other than himself. The independent compensation consultant for the Talent and Compensation Committee provides a similar analysis when recommending pay levels for the CEO. The CEO analysis includes a comparison of our CEO’s actual total direct compensation in the prior year to company performance on an absolute and relative basis. The analysis also includes a comparison of current target total direct compensation for our CEO to recently available data on CEO target total direct compensation for our peer group with an emphasis on peers that are headquartered in the United States. On average, the named executive officers’ target total direct compensation for 2023 was comparable to the median of the peer group.

**Components of Our Compensation**

Our 2023 executive compensation was primarily composed of three components:

- base salary;
- annual cash bonus, which is generally based on company performance relative to internal targets for revenue, EPS, and the progress of our pipeline; and
- three different forms of equity incentives:
  - performance award, which is a performance-based equity award that vests over three years. Payout is based on the company’s two-year growth in EPS relative to the median external analyst-anticipated peer group EPS growth. After the two-year performance period, the performance-adjusted shares are then subject to a 13-month service-vesting period.
  - shareholder value award, which is a performance-based equity award that pays out based on absolute company stock price growth measured over a three-year period, followed by a one-year holding period.
  - relative value award, which is a performance-based equity award that pays out based on company TSR results relative to peers measured over a three-year period, followed by a one-year holding period.

Executives also receive a company benefits package, described below under “Other Compensation Practices and Information—Employee Benefits.”

**Adjustments to Reported Financial Results**

The Talent and Compensation Committee has the authority to adjust the company’s reported revenue and EPS upon which incentive compensation payouts are determined to eliminate the distorting effect of unusual income or expense items. The adjustments are intended to:

- align award payments with the underlying performance of the core business;
- avoid volatile, artificial inflation or deflation of awards due to unusual items during the performance period;
- eliminate certain counterproductive short-term incentives—for example, incentives to refrain from acquiring new technologies, to defer disposing of underutilized assets, or to defer settling legacy legal proceedings to protect current bonus payments; and
- facilitate comparisons with peer companies.

The Talent and Compensation Committee considers the adjustments approved by the Audit Committee for reporting non-GAAP EPS and other adjustments, based on guidelines approved by the Talent and Compensation Committee. The Talent and Compensation Committee reviews and approves adjustments on a quarterly basis and may adjust payouts for items, including but not limited to, the impact of significant acquisitions or divestitures, the impact of share repurchases that differ significantly from business plan, and large swings in foreign exchange rates. Further details on the adjustments for 2023 and the rationale for making these adjustments are set forth in “Appendix A, Summary of Adjustments Related to the Annual Cash Bonus and Performance Award.” For ease of
reference, throughout the CD&A and the other compensation disclosures, we refer to “revenue”, “EPS”, and “adjusted non-GAAP EPS”, but we encourage you to review the information in Appendix A to understand the adjustments from reported revenue and EPS that were approved.

The Talent and Compensation Committee has general authority to apply downward discretion to bonus, performance award, shareholder value award, and relative value award payouts for individual or all executive officers.

1. Base Salary
In setting salaries, Lilly seeks to retain, motivate, and reward successful performers while maintaining affordability within the company’s business plan. Base salaries are reviewed and established annually and may be adjusted upon promotion, following a change in job responsibilities, or to maintain market competitiveness. Salaries are compared annually with peer group data and are based on each person’s level of contribution, responsibility, expertise, experience, performance over time, and competitiveness.

If an executive officer’s salary is deemed competitive given their experience and performance, no salary increase is provided.

2. Annual Cash Bonus (Bonus Plan)
The Bonus Plan is designed to reward the achievement of the company’s annual financial and innovation objectives. All the named executive officers participated in the Bonus Plan during 2023.

The Talent and Compensation Committee sets Bonus Plan performance goals and individual bonus targets at the beginning of each year. The bonus is based on three areas of company performance measured relative to internal targets: revenue, EPS, and pipeline progress. The annual cash bonus payout is calculated as follows:

\[
\text{bonus multiple} = \text{base salary earnings} \times \text{individual bonus target} \times \text{bonus multiple}
\]

Actual payouts can range from 0 to 200 percent of an individual’s bonus target. The Talent and Compensation Committee references the annual operating plan and pipeline objectives to establish performance targets and to assess the relative weighting for each objective. In 2023, the performance measures and weightings remained unchanged from the prior year:

<table>
<thead>
<tr>
<th>Lilly 2023 Goals</th>
<th>Weighting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue performance</td>
<td>25%</td>
</tr>
<tr>
<td>EPS performance</td>
<td>50%</td>
</tr>
<tr>
<td>Pipeline progress</td>
<td>25%</td>
</tr>
</tbody>
</table>

Based on this weighting, the company bonus multiple is calculated as follows:

\[
25\% \times \text{revenue multiple} + 50\% \times \text{EPS multiple} + 25\% \times \text{pipeline multiple} = \text{bonus multiple}
\]

3. Equity Incentives
The company grants three types of equity incentives to executives and certain other employees: performance awards that are designed to focus leaders on multi-year operational performance relative to peer companies, shareholder value awards that are intended to align earned compensation with long-term growth in shareholder value, and relative value awards which encourage TSR outperformance compared to our peer group. These awards, when considered together, align with shareholder interests by incenting long-term operational excellence, shareholder return, and peer company outperformance without encouraging excessive risk-taking behaviors.

Performance Awards
Performance awards vest after three years. Payouts are based on achieving EPS growth targets over a two-year performance period, followed by an additional 13-month service-vesting period for executive officers. During the service-vesting period, the award is held in the form of restricted stock units. The growth-rate targets are set relative to the median external analyst-anticipated EPS growth for our peer group over the same performance period. These awards do not accumulate dividends during the two-year performance period, but they do
accumulate dividend equivalent units during the service-vesting period.

The Talent and Compensation Committee believes EPS growth is an effective measure of operational performance because it is closely linked to shareholder value, is broadly communicated to the public, is understood by Lilly employees, and allows for comparisons to the performance of Lilly's peer group. Consistent with the objectives established by the Talent and Compensation Committee, Lilly company performance exceeding the expected peer group median results in above-target payouts, while Lilly company performance lagging the expected peer group median results in below-target payouts. Possible payouts range from 0 percent to 200 percent of the target number of shares, depending on Lilly EPS performance over the performance period.

The measure of EPS used in the performance award program differs from the measure used in the Bonus Plan in two ways. First, the EPS goal in the Bonus Plan is set with reference to internal goals that align to our annual operating plan, while the EPS goal in the performance award program is set based on the external analyst-anticipated EPS growth rates of our peer group. Second, the Bonus Plan measures EPS over a one-year period, while the performance award program measures EPS over a two-year period. In any given year, the Bonus Plan may pay above target while the performance award pays below target (or vice versa).

Shareholder Value Awards
Shareholder value awards are earned based on Lilly’s share price performance. Shareholder value awards pay above target if Lilly’s stock outperforms an expected rate of return and below target if Lilly’s stock underperforms that expected rate of return. The expected rate of return is based on the three-year TSR that a reasonable investor would consider appropriate when investing in a basket of large-cap U.S. companies, as determined by the Talent and Compensation Committee. The minimum price to achieve target is calculated by multiplying the starting share price of Lilly’s stock by the three-year compounded expected rate of return less Lilly’s dividend yield. Shareholder value awards have a three-year performance period, and any shares paid are subject to a one-year holding requirement. No dividends are accrued during the performance period. Possible payouts are based on share price growth and range from 0 to 200 percent of the target number of shares. Executive officers receive no payout if Lilly’s TSR for the three-year period is zero or negative.

Relative Value Awards
Relative value awards are earned based on Lilly’s TSR performance relative to our peer group. The minimum performance to achieve target is a TSR that is equal to the median TSR performance for the peer group. Relative value awards have a three-year performance period, and any shares paid are subject to a one-year holding requirement. No dividends are accrued during the performance period. Executive officers receive no payout if Lilly’s TSR for the three-year period is 24 or more percentage points below the median TSR performance for the peer group over the same time period. Possible payouts range from 0 to 200 percent of the target number of shares.

Pay for Performance
The mix of compensation for our named executive officers reflects Lilly’s desire to link executive compensation with individual and company performance. As reflected in the charts below, a substantial portion of the target pay for executive officers is performance-based. The annual cash bonus and equity payouts are contingent upon company performance, with the bonus factoring in performance over a one-year period, and equity compensation factoring in performance over multi-year periods. The charts depict the annualized mix of target compensation for Lilly’s CEO and the annualized average for Ms. Ashkenazi, Dr. Skovronsky, Ms. Hakim, and Mr. Van Naarden.
Target Total Compensation

Performance Review Process
In setting 2023 target compensation for the named executive officers, the Talent and Compensation Committee considered individual contributions, Lilly’s performance during 2022, internal relativity, peer group data, and input from the CEO for named executive officers other than himself.

Evaluation of Individual Named Executive Officer Performance
A summary of the Talent and Compensation Committee’s review of individual named executive officer performance in 2022 that influenced decisions on 2023 target compensation is provided below:

David Ricks, Chair, President, and CEO:
In accordance with the company’s corporate governance guidelines, the independent directors assessed Mr. Ricks’ performance led by the lead independent director. The independent directors believe the company largely met or exceeded its combined financial and strategic goals for 2022 under Mr. Ricks’ leadership. In 2022, Mr. Ricks and his team:

• Launched Mounjaro in the U.S. for the treatment of type 2 diabetes, and launched 30 new indications for already-marketed medicines to patients around the world, including Olumiant for alopecia areata and an alternate formulation of Taltz;
• Progressed nine and three potential new medicines into Phase 1 and Phase 2 clinical development, respectively, from both internal research and external sources;
• Initiated regulatory submissions for (i) tirzepatide for obesity and donanemab for Alzheimer’s Disease, with both being accepted for priority review by the FDA and (ii) pirtobrutinib, mirikizumab, and lebrikizumab;
• Continued contributions toward the fight against the global COVID-19 pandemic, including developing SARS-CoV-2 neutralizing antibodies and striving to protect the health and safety of Lilly employees who provided lifesaving medicines to people around the world;
• Completed numerous pre-clinical and new modality business development transactions to complement and expand internal research efforts, including the acquisition of Akouos to expand the company’s pipeline and capabilities with respect to genetic medicine;
• Continued to drive a cross-company productivity agenda resulting in savings that funded increased investment in research and development and commercialization of key medicines;
• Drove the company’s health equity strategy by spearheading numerous programs, including “Dip-In”, a program in Indianapolis to address differences of life expectancy based on access to healthcare and medicines and increasing the percentage of under-represented minorities in our clinical trials;
• Implemented a strategy that improved inclusion across the company, increased the representation of women and minorities in management and conducted pay equity studies to promote equality in pay. The company was ranked #5 on the DiversityInc Top 50 Companies for Diversity. Additionally, led the company’s comprehensive Racial Justice Commitment to help improve equity within Lilly and the communities in which it operates;
• Continued making progress toward Lilly’s environmental goals, including absolute reductions in greenhouse gas emissions, continued focus on diversification of energy sources, and achievement of zero-landfill targets at certain facilities; and
• The company was named one of the world’s most ethical companies by the Ethisphere Institute.

Anat Ashkenazi, Executive Vice President and Chief Financial Officer:
Ms. Ashkenazi has made numerous contributions to the strong financial performance of the company. In 2022, Ms. Ashkenazi:
• Played a key role in the company achieving its financial targets in 2022, and drove the company’s strategic planning and 2023 business planning process;
• Established a strong foundation from which to drive execution;
• Championed the company’s productivity agenda throughout 2022 and during the company’s strategic and operational planning processes;
• Led the capital allocation process allowing for investment in several business development transactions (including the acquisition of Akouos), increased funding for the advancement of new medicines through clinical development, and allocated resources to fund the potential launch of new medicines in 2023;
• Continued to build excellent rapport and represent the company with the investment community;
• Served as executive sponsor of Lilly’s Veteran Network, an employee resource group focused on recruiting and advancing people who served in the military.

Daniel Skovronsky, M.D., Ph.D., Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology:
Dr. Skovronsky advanced innovation for patients as the company's chief scientific and medical officer. In 2022, Dr. Skovronsky:
• Advanced innovative medicines through the product pipeline leading to the approval of Mounjaro in the U.S. for the treatment of type 2 diabetes, and 30 new indications for already-marketed medicines to patients around the world, including Olumiant for alopecia areata and an alternate formulation of Taltz;
• Progressed Lilly’s pipeline through achieving nine new Phase 1 entries, three new molecular entities, and eight new indications across our portfolio products;
• Initiated regulatory submissions for (i) tirzepatide for obesity and donanemab for Alzheimer's Disease, with both being accepted for priority review by the FDA and (ii) pirtobrutinib, mirikizumab, and lebrikizumab;
• Achieved industry leading product development cycle times, clinical success rates above the industry benchmark, and a highly valuable pipeline;
• Delivered several significant positive data readouts including for tirzepatide in obesity, donanemab, mirikizumab, and pirtobrutinib;
• Led numerous pre-clinical and new modality business development transactions to complement and expand internal research efforts, including the acquisition of Akouos to build the company’s product pipeline and capabilities in gene therapy;
• Led the company’s efforts in the fight against SARS-CoV-2, including developing SARS-CoV-2 neutralizing antibodies;
• Drove improvements in the company’s health equity strategy by increasing the percentage of under-represented minorities who participate in our clinical trials and the percentage of under-represented physicians who participate as investigators;
• Led inclusion strategies in research and development to improve innovation and productivity by promoting diversity in talent recruitment; and
• Served as executive sponsor of Lilly’s Chinese Culture Network.

Anat Hakim, Executive Vice President, General Counsel and Secretary:
Ms. Hakim was effective and influential as general counsel in 2022, and she was a productive partner with the executive team. In 2022, Ms. Hakim:

• Successfully defended several key patents around the world;
• Developed and implemented legal strategies in the areas of business development, intellectual property protection, product liability, regulatory reform and pharmaceutical pricing;
• Continued to drive a transformation effort to increase the capability of the company’s law division with emphasis on acquiring and protecting intellectual property;
• Provided invaluable legal counsel through numerous business development activities;
• Influenced the company’s ethics and compliance programs globally to help ensure the company lives its long-standing value of integrity;
• Partnered with the chief information and digital officer on cyber security efforts; and
• Served as executive sponsor of the company’s Women Leading in Lilly, an employee resource group.

Jake Van Naarden, Executive Vice President and President Loxo@Lilly:
Mr. Van Naarden demonstrated strong leadership of Loxo@Lilly, driving an effective strategy and strong execution. In 2022, Mr. Van Naarden:

• Established Loxo@Lilly as a fully integrated business unit, allowing for increase speed and focus across our oncology portfolio;
• Managed an oncology portfolio that exceeded its overall sales plan through strong growth of Verzenio and optimized Alimta commercial outcomes through patent expiry via effective contracting strategy;
• Directed a more focused strategy with Retevmo, including additional support in identifying patients who would benefit from targeted therapies;
• Generated positive movement in the pipeline, contributed to the advancement of pirtobrutinib for mantle cell lymphoma (MCL) and Retevmo for tumor-agnostic RET fusion-positive advanced or metastatic solid tumors; and
• Was a highly effective partner across our leadership team and provided valuable input and perspective across our discovery and development platforms.

Target Compensation
The information below reflects total compensation at target for named executive officers. The actual compensation received is summarized below in “Compensation Results.”

Rationale for Changes to Named Executive Officer Target Compensation
The Talent and Compensation Committee established the 2023 target total compensation for each named executive officer based on the named executive officer’s 2022 performance, internal relativity, and peer group data.

Base Salary
The following table shows the approved annualized salary for each named executive officer. Base pay amounts were adjusted for all named executive officers to align pay with their level of experience, internal relativity, peer group market data and individual performance. Each named executive officer’s actual base salary earned during
2023 is reflected in the Summary Compensation Table (SCT) in the “Executive Compensation” section of this proxy statement.

<table>
<thead>
<tr>
<th>Name</th>
<th>2022 Annual Base Salary Effective March 6, 2022</th>
<th>2023 Annual Base Salary Effective March 5, 2023</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>$1,500,000</td>
<td>$1,650,000</td>
<td>10.0%</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>$950,000</td>
<td>$1,050,000</td>
<td>10.5%</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>$1,250,000</td>
<td>$1,350,000</td>
<td>8.0%</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>$900,000</td>
<td>$1,000,000</td>
<td>11.1%</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>$750,000</td>
<td>$850,000</td>
<td>13.3%</td>
</tr>
</tbody>
</table>

**Annual Cash Bonus Targets**

Based on a review of internal relativity, peer group market data, and individual performance, the Talent and Compensation Committee retained the same percent-of-salary bonus targets as in 2022 for Mr. Ricks, Ms. Ashkenazi, Dr. Skovronsky, Ms. Hakim, and Mr. Van Naarden. The 2022 and 2023 Bonus targets were:

<table>
<thead>
<tr>
<th>Name</th>
<th>2022 Bonus Target</th>
<th>2023 Bonus Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>150%</td>
<td>150%</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Equity Incentives - Target Grant Values**

For 2023 equity grants, the Talent and Compensation Committee set the total target values for named executive officers based on internal relativity, peer group market data and individual performance. Named executive officers have 35 percent of their equity target allocated to shareholder value awards and relative value awards, respectively, and 30 percent to performance awards. Total target values for the 2022 and 2023 equity grants to the named executive officers were as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>2022 Annual Equity Grant</th>
<th>2023 Annual Equity Grant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>$16,250,000</td>
<td>$17,875,000</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>$3,000,000</td>
<td>$3,500,000</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>$5,500,000</td>
<td>$7,100,000</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>$3,000,000</td>
<td>$3,750,000</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>$1,850,000</td>
<td>$2,300,000</td>
</tr>
</tbody>
</table>

**Performance Goals for Incentive Programs**

**Annual Cash Bonus Goals**

The Talent and Compensation Committee established the company performance targets using the company’s 2023 annual operating plan, which was approved by the board in 2022. These targets are described below under “Compensation Results.”

**Performance Award**

In February 2023, the Talent and Compensation Committee established a two-year EPS growth target of 2.0 percent per year based on investment analysts’ EPS growth estimates for our peer group companies. When this growth rate was applied to the 2022 EPS baseline of $8.84, the two-year cumulative target EPS was calculated as follows:
Payouts for the 2023-2025 performance award can range from 0 to 200 percent of the target number of shares, as shown below:

### 2023-2025 Performance Award

<table>
<thead>
<tr>
<th>EPS Growth</th>
<th>Payout threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cumulative 2-Year EPS</td>
<td>-6.0%</td>
</tr>
<tr>
<td>$8.84</td>
<td>$16.12</td>
</tr>
</tbody>
</table>

### Shareholder Value Award

For purposes of establishing the stock price target for the shareholder value awards, the starting price was $363.15 per share, the average closing stock price for all trading days in November and December 2022. The target share price was established using the expected annual rate of return for large-cap companies (8.00 percent) as determined by the Talent and Compensation Committee, less an assumed Lilly dividend yield (1.25 percent). To determine payout, the ending price will be the average closing price of company stock for all trading days in November and December 2025. The award is designed to deliver no payout to executive officers if the shareholder return (including projected dividends) is zero or negative. Possible payouts based on final average share price are illustrated in the graphic below.

### 2023-2025 Shareholder Value Award

<table>
<thead>
<tr>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>0%</td>
</tr>
<tr>
<td>Final Stock Price</td>
</tr>
</tbody>
</table>

### Relative Value Award

The relative value award is based on the three-year Lilly TSR performance compared to our peer group. To determine payout, the TSR performance is calculated for Lilly and its peers. This calculation compares the average closing price of each company’s stock for all trading days in November and December 2022 to the average closing price of each company’s stock for all trading days in November and December 2025, assuming reinvestment of dividends, to obtain the TSR for each company. The median TSR for the peer companies is then subtracted from Lilly’s TSR to determine what payout has been earned. For example, if Lilly’s TSR was 55 percent over the three-year performance period and the median peer company performance was 40 percent, Lilly would have outperformed by 15 percentage points (55 percent - 40 percent). This outperformance would have resulted in a 150 percent payout based on the payout graphic below.
2023-2025 Relative Value Award

<table>
<thead>
<tr>
<th>Target</th>
<th>≤-24.0pp</th>
<th>-16.0pp</th>
<th>-8.0pp</th>
<th>Peer Median TSR</th>
<th>+7.5pp</th>
<th>+15.0pp</th>
<th>+22.5pp</th>
<th>≥30.0pp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute Percentage Point (pp) Difference from Peer Median TSR</td>
<td>0%</td>
<td>1 - 32%</td>
<td>33 - 66%</td>
<td>67 - 99%</td>
<td>100 - 124%</td>
<td>125 - 149%</td>
<td>150 - 174%</td>
<td>175 - 199%</td>
</tr>
</tbody>
</table>

Compensation Results

The information in this section reflects the amounts paid to named executive officers under the Bonus Plan and for equity awards granted in prior years for which the relevant performance period ended in 2023.

Lilly Performance

In 2023, the company exceeded our revenue target, EPS target, and pipeline goals used to set the Bonus Plan performance multiple. A subset of the 2023 pipeline progression highlights include:

- Lilly announced that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from the SURMOUNT-2 clinical trial. The study met both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimands. Those taking tirzepatide lost up to 15.7 percent (34.4 lb. or 15.6 kg) of body weight for the efficacy estimand. SURMOUNT-2 is the second global Phase 3 clinical trial that evaluated the efficacy and safety of tirzepatide for chronic weight management.
- Lilly announced results of two Phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo. Across SURMOUNT-3 and SURMOUNT-4, participants on tirzepatide following intensive lifestyle intervention or with continued tirzepatide treatment, achieved up to 26.6 percent mean weight loss, for the efficacy estimand.
- The FDA approved Lilly's Zepbound™ (tirzepatide) for adults with obesity or overweight with weight-related comorbidities, a powerful new option for the treatment of obesity or weight-related medical problems.
- The FDA approved Jaypirca™ for the treatment of adult patients with relapsed or refractory MCL after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Jaypirca was approved under the FDA's Accelerated Approval pathway based on response rate from the open-label, single-arm, international, Phase 1/2 BRUIN trial.
- The FDA approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
- The FDA approved Lilly's Omvoh™ (mirikizumab-mrkz), a first-in-class treatment for adults with moderately to severely active ulcerative colitis.
- The FDA approved an expanded indication for Verzenio, for the adjuvant treatment of adult patients with HR+, HER2-, node-positive early breast cancer at high risk of recurrence. This expanded indication removes the Ki-67 score requirement for patients.
- The FDA approved Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older.
- The FDA approved Jardiance® for the treatment of adults with chronic kidney disease.
- Lilly announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.
- Retevmo® (selpercatinib) was the first targeted therapy to demonstrate superior progression-free survival compared to a PD-1 inhibitor plus chemotherapy for adults with newly-diagnosed advanced or metastatic RET fusion-positive non-small cell lung cancer in the Phase 3 LIBRETTO-431 study.
- Retevmo® (selpercatinib) demonstrated superior progression-free survival compared to approved multikinase inhibitors in RET-mutant medullary thyroid cancer in the Phase 3 LIBRETTO-531 study.
Mirikizumab met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease.

For additional highlights, see “Proxy Statement Summary—Highlights of 2023 Performance.”

By the end of 2023, Lilly exceeded its two-year EPS growth target for the performance award, our three-year stock price growth target for the shareholder value award and the median total shareholder return of our peer companies for the relative value award. The discussion below details the measures used in each program, what the performance goal was to obtain target performance, how performance outcomes were assessed and what the Talent and Compensation Committee approved as the final payout multiple.

**Bonus Plan**
The company utilized revenue, EPS, and pipeline progress to incentivize the achievement of 2023 company objectives. Each measure contributes to the final payout multiple on a weighted basis: revenue (25 percent), EPS (50 percent), and pipeline progress (25 percent). Each performance measure is assessed a payout multiple of 0 to 200 percent.

The Science and Technology Committee’s assessment of the company’s product pipeline achievements is detailed below:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Objective</th>
<th>Achievement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approvals</td>
<td>2 new drug first approvals</td>
<td>3 new drug first approvals</td>
</tr>
<tr>
<td></td>
<td>9 other approvals</td>
<td>17 other approvals</td>
</tr>
<tr>
<td>Potential new drug Phase 3 starts</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Potential new drug Phase 1 starts</td>
<td>14-16</td>
<td>15</td>
</tr>
<tr>
<td>Potential new indication or line extension Phase 3 starts</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Plan Boldly</td>
<td>Meet industry benchmark for speed of development</td>
<td>Exceeded industry benchmark for speed of development</td>
</tr>
<tr>
<td>Deliver to Launch</td>
<td>Meet planned project timelines</td>
<td>Met project timelines</td>
</tr>
<tr>
<td>Qualitative Assessment</td>
<td>Assessment of the chief scientific and medical officer’s evaluation of performance against strategic objectives</td>
<td></td>
</tr>
<tr>
<td>Game Changer Event¹</td>
<td>Assessment by the Science and Technology Committee of the board regarding significant scientific events</td>
<td></td>
</tr>
</tbody>
</table>

¹ A Game Changer Event is a significant scientific advancement that the Science and Technology Committee deems could capture significant value for patients and for the company.

The Science and Technology Committee may also recommend that the Talent and Compensation Committee use downward discretion on the pipeline metric result if clinical development for a potential major asset is unsuccessful. The Science and Technology Committee did not recommend that the Talent and Compensation Committee exercise this discretion related to the 2023 pipeline multiple.

Based on the recommendation of the Science and Technology Committee, the Talent and Compensation Committee approved a pipeline multiple of 1.86.
The company’s strong financial performance and pipeline progress compared to targets resulted in an above target bonus multiple as illustrated below:

<table>
<thead>
<tr>
<th>Metric</th>
<th>Threshold 0%</th>
<th>Target 100%</th>
<th>Max 200%</th>
<th>Metric Multiple</th>
<th>Weight</th>
<th>Weighted Payout</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted Revenue</td>
<td>$32.45 billion</td>
<td>$30.812 billion</td>
<td>$9.14</td>
<td>2.00</td>
<td>25%</td>
<td>0.50</td>
</tr>
<tr>
<td>Adjusted Non-GAAP EPS</td>
<td>$1.86</td>
<td>$8.54</td>
<td>1.70</td>
<td>0.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pipeline</td>
<td>Various objectives (see above)</td>
<td>1.86</td>
<td>25%</td>
<td>0.47</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bonus Payout Multiple** 1.81

* The sum of weighted payouts may not add to the Bonus Payout Multiple due to rounding.

For additional information on financial results, see Appendix A, “Summary of Adjustments Related to the Annual Cash Bonus and Performance Award.”

**Bonus Payments**

The 2023 bonuses paid to the applicable named executive officers under the Bonus Plan were as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>2023 Bonus ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>$4,401,433</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>$1,865,692</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>$2,408,692</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>$1,775,192</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>$1,503,692</td>
</tr>
</tbody>
</table>

**2022-2024 Performance Awards**

The target cumulative EPS for the 2022-2024 performance award was originally set in the first quarter of 2022, reflecting expected peer group EPS growth of 6.3 percent each year and a total cumulative target EPS of $17.89 over the two-year performance period. In May 2022, following the change to its presentation of non-GAAP measures, the Talent and Compensation Committee updated the award to align with the new SEC guidance to exclude adjustments for acquired IPR&D and development milestone charges from its non-GAAP results. The updated award retained the Talent and Compensation Committee’s decision to establish a two-year EPS growth target of 6.3 percent per year, but the growth was applied to an adjusted 2021 non-GAAP EPS of $8.25 that excluded acquired IPR&D and development milestone charges. Using this methodology, the updated cumulative EPS target became $18.09 for the two-year performance period of 2022-2023. The company’s actual adjusted non-GAAP EPS over the performance period was $19.26 representing a growth rate of 10.8 percent and a final payout percentage of 128 percent.
For each named executive officer, shares earned for the 2022-2023 performance period are subject to an additional 13-month service-vesting period and are shown in the table below as restricted stock units.

<table>
<thead>
<tr>
<th>Name</th>
<th>Target Shares</th>
<th>RSUs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>20,751</td>
<td>26,561</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>3,831</td>
<td>4,904</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>7,023</td>
<td>8,989</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>3,831</td>
<td>4,904</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>2,362</td>
<td>3,023</td>
</tr>
</tbody>
</table>

The target stock price range of $180.03 to $199.69 (18.3 percent to 31.2 percent total stock price growth) for the 2021-2023 shareholder value award was set in 2021 based on a beginning stock price of $152.16, which was the average closing price for Lilly stock for all trading days in November and December 2020. The ending stock price of $587.42, which was the average closing price for Lilly stock for all trading days in November and December 2023, represents stock price growth of 286.1 percent over the relevant three-year period resulting in a payout percentage of 175 percent.

### 2021-2023 Shareholder Value Award

The target stock price range of $180.03 to $199.69 (18.3 percent to 31.2 percent total stock price growth) for the 2021-2023 shareholder value award was set in 2021 based on a beginning stock price of $152.16, which was the average closing price for Lilly stock for all trading days in November and December 2020. The ending stock price of $587.42, which was the average closing price for Lilly stock for all trading days in November and December 2023, represents stock price growth of 286.1 percent over the relevant three-year period resulting in a payout percentage of 175 percent.

### 2021-2023 Shareholder Value Award Payout

<table>
<thead>
<tr>
<th>% of Target</th>
<th>Stock Price</th>
<th>Target Shares</th>
<th>Shares Paid Out</th>
</tr>
</thead>
<tbody>
<tr>
<td>0%</td>
<td>&lt;$140.70</td>
<td>22,541</td>
<td>39,447</td>
</tr>
<tr>
<td>50%</td>
<td>$140.70 - $160.36</td>
<td>2,351</td>
<td>4,114</td>
</tr>
<tr>
<td>75%</td>
<td>$160.37 - $180.02</td>
<td>7,567</td>
<td>13,242</td>
</tr>
<tr>
<td>100%</td>
<td>$180.03 - $199.69</td>
<td>3,381</td>
<td>5,917</td>
</tr>
<tr>
<td>125%</td>
<td>$199.70 - $219.36</td>
<td>1,389</td>
<td>2,431</td>
</tr>
<tr>
<td>150%</td>
<td>$219.37 - $239.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>175%</td>
<td>&gt;$239.03</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The number of shares paid to each named executive officers for the 2021-2023 shareholder value award performance period were as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>Target Shares</th>
<th>Shares Paid Out</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>22,541</td>
<td>39,447</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>2,351</td>
<td>4,114</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>7,567</td>
<td>13,242</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>3,381</td>
<td>5,917</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>1,389</td>
<td>2,431</td>
</tr>
</tbody>
</table>

1 Ms. Ashkenazi’s and Mr. Van Naarden’s 2021-2023 shareholder value awards were granted prior to becoming an executive officer.

### 2021-2023 Relative Value Award

The relative value award is based on the three-year Lilly TSR performance compared to our peer group. To determine relative performance, the calculation compares the average closing price adjusted for dividend reinvestment of each company’s stock for all trading days in November and December 2020 to the average closing price adjusted for dividend reinvestment of each company’s stock for all trading days in November and December 2023.

<table>
<thead>
<tr>
<th>Name</th>
<th>Target Shares</th>
<th>Shares Paid Out</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>22,541</td>
<td>39,447</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>2,351</td>
<td>4,114</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>7,567</td>
<td>13,242</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>3,381</td>
<td>5,917</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>1,389</td>
<td>2,431</td>
</tr>
</tbody>
</table>

1 Ms. Ashkenazi’s and Mr. Van Naarden’s 2021-2023 shareholder value awards were granted prior to becoming an executive officer.
December 2023 to obtain the TSR for each company. The median TSR for the peer companies is then subtracted from Lilly’s TSR to determine what payout has been earned.

Lilly’s TSR over the performance period was 301.4 percent. The median TSR for the peer companies was 17.2 percent thereby making Lilly’s peer outperformance 284.2 percentage points (301.4 percent minus 17.2 percent). This level of outperformance yields a 175 percent payout as depicted in the chart below.

The number of shares paid to each named executive officer for the 2021-2023 relative value award performance period were as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>Target Shares</th>
<th>Shares Paid Out</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>17,090</td>
<td>29,908</td>
</tr>
<tr>
<td>Ms. Ashkenazi¹</td>
<td>1,918</td>
<td>3,357</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>5,738</td>
<td>10,042</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>2,564</td>
<td>4,487</td>
</tr>
<tr>
<td>Mr. Van Naarden¹</td>
<td>1,134</td>
<td>1,985</td>
</tr>
</tbody>
</table>

¹ Ms. Ashkenazi’s and Mr. Van Naarden’s 2021-2023 relative value awards were granted prior to becoming an executive officer.

Other Compensation Practices and Information

Employee Benefits
The company offers core employee benefits coverage to:

- provide our workforce with a reasonable level of financial support in the event of illness or injury,
- provide post-retirement income, and
- enhance productivity and job satisfaction through benefit programs that focus on overall well-being.

The benefit programs available to executive officers are offered to all eligible U.S. employees and include benefits such as medical and dental coverage, disability insurance, and life insurance. In addition, the 401(k) Plan and The Lilly Retirement Plan (the "Retirement Plan") are intended to provide U.S. employees a reasonable level of retirement income reflecting employees’ careers with the company. To the extent that any employee’s calculated retirement benefit exceeds Internal Revenue Service (IRS) limits for amounts that can be paid through a qualified plan, the company also offers a nonqualified pension plan ("Nonqualified Pension Plan") and a nonqualified savings plan ("Nonqualified Savings Plan"). These plans provide only the difference between the calculated benefits and the applicable IRS limits, and the formula is the same for all participating employees. The cost of employee benefits is partially borne by the employee, including each executive officer.
Perquisites
The company provides limited perquisites to executive officers. Mr. Ricks received reimbursement of HSR filings fees and was granted personal use of the corporate aircraft up to a maximum incremental cost established by the Talent and Compensation Committee as a means to (i) increase his time available for company business and (ii) protect his health and safety. The reimbursement of HSR filings fees and the incremental cost of personal use of the corporate aircraft are included as perquisites in the Summary Compensation Table under the heading “All Other Compensation.”

The Lilly Deferred Compensation Plan
Members of senior management may defer receipt of part or all of their cash compensation under The Lilly Deferred Compensation Plan (Deferred Compensation Plan), which allows them to save for retirement in a tax-effective way at minimal cost to the company. Under this unfunded plan, amounts deferred by the executive are credited at an interest rate of 120 percent of the applicable federal long-term rate, as described in more detail following the “Nonqualified Deferred Compensation in 2023” table.

Severance and Other Post-Termination Benefits
Except in the case of certain terminations following a change in control of the company, the company is generally not obligated to pay severance to executive officers upon termination of their employment; any such payments are at the discretion of the Talent and Compensation Committee. In addition, if the company chooses to enforce restrictive covenant agreements it has entered into with certain executive officers, such executive officers would be entitled to post-termination payments (absent a change in control), which payments are described and quantified in “Payments upon Termination or Change in Control” for the applicable named executive officers.

The company has adopted change-in-control severance pay plans for nearly all employees, including executive officers. The plans are intended to preserve employee morale and productivity and encourage retention in the face of the disruptive impact of an actual or rumored change in control. In addition, the plans are intended to align executive and shareholder interests by enabling executives to evaluate corporate transactions that may be in the best interests of the shareholders and other constituents of the company without undue concern over whether the transactions may jeopardize the executives’ own employment.

Highlights of Our Change-in-Control Severance Plans
• all regular employees are covered
• double trigger required
• no tax gross-ups
• up to two-year pay protection
• 18-month benefit continuation

Although benefit levels may differ depending on the employee’s job level and seniority, the basic elements of the plans are comparable for all eligible employees:

• **Double trigger:** Unlike “single trigger” plans that pay out immediately upon a change in control, our plans require a “double trigger”—a change in control followed by an involuntary loss of employment within two years. This is consistent with the plans’ intent to provide employees with financial protection upon loss of employment. With respect to unvested equity, performance to the date of the change in control will be used to determine the number of shares earned under an award, but vesting does not accelerate immediately upon a change in control. Rather, the performance-adjusted awards will convert to time-based restricted stock units that continue to vest with the new company. Shares will pay out upon the earlier of the completion of the original award period; upon a covered termination; or if the successor entity does not assume, substitute, or otherwise replace the awards.

• **Covered terminations:** Employees are eligible for payments if, within two years of the change in control, their employment is terminated (i) without cause by the company or (ii) for good reason by the employee, each as defined in the plans. See “Compensation—Executive Compensation—Payments upon Termination or Change in Control” for a more detailed discussion, including a discussion of what constitutes a change in control.
• **Employees who suffer a covered termination receive up to two years of pay and 18 months of benefits protection:** These provisions ensure employees a reasonable period of protection of their income and core employee benefits.
  
  – Severance payment. Eligible terminated employees would receive a severance payment ranging from six months' to two years' base salary. Executives are all eligible for two years' base salary plus two times the then-current year’s target bonus.
  
  – Benefit continuation. Basic employee benefits such as health, dental, life insurance and long-term disability would continue for 18 months following termination of employment, unless the individual becomes eligible for coverage with a new employer. All employees would receive an additional two years of both age and years-of-service credit for purposes of determining eligibility for retiree medical and dental benefits.

• **Accelerated vesting of equity awards:** Any unvested equity awards would vest at the time of a covered termination.

• **Excise tax:** In some circumstances, the payments or other benefits received by the employee in connection with a change in control could exceed limits established under Section 280G of the Internal Revenue Code. The employee would then be subject to an excise tax on top of normal federal income tax. The company does not reimburse employees for these taxes. However, the amount of any change-in-control-related benefit will be reduced to the 280G limit if the effect would be to deliver a greater after-tax benefit than the employee would receive with an unreduced benefit.

### Share Ownership and Retention Guidelines

Share ownership and retention guidelines help create direct alignment of interests between senior management and shareholders over the longer term. Lilly has established a formal share ownership policy under which the CEO and other senior executives are required to acquire and hold Lilly shares in an amount representing a multiple of base salary. The share ownership requirement for the CEO is 12 times his annual base salary and the share ownership requirement for the other named executive officers is 6 times their annual base salary.

Until ownership of the required number of shares is reached, an executive officer must hold 50 percent of all shares, net of tax, from all equity payouts. Executive officers are also required to hold all shares received from equity program payouts, net of taxes, for at least one year, even once share ownership requirements have been met. For performance awards granted to executive officers, this holding requirement is met by the 13-month service-vesting period after the end of the performance period.

All the named executive officers are compliant with the share ownership guidelines. The following graphic shows each respective named executive officer’s guideline, and each named executive officer’s holdings as of December 31, 2023.

#### Share Ownership and Retention Guidelines

<table>
<thead>
<tr>
<th>Executive Officer</th>
<th>12x Base Salary Ownership Requirement</th>
<th>6x Base Salary Ownership Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>199x</td>
<td>21x</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>76x</td>
<td></td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>13x</td>
<td></td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>11x</td>
<td></td>
</tr>
</tbody>
</table>

### Prohibition on Hedging and Pledging Shares

Non-employee directors and employees, including executive officers, are not permitted to hedge their economic exposures to company stock through short sales or derivative transactions. Non-employee directors and
employees, including executive officers, are prohibited from pledging any company stock (i.e., using company stock as collateral for a loan or trading shares on margin).

**Executive Compensation Recovery Policy**

Lilly has adopted a robust executive compensation recovery policy (the Executive Compensation Recovery Policy) that complies with SEC rules and applicable NYSE listing standards. Pursuant to the Executive Compensation Recovery Policy, if Lilly is required to prepare an accounting restatement, the Talent and Compensation Committee will require the recoupment of the incentive compensation overpayments to executive officers during the three fiscal years immediately preceding the date on which Lilly must prepare such accounting restatement and any transition period within or immediately following those three fiscal years in all cases subject and in accordance with the terms of the Executive Compensation Recovery Policy.

In addition, Lilly’s Executive Compensation Recovery Policy generally permits recoupment of incentive compensation (cash or equity) and/or non-qualified benefits previously granted or paid to executives (including certain non-executive officers) in the event of: (a) payments that were based on materially inaccurate assessments of performance, (b) certain financial restatements resulting from misconduct or (c) other misconduct resulting in material violations of law or company policy that causes significant harm to the company. Subsequent changes in status, including retirement or termination of employment, do not affect the company’s rights to recover compensation under the Executive Compensation Recovery Policy. Furthermore, all outstanding incentive awards and/or non-qualified benefits are subject to forfeiture or reduction in the event an executive is subject to disciplinary action by Lilly for misconduct.

The Executive Compensation Recovery Policy is administered by the Talent and Compensation Committee. The company will disclose decisions to take action pursuant to the Executive Compensation Recovery Policy in its proxy materials when required by, and in compliance with, SEC rules and regulations and other applicable laws. In addition, when legally permissible to do so, the company will disclose a decision to act under this policy when the facts and circumstances of the matter that triggered application of the policy have been publicly disclosed in the company’s filings with the SEC and where disclosure can be made without prejudicing the company and its shareholders. This summary Executive Compensation Recovery Policy does not purport to be complete and is qualified in its entirety by reference to such policy, which has been filed as Exhibit 97 of Lilly’s Form 10-K for the fiscal year ended December 31, 2023.
## Executive Compensation

### Summary Compensation Table

<table>
<thead>
<tr>
<th>Name and Principal Position</th>
<th>Year</th>
<th>Salary ($)</th>
<th>Bonus ($)</th>
<th>Stock Awards ($) ¹</th>
<th>Non-Equity Incentive Plan Compensation ($) ²</th>
<th>Change in Pension Value ($) ³</th>
<th>All Other Compensation ($) ⁴</th>
<th>Total Compensation ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>David A. Ricks</td>
<td>2023</td>
<td>$1,621,154</td>
<td>$0</td>
<td>$18,840,250</td>
<td>$4,401,433</td>
<td>$1,439,822</td>
<td>$263,073</td>
<td>$26,565,732</td>
</tr>
<tr>
<td>Chair, President, and Chief Executive Officer</td>
<td>2022</td>
<td>$1,500,000</td>
<td>$0</td>
<td>$16,981,250</td>
<td>$2,700,000</td>
<td>$0</td>
<td>$216,885</td>
<td>$21,398,135</td>
</tr>
<tr>
<td></td>
<td>2021</td>
<td>$1,500,000</td>
<td>$0</td>
<td>$14,966,000</td>
<td>$2,475,000</td>
<td>$2,442,235</td>
<td>$126,750</td>
<td>$21,509,985</td>
</tr>
<tr>
<td>Anat Ashkenazi</td>
<td>2023</td>
<td>$1,030,769</td>
<td>$0</td>
<td>$3,689,000</td>
<td>$1,865,692</td>
<td>$951,950</td>
<td>$61,846</td>
<td>$7,599,257</td>
</tr>
<tr>
<td>Executive Vice President and Chief Financial Officer</td>
<td>2022</td>
<td>$940,385</td>
<td>$0</td>
<td>$3,135,000</td>
<td>$1,128,462</td>
<td>$0</td>
<td>$56,423</td>
<td>$5,260,270</td>
</tr>
<tr>
<td></td>
<td>2021</td>
<td>$850,432</td>
<td>$0</td>
<td>$2,453,000</td>
<td>$906,894</td>
<td>$395,335</td>
<td>$51,026</td>
<td>$4,656,887</td>
</tr>
<tr>
<td>Daniel M. Skovronsky, M.D., Ph.D.</td>
<td>2023</td>
<td>$1,330,769</td>
<td>$0</td>
<td>$7,483,400</td>
<td>$2,408,692</td>
<td>$551,222</td>
<td>$79,846</td>
<td>$11,853,929</td>
</tr>
<tr>
<td>Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology</td>
<td>2022</td>
<td>$1,201,923</td>
<td>$0</td>
<td>$5,747,500</td>
<td>$1,442,308</td>
<td>$0</td>
<td>$72,115</td>
<td>$8,463,846</td>
</tr>
<tr>
<td></td>
<td>2021</td>
<td>$1,000,000</td>
<td>$0</td>
<td>$5,024,300</td>
<td>$1,100,000</td>
<td>$342,792</td>
<td>$60,000</td>
<td>$7,527,092</td>
</tr>
<tr>
<td>Anat Hakim</td>
<td>2023</td>
<td>$980,769</td>
<td>$0</td>
<td>$3,952,500</td>
<td>$1,775,192</td>
<td>$239,430</td>
<td>$58,846</td>
<td>$7,006,737</td>
</tr>
<tr>
<td>Executive Vice President, General Counsel and Secretary</td>
<td>2022</td>
<td>$875,962</td>
<td>$0</td>
<td>$3,135,000</td>
<td>$1,051,154</td>
<td>$146,792</td>
<td>$52,558</td>
<td>$5,261,466</td>
</tr>
<tr>
<td></td>
<td>2021</td>
<td>$775,000</td>
<td>$0</td>
<td>$2,244,900</td>
<td>$852,500</td>
<td>$98,953</td>
<td>$46,500</td>
<td>$4,017,853</td>
</tr>
<tr>
<td>Jake Van Naarden</td>
<td>2023</td>
<td>$830,769</td>
<td>$0</td>
<td>$2,424,200</td>
<td>$1,503,692</td>
<td>$78,013</td>
<td>$49,846</td>
<td>$4,886,520</td>
</tr>
<tr>
<td>Executive Vice President and President, Loxo@Lilly</td>
<td>2022</td>
<td>$735,577</td>
<td>$0</td>
<td>$1,933,250</td>
<td>$882,692</td>
<td>$26,178</td>
<td>$44,135</td>
<td>$3,621,832</td>
</tr>
<tr>
<td></td>
<td>2021</td>
<td>$745,649</td>
<td>⁶ $218,715</td>
<td>⁶ $4,099,500 ⁷</td>
<td>⁷ $1,029,507</td>
<td>$16,909</td>
<td>$12,462</td>
<td>$6,122,742</td>
</tr>
</tbody>
</table>

¹ This column shows the grant date fair value of performance awards, shareholder value awards and relative value awards for all named executive officers computed in accordance with FASB ASC Topic 718. See Note 12 of the consolidated financial statements in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for additional detail regarding assumptions underlying the valuation of equity awards. All values in the “Stock Awards” column were based upon the probable outcome of performance conditions as of the grant date, which vary year to year.

The table below shows the target and maximum payouts (valuing the number of shares that would vest at each payout level using the grant date fair value) for the 2023-2025 performance award, the 2023-2025 shareholder value award, and the 2023-2025 relative value award, each of which are included in the Summary Compensation Table above. All awards below pay out in February 2026 and have a minimum payout of $0.

<table>
<thead>
<tr>
<th>Name</th>
<th>2023-2025 PA Target</th>
<th>2023-2025 PA Maximum</th>
<th>2023-2025 SVA Target</th>
<th>2023-2025 SVA Maximum</th>
<th>2023-2025 RVA Target</th>
<th>2023-2025 RVA Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>$5,362,500</td>
<td>$10,725,000</td>
<td>$6,256,250</td>
<td>$12,512,500</td>
<td>$6,256,250</td>
<td>$12,512,500</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>$1,050,000</td>
<td>$2,100,000</td>
<td>$1,225,000</td>
<td>$2,450,000</td>
<td>$1,225,000</td>
<td>$2,450,000</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>$2,130,000</td>
<td>$4,260,000</td>
<td>$2,485,000</td>
<td>$4,970,000</td>
<td>$2,485,000</td>
<td>$4,970,000</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>$1,125,000</td>
<td>$2,250,000</td>
<td>$1,312,500</td>
<td>$2,625,000</td>
<td>$1,312,500</td>
<td>$2,625,000</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>$690,000</td>
<td>$1,380,000</td>
<td>$805,000</td>
<td>$1,610,000</td>
<td>$805,000</td>
<td>$1,610,000</td>
</tr>
</tbody>
</table>

² Payments under the Bonus Plan for performance in the years represented.

³ The amounts in this column reflect the change in pension value for each individual, calculated by an actuary. The changes in pension values in 2023 were driven by changes in actuarial assumptions offset by pay changes and an additional year of credited service. The design of the pension benefit plan did not change. See the Pension Benefits in 2023 table below for information about the standard actuarial assumptions used. No named executive officer received preferential or above-market earnings on deferred compensation.

⁴ The amounts in this column are company matching contributions into each individual’s 401(k) and Nonqualified Savings Plan contributions. For Mr. Ricks, the amount in this column reflects $97,769 of company matching contributions and Nonqualified Savings Plan contributions and $65,804 of aggregate incremental cost for his personal use of the corporate aircraft. The aggregate incremental costs for personal use of our aircraft are calculated based on our variable operating costs, which include crew travel expenses, on-board catering, landing fees, trip-related hangar/parking costs, fuel, trip-related maintenance, and other smaller variable costs. Because the vast majority of the use of
the corporate aircraft is for business purposes, fixed costs such as aircraft purchase costs, maintenance not related to personal trips, and flight crew salaries are not included. The company does not reimburse executives for taxes outside of the limited circumstance of taxes related to a domestic employee relocation or a prior international assignment.

Additionally, the value of company stock owned by Mr. Ricks exceeded the Hart-Scott-Rodino Antitrust Improvement Act of 1976 ("HSR") size-of-transaction threshold limits set forth in the HSR regulations. Accordingly, Mr. Ricks was required to make a filing under HSR in 2023. Due to his position as Chief Executive Officer and Chair of the company, he is not able to rely on the passive investor exemption contained in the HSR regulations. Without this filing, Mr. Ricks would not be able to participate in our long-term incentive program and therefore, the Talent and Compensation Committee determined that it was appropriate for the company to reimburse Mr. Ricks for such expenses. The HSR filing fee for Mr. Ricks in 2023 was $100,000, which was processed as imputed income so taxes could be withheld. The company did not gross up the payment.

For Mr. Van Naarden, 2021 salary reflects $668,399 in salary payments and $77,250 of unused vacation pay from Loxo Oncology, Inc.

For Mr. Van Naarden, 2021 bonus represents a one-time cash payment of $218,715 in lieu of compensation and benefits Mr. Van Naarden was no longer eligible to receive following his transition to his new role, including compensation for the difference between the bonus he would have earned under the Loxo Bonus Plan and the Lilly Bonus Plan, and changes in his expected out-of-pocket costs for healthcare expenses.

Mr. Van Naarden became an executive officer effective September 5, 2021; as such, he was not an executive officer at grant date for 2021 performance awards.

Grants of Plan-Based Awards During 2023

The compensation plans under which the grants in the following table were made are described in the CD&A above and consist of the Bonus Plan (a non-equity incentive plan) and the Amended and Restated 2002 Lilly Stock Plan which provides for performance awards, shareholder value awards, relative value awards, and restricted stock units, among others.

To receive a payout under a performance award, a shareholder value award and a relative value award issued annually to executive officers, the participant must remain employed with the company through the end of the relevant performance period, retire after December 31 of the year in which the award was granted or be subject to termination events outside of the control of the employee (death, plant closing or reduction in workforce). Annual awards granted to executive officers are also generally subject to non-competition and non-solicitation covenants that apply during the one-year period following termination of employment. Subject to the terms of the applicable award agreement, in the event of a restrictive covenant breach, the award will be immediately rescinded and the holder will forfeit any rights they have with respect to such award.

No dividends accrue on performance awards, shareholder value awards, or relative value awards during the performance period. During the performance award 13-month service-vesting period and restricted stock unit award restriction period, non-preferential dividends accrue and are paid upon vesting.
<table>
<thead>
<tr>
<th>Name</th>
<th>Award</th>
<th>Grant Date</th>
<th>Compensation Committee Action Date</th>
<th>Estimated Future Payouts Under Non-Equity Incentive Plan Awards 1</th>
<th>Estimated Future Payouts Under Equity Incentive Plan Awards</th>
<th>Grant Date Fair Value of Stock and Option Awards 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>2023-2025 PA</td>
<td>3 2/10/2023 12/12/2022</td>
<td>$607,933</td>
<td>$2,431,731</td>
<td>$4,863,462</td>
<td>7,983</td>
</tr>
<tr>
<td></td>
<td>2023-2025 SVA</td>
<td>4 2/10/2023 12/12/2022</td>
<td>$7,956</td>
<td>19,512</td>
<td>39,024</td>
<td>$6,256,250</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5 2/10/2023 12/12/2022</td>
<td>$7,861</td>
<td>15,721</td>
<td>31,442</td>
<td>$6,256,250</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>2023-2025 PA</td>
<td>3 2/10/2023 12/12/2022</td>
<td>$257,692</td>
<td>$1,030,769</td>
<td>$2,061,538</td>
<td>1,563</td>
</tr>
<tr>
<td></td>
<td>2023-2025 SVA</td>
<td>4 2/10/2023 12/12/2022</td>
<td>$1,910</td>
<td>3,820</td>
<td>7,640</td>
<td>$1,225,000</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5 2/10/2023 12/12/2022</td>
<td>$1,539</td>
<td>3,078</td>
<td>6,157</td>
<td>$1,225,000</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>2023-2025 PA</td>
<td>3 2/10/2023 12/12/2022</td>
<td>$332,692</td>
<td>$1,330,769</td>
<td>$2,661,538</td>
<td>3,171</td>
</tr>
<tr>
<td></td>
<td>2023-2025 SVA</td>
<td>4 2/10/2023 12/12/2022</td>
<td>$3,875</td>
<td>7,750</td>
<td>15,500</td>
<td>$2,485,000</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5 2/10/2023 12/12/2022</td>
<td>$3,122</td>
<td>6,245</td>
<td>12,489</td>
<td>$2,485,000</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>2023-2025 PA</td>
<td>3 2/10/2023 12/12/2022</td>
<td>$245,192</td>
<td>$980,769</td>
<td>$1,961,538</td>
<td>1,675</td>
</tr>
<tr>
<td></td>
<td>2023-2025 SVA</td>
<td>4 2/10/2023 12/12/2022</td>
<td>$2,047</td>
<td>4,093</td>
<td>8,186</td>
<td>$1,312,500</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5 2/10/2023 12/12/2022</td>
<td>$1,649</td>
<td>3,298</td>
<td>6,596</td>
<td>$1,312,500</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>2023-2025 PA</td>
<td>3 2/10/2023 12/12/2022</td>
<td>$207,692</td>
<td>$830,769</td>
<td>$1,661,538</td>
<td>1,027</td>
</tr>
<tr>
<td></td>
<td>2023-2025 SVA</td>
<td>4 2/10/2023 12/12/2022</td>
<td>$1,256</td>
<td>2,511</td>
<td>5,022</td>
<td>$805,000</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5 2/10/2023 12/12/2022</td>
<td>$1,011</td>
<td>2,023</td>
<td>4,046</td>
<td>$805,000</td>
</tr>
</tbody>
</table>

1 These columns show the threshold, target and maximum payouts for performance under the Bonus Plan. The Bonus Plan payouts range from 0 to 200 percent of target. The Bonus Plan payout for 2023 performance was 181 percent of target. Actual payouts are shown in the Summary Compensation Table in the column titled “Non-Equity Incentive Plan Compensation.”

2 To assure grant timing is not manipulated for employee gain, the annual grant date is established in advance by the Talent and Compensation Committee.

3 This row shows the possible payouts for the 2023-2025 performance awards ranging from 0 to 200 percent of target. This performance award will pay out in February 2026 based on achievement of the EPS growth targets.

4 This row shows the range of payouts for the 2023-2025 shareholder value awards. This shareholder value award will pay out in February 2026, with payouts ranging from 0 to 200 percent of target based on share price performance.

5 This row shows the range of payouts for the 2023-2025 relative value awards. This relative value award will pay out in February 2026, with payouts ranging from 0 to 200 percent of target based on relative TSR performance.

6 The amounts in this column reflect the grant date fair value of the performance awards, shareholder value awards, and relative value awards computed in accordance with the requirements of ASC Topic 718 and were based upon the probable outcome of performance conditions.
Outstanding Equity Awards on December 31, 2023

The 2023 closing stock price used to calculate the values in the table below was $582.92.

<table>
<thead>
<tr>
<th>Name</th>
<th>Award</th>
<th>Number of Shares or Units of Stock That Have Not Vested (**)</th>
<th>Market Value of Shares or Units of Stock That Have Not Vested ($)</th>
<th>Equity Incentive Plan Awards: Number of Unearned Shares, Units, or Other Rights That Have Not Vested (**)</th>
<th>Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units, or Other Rights That Have Not Vested ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>2023-2025 SVA</td>
<td>34,146</td>
<td>$19,904,386</td>
<td>1</td>
<td>$19,904,386</td>
</tr>
<tr>
<td></td>
<td>2022-2024 SVA</td>
<td>56,651</td>
<td>$33,023,001</td>
<td>2</td>
<td>$33,023,001</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>27,512</td>
<td>$16,037,295</td>
<td>3</td>
<td>$16,037,295</td>
</tr>
<tr>
<td></td>
<td>2022-2024 RVA</td>
<td>43,274</td>
<td>$25,225,280</td>
<td>4</td>
<td>$25,225,280</td>
</tr>
<tr>
<td></td>
<td>2023-2025 PA</td>
<td>27,941</td>
<td>$16,287,368</td>
<td>5</td>
<td>$16,287,368</td>
</tr>
<tr>
<td></td>
<td>2022-2024 PA</td>
<td>26,561</td>
<td>$15,482,938</td>
<td>6</td>
<td>$15,482,938</td>
</tr>
<tr>
<td></td>
<td>2021-2023 PA</td>
<td>29,611</td>
<td>$17,260,844</td>
<td>7</td>
<td>$17,260,844</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>2023-2025 SVA</td>
<td>6,685</td>
<td>$3,896,820</td>
<td>1</td>
<td>$3,896,820</td>
</tr>
<tr>
<td></td>
<td>2022-2024 SVA</td>
<td>10,458</td>
<td>$6,096,177</td>
<td>2</td>
<td>$6,096,177</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5,387</td>
<td>$3,140,190</td>
<td>3</td>
<td>$3,140,190</td>
</tr>
<tr>
<td></td>
<td>2022-2024 RVA</td>
<td>7,989</td>
<td>$4,656,948</td>
<td>4</td>
<td>$4,656,948</td>
</tr>
<tr>
<td></td>
<td>2023-2025 PA</td>
<td>5,471</td>
<td>$3,189,155</td>
<td>5</td>
<td>$3,189,155</td>
</tr>
<tr>
<td></td>
<td>2022-2024 PA</td>
<td>4,904</td>
<td>$2,858,640</td>
<td>6</td>
<td>$2,858,640</td>
</tr>
<tr>
<td></td>
<td>RSU</td>
<td>11,499</td>
<td>$6,702,997</td>
<td>8</td>
<td>$6,702,997</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>2023-2025 SVA</td>
<td>13,563</td>
<td>$7,906,144</td>
<td>1</td>
<td>$7,906,144</td>
</tr>
<tr>
<td></td>
<td>2022-2024 SVA</td>
<td>19,175</td>
<td>$11,177,491</td>
<td>2</td>
<td>$11,177,491</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>10,929</td>
<td>$6,370,733</td>
<td>3</td>
<td>$6,370,733</td>
</tr>
<tr>
<td></td>
<td>2022-2024 RVA</td>
<td>14,648</td>
<td>$8,538,612</td>
<td>4</td>
<td>$8,538,612</td>
</tr>
<tr>
<td></td>
<td>2023-2025 PA</td>
<td>11,099</td>
<td>$6,469,829</td>
<td>5</td>
<td>$6,469,829</td>
</tr>
<tr>
<td></td>
<td>2022-2024 PA</td>
<td>8,999</td>
<td>$5,239,868</td>
<td>6</td>
<td>$5,239,868</td>
</tr>
<tr>
<td></td>
<td>2021-2023 PA</td>
<td>9,941</td>
<td>$5,794,808</td>
<td>7</td>
<td>$5,794,808</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>2023-2025 SVA</td>
<td>7,163</td>
<td>$4,175,456</td>
<td>1</td>
<td>$4,175,456</td>
</tr>
<tr>
<td></td>
<td>2022-2024 SVA</td>
<td>10,458</td>
<td>$6,096,177</td>
<td>2</td>
<td>$6,096,177</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>5,772</td>
<td>$3,364,614</td>
<td>3</td>
<td>$3,364,614</td>
</tr>
<tr>
<td></td>
<td>2022-2024 RVA</td>
<td>7,989</td>
<td>$4,656,948</td>
<td>4</td>
<td>$4,656,948</td>
</tr>
<tr>
<td></td>
<td>2023-2025 PA</td>
<td>5,863</td>
<td>$3,417,660</td>
<td>5</td>
<td>$3,417,660</td>
</tr>
<tr>
<td></td>
<td>2022-2024 PA</td>
<td>4,904</td>
<td>$2,858,640</td>
<td>6</td>
<td>$2,858,640</td>
</tr>
<tr>
<td></td>
<td>2021-2023 PA</td>
<td>4,442</td>
<td>$2,589,331</td>
<td>7</td>
<td>$2,589,331</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>2023-2025 SVA</td>
<td>4,394</td>
<td>$2,561,350</td>
<td>1</td>
<td>$2,561,350</td>
</tr>
<tr>
<td></td>
<td>2022-2024 SVA</td>
<td>6,449</td>
<td>$3,759,251</td>
<td>2</td>
<td>$3,759,251</td>
</tr>
<tr>
<td></td>
<td>2023-2025 RVA</td>
<td>3,540</td>
<td>$2,063,537</td>
<td>3</td>
<td>$2,063,537</td>
</tr>
<tr>
<td></td>
<td>2022-2024 RVA</td>
<td>4,926</td>
<td>$2,871,464</td>
<td>4</td>
<td>$2,871,464</td>
</tr>
<tr>
<td></td>
<td>2023-2025 PA</td>
<td>3,595</td>
<td>$2,095,597</td>
<td>5</td>
<td>$2,095,597</td>
</tr>
<tr>
<td></td>
<td>2022-2024 PA</td>
<td>3,023</td>
<td>$1,762,167</td>
<td>6</td>
<td>$1,762,167</td>
</tr>
<tr>
<td></td>
<td>RSU</td>
<td>3,618</td>
<td>$2,109,005</td>
<td>8</td>
<td>$2,109,005</td>
</tr>
</tbody>
</table>

1 Shareholder value awards granted for the 2023-2025 performance period will vest on December 31, 2025. The number of shares reported reflects the maximum payout, which will be made if the average closing stock price in November and December 2025 exceeds $584.73. Actual payouts may vary from 0 to 200 percent of target. Net shares from any payout must be held by executive officers for a minimum of one year. Had the performance period ended December 31, 2023, the payout would have been at 200 percent of target.

2 Shareholder value awards granted for the 2022-2024 performance period will vest on December 31, 2024. The number of shares reported reflects the maximum payout, which will be made if the average closing stock price in November and December 2024 exceeds $416.32. Actual payouts may vary from 0 to 175 percent of target. Net shares from any payout must be held by executive officers for a minimum of one year. Had the performance period ended December 31, 2023, the payout would have been 175 percent of target.

3 Relative value awards granted for the 2023-2025 performance period will vest on December 31, 2025. The number of shares reported reflects the maximum payout, which will be paid if Lilly’s absolute TSR exceeds the median peer absolute TSR by 30 percentage points or
more. Net shares from any payout must be held by executive officers for a minimum of one year. Had the performance period ended December 31, 2023, the payout would have been 200 percent of target.

Relative value awards granted for the 2022-2024 performance period will vest on December 31, 2024. The number of shares reported reflects the maximum payout, which will be paid if Lilly’s absolute TSR exceeds the median peer absolute TSR by 30 percentage points or more. Net shares from any payout must be held by executive officers for a minimum of one year. Had the performance period ended December 31, 2023, the payout would have been 175 percent of target.

This number represents the maximum number of performance award shares that could pay out for the 2023-2025 performance awards, provided performance goals are met. Once the combined cumulative adjusted non-GAAP EPS result and associated payout level are determined at the end of the 2023-2024 performance period, the associated number of shares will be granted as restricted stock units, vesting in February 2026. Actual payouts may vary from 0 to 200 percent of target. The number of shares recorded in the table reflects the payout if the combined cumulative adjusted non-GAAP EPS for 2023 and 2024 is at least $21.57 under the 2023-2025 performance award grid.

The performance period ended December 31, 2023, for the 2022-2024 performance award, resulting in the issuance of restricted stock units for 128 percent of target shares. These restricted stock units will vest in February 2025.

The performance period ended December 31, 2022 for the 2021-2023 performance award, resulting in the issuance of restricted stock units that vested on February 1, 2024.

These grants were made outside of the normal annual cycle in 2020, and 4,600 units will vest on November 1, 2024, and 6,899 units will vest on November 1, 2026.

This grant was made outside the normal annual cycle in 2021 and 3,618 will vest on February 1, 2024.

**Option Exercises and Stock Vested in 2023**

<table>
<thead>
<tr>
<th>Name</th>
<th>Number of Shares Acquired on Vesting (#)</th>
<th>Value Realized on Vesting ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>47,786</td>
<td>$16,445,552</td>
</tr>
<tr>
<td></td>
<td>39,447</td>
<td>$29,082,695</td>
</tr>
<tr>
<td></td>
<td>29,908</td>
<td>$22,049,972</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>4,114</td>
<td>$3,033,088</td>
</tr>
<tr>
<td></td>
<td>3,357</td>
<td>$2,474,982</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>15,675</td>
<td>$5,394,551</td>
</tr>
<tr>
<td></td>
<td>13,242</td>
<td>$9,762,797</td>
</tr>
<tr>
<td></td>
<td>10,042</td>
<td>$7,403,565</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>7,646</td>
<td>$5,637,090</td>
</tr>
<tr>
<td></td>
<td>5,917</td>
<td>$4,362,367</td>
</tr>
<tr>
<td></td>
<td>4,487</td>
<td>$3,308,086</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>2,431</td>
<td>$1,792,279</td>
</tr>
<tr>
<td></td>
<td>1,985</td>
<td>$1,463,461</td>
</tr>
<tr>
<td></td>
<td>2,785</td>
<td>$933,003</td>
</tr>
</tbody>
</table>

1 Amounts reflect the market value of Lilly stock on the day value is realized.
2 Restricted stock units resulting from the 2020-2022 performance award that vested in February 2023.
3 Payout of the 2021-2023 shareholder value award at 175 percent of target.
4 Payout of the 2021-2023 relative value award at 175 percent of target.
5 Restricted stock units resulting from a one-time award following Lilly’s acquisition of Loxo Oncology, Inc. that vested in February 2023.

**Retirement Benefits**

We provide retirement income to eligible U.S. employees, including executive officers, through the following plans:

- The 401(k) Plan, a defined contribution plan qualified under Sections 401(a) and 401(k) of the Internal Revenue Code. Participants may elect to contribute a portion of their base salary to the plan, and the company provides matching contributions on employees’ contributions up to 6 percent of base salary up to IRS limits. The employee contributions, company contributions, and earnings thereon are paid out in accordance with elections made by the participant and the terms of the plan. See the “All Other Compensation” column in the Summary Compensation Table for information about company contributions under the 401(k) Plan for the named executive officers.

- The Retirement Plan, a tax-qualified defined benefit plan that provides monthly benefits to retirees. See the Pension Benefits in 2023 table below for additional information about the value of these pension benefits.
Sections 401 and 415 of the Internal Revenue Code generally limit the amount of annual pension that can be paid from a tax-qualified plan ($265,000 in 2023 and $275,000 in 2024) as well as the amount of annual earnings that can be used to calculate a pension benefit ($330,000 in 2023 and $345,000 in 2024). However, since 1975 the company has maintained a Nonqualified Pension Plan that pays eligible retirees the difference between the amount payable under the Retirement Plan and the amount they would have received without the Internal Revenue Code limits. The Nonqualified Pension Plan is unfunded and subject to forfeiture in the event of bankruptcy. Likewise, the company maintains a nonqualified savings plan that allows participants to contribute up to 6 percent of base salary exceeding the IRS limit. The company matches these contributions in the same manner as described in the 401(k) Plan. For more information, see footnote 2 to the “Nonqualified Deferred Compensation in 2023” table.

The following table shows benefits that the named executive officers have accrued under the Retirement Plan and the Nonqualified Pension Plan.

### Pension Benefits in 2023

<table>
<thead>
<tr>
<th>Name</th>
<th>Plan Name</th>
<th>Number of Years Credited Service (#)</th>
<th>Present Value of Accumulated Benefit ($)</th>
<th>Payments During Last Fiscal Year ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>Retirement Plan (pre-2010)</td>
<td>14</td>
<td>$706,580</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retirement Plan (post-2009)</td>
<td>14</td>
<td>$427,692</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (pre-2010)</td>
<td>14</td>
<td>$10,088,613</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (post-2009)</td>
<td>14</td>
<td>$5,466,151</td>
<td></td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td>$16,689,036</td>
<td>$0</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>Retirement Plan (pre-2010)</td>
<td>9</td>
<td>$363,498</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Retirement Plan (post-2009)</td>
<td>14</td>
<td>$328,505</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (pre-2010)</td>
<td>9</td>
<td>$1,333,867</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (post-2009)</td>
<td>14</td>
<td>$1,208,340</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td>$3,234,210</td>
<td>$0</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>Retirement Plan (post-2009)</td>
<td>11</td>
<td>$256,890</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (post-2009)</td>
<td>11</td>
<td>$1,769,771</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td>$2,026,661</td>
<td>$0</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>Retirement Plan (post-2009)</td>
<td>4</td>
<td>$116,250</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (post-2009)</td>
<td>4</td>
<td>$456,773</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td>$573,023</td>
<td>$0</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>Retirement Plan (post-2009)</td>
<td>2</td>
<td>$30,638</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Nonqualified Plan (post-2009)</td>
<td>2</td>
<td>$90,462</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td></td>
<td>$121,100</td>
<td>$0</td>
</tr>
</tbody>
</table>

1 The following standard actuarial assumptions were used to calculate the present value of each individual’s accumulated pension benefit:

- **Discount rate:** 5.10 percent for the qualified plan and 5.04 percent for nonqualified plan
- **Mortality (post-retirement decrement only):** Private 2012 white collar table with generational projection using Scale MP-2021
- **Pre-2010 joint and survivor benefit (% of pension):** 50 percent until age 62; 25 percent thereafter
- **Post-2009 benefit payment form:** Life annuity

The Retirement Plan benefits shown in the table are net present values. The benefits are not payable as a lump sum; they are generally paid as a monthly annuity for the life of the retiree and, if elected, any qualifying survivor. The annual benefit under the Retirement Plan is calculated using years of service and the average of the annual earnings (salary plus bonus) for the highest five out of the last ten calendar years of service (final average earnings).

**Post-2009 Plan Information:** Following amendment of our Retirement Plan formulas, employees first hired on or after February 1, 2008, have accrued retirement benefits only under the new plan formula. Employees hired before that date have accrued benefits under both the old and new plan formulas. All eligible employees, including those hired on or after February 1, 2008, can currently retire at age 65 with at least five years of service and receive an unreduced benefit. The annual benefit under the new plan formula is equal to 1.2 percent of final
average earnings multiplied by years of service. Early retirement benefits under this plan formula are reduced six percent for each year under age 65. Transition benefits were afforded to employees with 50 points (age plus service) or more as of December 31, 2009. These benefits were intended to ease the transition to the new retirement formula for those employees who were closer to retirement or had been with the company longer at the time the plan was changed. For the transition group, early retirement benefits are reduced three percent for each year from age 65 to age 60 and six percent for each year under age 60. Mr. Ricks and Ms. Ashkenazi are in this transition group.

**Pre-2010 Plan Information:** Employees hired prior to February 1, 2008 accrued benefits under both plan formulas. For these employees, benefits that accrued before January 1, 2010 were calculated under the old plan formula. The amount of the benefit is calculated using actual years of service through December 31, 2009, while total years of service are used to determine eligibility and early retirement reductions. The benefit amount is increased (but not decreased) proportionately based on final average earnings at termination compared to final average earnings on December 31, 2009. Full retirement benefits are earned by employees with 90 or more points (the sum of his or her age plus years of service). Employees electing early retirement receive reduced benefits as described below:

- The benefit for employees with between 80 and 90 points is reduced by three percent for each year before the earlier of 90 points or age 62.
- The benefit for employees who have fewer than 80 points, but who reached age 55 and have at least ten years of service, is reduced as described above and is further reduced by six percent for each year before the earlier of 80 points or age 65.

### Nonqualified Deferred Compensation in 2023

<table>
<thead>
<tr>
<th>Name</th>
<th>Plan</th>
<th>Executive Contributions in Last Fiscal Year ($\textsuperscript{1})</th>
<th>Registrant Contributions in Last Fiscal Year ($\textsuperscript{2})</th>
<th>Aggregate Earnings in Last Fiscal Year ($)</th>
<th>Aggregate Withdrawals/ Distributions in Last Fiscal Year ($)</th>
<th>Aggregate Balance at Last Fiscal Year End ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>Nonqualified Savings Plan</td>
<td>$77,469</td>
<td>$77,469</td>
<td>$2,301,167</td>
<td>$0</td>
<td>$6,617,143</td>
</tr>
<tr>
<td></td>
<td>Deferred Compensation Plan</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td>$77,469</td>
<td>$77,469</td>
<td>$2,301,167</td>
<td>$0</td>
<td>$6,617,143</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>Nonqualified Savings Plan</td>
<td>$42,046</td>
<td>$42,046</td>
<td>$57,435</td>
<td>$0</td>
<td>$405,960</td>
</tr>
<tr>
<td></td>
<td>Deferred Compensation Plan</td>
<td>$0</td>
<td>$0</td>
<td>$45,219</td>
<td>$0</td>
<td>$931,858</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td>$42,046</td>
<td>$42,046</td>
<td>$102,654</td>
<td>$0</td>
<td>$1,337,818</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>Nonqualified Savings Plan</td>
<td>$60,046</td>
<td>$60,046</td>
<td>$232,120</td>
<td>$0</td>
<td>$1,201,700</td>
</tr>
<tr>
<td></td>
<td>Deferred Compensation Plan</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td>$60,046</td>
<td>$60,046</td>
<td>$232,120</td>
<td>$0</td>
<td>$1,201,700</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>Nonqualified Savings Plan</td>
<td>$39,046</td>
<td>$39,046</td>
<td>$51,618</td>
<td>$0</td>
<td>$303,853</td>
</tr>
<tr>
<td></td>
<td>Deferred Compensation Plan</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td>$39,046</td>
<td>$39,046</td>
<td>$51,618</td>
<td>$0</td>
<td>$303,853</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>Nonqualified Savings Plan</td>
<td>$30,046</td>
<td>$30,046</td>
<td>$20,058</td>
<td>$0</td>
<td>$153,051</td>
</tr>
<tr>
<td></td>
<td>Deferred Compensation Plan</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>total</td>
<td>$30,046</td>
<td>$30,046</td>
<td>$20,058</td>
<td>$0</td>
<td>$153,051</td>
</tr>
</tbody>
</table>

\textsuperscript{1} The amounts in this column are also included in the Summary Compensation Table (SCT) in the “Salary” column (with respect to the Nonqualified Savings Plan) or the “Non-Equity Incentive Plan Compensation” column (with respect to the Deferred Compensation Plan).

\textsuperscript{2} The amounts in this column are also included in the SCT in the “All Other Compensation” column as a portion of the Nonqualified Savings Plan company match.

\textsuperscript{3} Of the totals in this column, the following amounts have previously been reported in the SCT for this year and for previous years:
<table>
<thead>
<tr>
<th>Name</th>
<th>2023 ($)</th>
<th>Previous Years ($)</th>
<th>Total ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td>$154,939</td>
<td>$836,015</td>
<td>$990,954</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td>$84,092</td>
<td>$1,014,955</td>
<td>$1,099,047</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td>$120,093</td>
<td>$417,608</td>
<td>$537,701</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td>$78,093</td>
<td>$68,516</td>
<td>$146,609</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td>$60,092</td>
<td>$76,593</td>
<td>$136,685</td>
</tr>
</tbody>
</table>

The table above reports information about two company programs: the Nonqualified Savings Plan and the Deferred Compensation Plan. The Nonqualified Savings Plan is designed to allow each employee to contribute up to 6 percent of his or her base salary and receive a company match, beyond the contribution limits prescribed by the IRS with regards to 401(k) plans. This plan is administered in the same manner as the 401(k) Plan, with the same participation and investment elections. Executive officers and other U.S. executives may also defer receipt of all or part of their cash compensation under the Deferred Compensation Plan. Amounts deferred by executives under this plan are credited with interest at 120 percent of the applicable federal long-term rate as established the preceding December by the U.S. Treasury Department under Section 1274(d) of the Internal Revenue Code with monthly compounding, which was 5.1 percent for 2023 and is 5.89 percent for 2024. Participants may elect to receive the funds in a lump sum or in up to 10 annual installments following termination of employment but may not make withdrawals while employed by the company, except in the event of hardship as approved by the Talent and Compensation Committee. All deferral elections and associated distribution schedules are irrevocable. Both plans are unfunded and subject to forfeiture in the event of company bankruptcy.

**Payments upon Termination or Change in Control (as of December 31, 2023)**

The following table describes the potential payments and benefits under the company’s compensation and benefit plans and arrangements to which the named executive officers would be eligible upon qualifying termination of employment. Except for certain terminations following a change in control of the company, as described below, there are no agreements, arrangements, or plans that entitle named executive officers to severance, perquisites, or other enhanced benefits upon termination of their employment. Any agreement to provide such payments or benefits to a terminating executive officer (other than following a change in control) would be at the discretion of the Talent and Compensation Committee.

<table>
<thead>
<tr>
<th>Name</th>
<th>Cash Severance Payment 1</th>
<th>Continuation of Medical / Welfare Benefits (present value) 2</th>
<th>Acceleration and Continuation of Equity Awards as of 12/31/2023</th>
<th>Total Termination Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Ricks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Retirement or Involuntary termination</td>
<td>$0</td>
<td>$0</td>
<td>$32,743,945</td>
<td>$32,743,945</td>
</tr>
<tr>
<td>• Involuntary or good-reason termination after change in control</td>
<td>$8,250,000</td>
<td>$52,147</td>
<td>$150,682,069</td>
<td>$158,984,216</td>
</tr>
<tr>
<td>Ms. Ashkenazi</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Retirement or Involuntary termination</td>
<td>$0</td>
<td>$0</td>
<td>$9,561,450</td>
<td>$9,561,450</td>
</tr>
<tr>
<td>• Involuntary or good-reason termination after change in control</td>
<td>$4,200,000</td>
<td>$62,852</td>
<td>$32,000,810</td>
<td>$36,263,662</td>
</tr>
<tr>
<td>Dr. Skovronsky</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Retirement or Involuntary termination</td>
<td>$0</td>
<td>$0</td>
<td>$11,034,932</td>
<td>$11,034,932</td>
</tr>
<tr>
<td>• Involuntary or good-reason termination after change in control</td>
<td>$5,400,000</td>
<td>$52,335</td>
<td>$54,460,286</td>
<td>$59,912,621</td>
</tr>
<tr>
<td>Ms. Hakim</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Retirement or Involuntary termination</td>
<td>$0</td>
<td>$0</td>
<td>$5,447,784</td>
<td>$5,447,784</td>
</tr>
<tr>
<td>• Involuntary or good-reason termination after change in control</td>
<td>$4,000,000</td>
<td>$63,016</td>
<td>$28,723,051</td>
<td>$32,786,067</td>
</tr>
<tr>
<td>Mr. Van Naarden</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Retirement or Involuntary termination</td>
<td>$0</td>
<td>$0</td>
<td>$3,871,382</td>
<td>$3,871,382</td>
</tr>
<tr>
<td>• Involuntary or good-reason termination after change in control</td>
<td>$3,400,000</td>
<td>$62,540</td>
<td>$18,182,650</td>
<td>$21,645,190</td>
</tr>
</tbody>
</table>

1 See “Change-in-Control Severance Pay Plan—Cash Severance Payment” below.
2 See “Accrued Pay and Regular Retirement Benefits” and “Change-in-Control Severance Pay Plan—Continuation of Medical and Welfare Benefits” below.
Accrued Pay and Regular Retirement Benefits: The amounts shown in the table above do not include certain payments and benefits to the extent they are provided on a non-discriminatory basis to salaried employees generally upon termination of employment. These include:

- accrued salary and vacation pay;
- regular pension benefits under the Retirement Plan and the Nonqualified Pension Plan. See “Retirement Benefits” above;
- welfare benefits provided to eligible U.S. retirees, including retiree medical and dental insurance. The amounts shown in the table above as “Continuation of Medical/Welfare Benefits” are explained below; and
- distributions of plan balances under the 401(k) Plan, the Nonqualified Savings Plan, and the Deferred Compensation Plan. See the narrative following the Nonqualified Deferred Compensation in 2023 table for information about these plans.

Death and Disability: A termination of employment due to death or disability does not entitle named executive officers to any payments or benefits that are not available to U.S. employees generally.

Termination for Cause: Executives terminated for cause receive no severance or enhanced benefits and forfeit any unvested equity grants.

Equity Acceleration: Pursuant to the award agreements granted under the Amended and Restated 2022 Lilly Stock Plan, in the event an applicable transaction occurs prior to the end of the applicable performance period, the unvested equity awards would convert into restricted stock units of the new company, with the number of shares earned based on the accrued performance at the time of the transaction. The restricted stock units will continue to vest and pay out upon the earlier of the completion of the original award period; upon a covered termination; or if the successor entity does not assume, substitute, or otherwise replace the award.

Change-in-Control Severance Pay Plan: As described in the CD&A under “Other Compensation Practices and Information—Severance Benefits,” the company maintains a change-in-control severance pay plan for nearly all employees, including the named executive officers. The change-in-control plan for executive officers defines a change in control specifically, but generally the terms include the occurrence of one of the following: (i) acquisition by any person of 20 percent or more of the company’s stock; (ii) replacement by the shareholders of one-half or more of the board of directors; (iii) consummation of a merger, share exchange, or consolidation of the company (other than a transaction that results in the Lilly shareholders prior to the transaction continuing to hold more than 60 percent of the voting stock of the combined entity); or (iv) complete liquidation of the company or sale or disposition of all or substantially all of its assets (other than a sale or disposition to any subsidiary of the company). The amounts shown in the table above for “involuntary or good-reason termination after change in control” are based on the following assumptions and plan provisions and are conditioned upon the executive’s execution and non-revocation of a general release of claims:

- **Covered terminations.** The table assumes a termination of employment that is eligible for severance under the terms of the plan, based on the named executive officer’s compensation, benefits, age, and service credit on December 31, 2023. Eligible terminations include an involuntary termination for reasons other than “cause” or a voluntary termination by the executive for “good reason,” each as defined in the plan, within two years following the change in control.
  - A termination of an executive officer by the company is for “cause,” in general, if it is for any of the following reasons: (i) the employee’s willful refusal to perform, without legal cause, his or her material duties, resulting in demonstrable economic harm to the company or participating employers; (ii) any act of fraud, dishonesty, or gross misconduct resulting in significant economic harm or other significant harm to the company or participating employers or to the business reputation of the company or participating employers; or (iii) conviction by a court of competent jurisdiction of any crime (or the entering of a plea of guilty or nolo contendere to a charge of any crime) constituting a felony.
  - A termination by the executive officer is for “good reason,” in general, if it results from: (i) a material diminution in the nature or status of the executive’s position, title, reporting relationship, duties, responsibilities, or authority, or the assignment to him or her of additional responsibilities that materially increase his or her workload; (ii) any reduction in the executive’s then-current base salary; (iii) a material reduction in the executive’s opportunities to earn incentive bonuses below those in effect for
the year prior to the change in control; (iv) a material reduction in the executive’s employee benefits from the benefit levels in effect immediately prior to the change in control; (v) the failure to grant to the executive stock options, stock units, performance shares, or similar incentive rights during each 12-month period following the change in control on the basis of a number of shares or units and all other material terms at least as favorable to the executive as those rights granted to him or her on an annualized average basis for the three-year period immediately prior to the change in control; (vi) relocation of the executive by more than 50 miles from his or her regularly assigned workplace in effect immediately prior to the change in control; or (vii) any failure by a successor entity to the company in connection with a change in control to assume the obligations of the company under the plan, or any attempted amendment, termination or repudiation of the plan by such successor entity.

- **Cash severance payment.** The cash severance payment amounts, in general, equal two times the executive officer’s annual base salary plus two times the executive officer’s bonus target for that year under the Bonus Plan, to be paid in a lump sum.

- **Continuation of medical and welfare benefits.** This amount represents the present value of the change-in-control plan’s provision, following a covered termination, of 18 months of continued coverage equivalent to the company’s current active employee medical, dental, group life, company-provided death benefit, and long-term disability insurance. Similar actuarial assumptions to those used to calculate incremental pension benefits apply to the calculation for continuation of medical and welfare benefits, with the addition of actual COBRA rates based on current benefit elections. In addition, the executive will receive two years of additional age and service credit for eligibility purposes under the retiree medical plan.

- **Excise taxes.** Upon a change in control, employees may be subject to certain excise taxes under Section 280G of the Internal Revenue Code. The company does not reimburse the affected employees for those excise taxes or any income taxes payable by the employee. To reduce the employee’s exposure to potential excise taxes, the employee’s change-in-control benefit will be decreased to maximize the after-tax benefit to the individual.

- **Payments upon Change in Control Alone.** The change-in-control plan is a “double trigger” plan, meaning payments are made only if the employee suffers a covered termination of employment within two years following the change in control, or in the case of equity awards, if the successor entity does not assume, substitute, or otherwise replace the awards.

**CEO Pay Ratio**

Lilly’s compensation and benefits philosophy across the organization is to encourage and reward all employees who contribute to our success. We strive to ensure that the pay of every Lilly employee reflects the level of their job impact and responsibilities and is competitive within our peer group. Lilly’s ongoing commitment to pay equity is critical to our success in supporting a diverse workforce with opportunities for all employees to grow, develop, and contribute.

Below is the 2023 annual total compensation of our CEO and our median employee and the ratio of the annual total compensation of our CEO to that of our median employee.

<table>
<thead>
<tr>
<th>CEO Pay Ratio:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO Annual Total Compensation*</td>
<td>$26,565,732</td>
</tr>
<tr>
<td>Median Employee Annual Total Compensation</td>
<td>$157,937</td>
</tr>
<tr>
<td>CEO to Median Employee Pay Ratio</td>
<td>168:1</td>
</tr>
</tbody>
</table>

*This annual total compensation is the SCT amount.

**Methodology:**

- **Measurement Date:** We identified the median employee using our employee population (excluding the CEO) on October 31, 2023. On this date, Lilly employed approximately 43,400 people, with approximately 19,800 members of our workforce located in the United States and approximately 23,600 members of our workforce located outside of the United States.

- **Identification of Median Employee:** In a manner consistent with SEC rules, we identified the median employee by use of a “consistently applied compensation measure,” or CACM. Specifically, we identified the median employee by looking at annual base pay, bonus opportunity at target, and the grant date fair
value for annual equity awards. We did not adjust the compensation paid to part-time employees to calculate what they would have been paid on a full-time basis.

• De Minimis Exception: Lilly has employees in 66 countries. In identifying the median employee, we excluded 418 workers in the following 10 countries, which represent approximately one percent of our workforce: Bahrain, Costa Rica, Egypt, Greece, Kuwait, Pakistan, Panama, Qatar, Russia, and United Arab Emirates.

• Calculated CEO Pay Ratio: After applying our CACM and excluding the employees listed above, we identified the median employee. Once the median employee was identified, we calculated the median employee’s total annual compensation in accordance with the requirements of the SCT.

Pay versus Performance

The Talent and Compensation Committee approves and administers compensation programs that are designed to attract, retain, engage, and incentivize our workforce to deliver medicines that make life better for people around the world. Our program aligns executive pay with shareholder interests and links pay to performance through a blend of short-, mid- and long-term performance measures. In 2023, incentive pay made up 92 percent of our CEO’s target compensation and, on average, 83 percent of our other named executive officers’ target compensation. The high utilization of incentive compensation results in higher total realized pay when leadership exceeds the Talent and Compensation Committee-approved performance targets. Conversely, failure to achieve approved targets results in lower realized pay including the possibility that some awards pay zero at the end of their performance period.

Pay versus Performance

<table>
<thead>
<tr>
<th>Year</th>
<th>Summary Compensation Table Total for PEO</th>
<th>Compensation Actually Paid to PEO</th>
<th>Average Summary Compensation Table Total for Non-PEO NEOs</th>
<th>Average Compensation Actually Paid to Non-PEO NEOs</th>
<th>Total Shareholder Return</th>
<th>Peer Group Total Shareholder Return</th>
<th>Net Income ($ millions)</th>
<th>Company Selected Measure (CSM) –Adjusted Non-GAAP EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>$26,565,732</td>
<td>$120,865,280</td>
<td>$7,836,611</td>
<td>$27,249,897</td>
<td>$470.13</td>
<td>$132.57</td>
<td>$5,240</td>
<td>$10.42</td>
</tr>
<tr>
<td>2022</td>
<td>$21,398,135</td>
<td>$64,088,705</td>
<td>$5,769,810</td>
<td>$13,893,269</td>
<td>$292.18</td>
<td>$133.61</td>
<td>$6,245</td>
<td>$8.84</td>
</tr>
<tr>
<td>2021</td>
<td>$21,509,985</td>
<td>$75,705,116</td>
<td>$4,730,690</td>
<td>$4,563,545</td>
<td>$217.66</td>
<td>$121.90</td>
<td>$5,582</td>
<td>$8.25</td>
</tr>
<tr>
<td>2020</td>
<td>$23,708,629</td>
<td>$51,253,831</td>
<td>$6,787,934</td>
<td>$10,732,708</td>
<td>$131.06</td>
<td>$102.07</td>
<td>$6,194</td>
<td>$6.89</td>
</tr>
</tbody>
</table>

1 All calculations for the PEO Compensation Actually Paid (CAP) and for Average Non-PEO NEO CAP do not reflect the actual amount of compensation earned by or paid to our NEOs. The amounts are based on valuation assumptions required by the SEC under Item 402(v) of Regulation S-K. The value actually realized from unvested awards, if any, will be determined when the award fully vests and settles.

2 Mr. Ricks was the PEO for each year represented in the table. The PEO Summary Compensation Table (SCT) to compensation actually paid reconciliation is summarized in the following table.

<table>
<thead>
<tr>
<th>Year</th>
<th>SCT Total Compensation for PEO</th>
<th>SCT in Change in Pension Value</th>
<th>Pension Service Cost</th>
<th>SCT Equity Value</th>
<th>Change in Value: Equity Granted in Current Year</th>
<th>Change in Value: Unvested Equity</th>
<th>Final Value: Vested Equity</th>
<th>Compensation Actually Paid to PEO</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>$26,565,732</td>
<td>$1,439,822</td>
<td>$491,959</td>
<td>$18,840,250</td>
<td>$20,443,264</td>
<td>$36,659,046</td>
<td>$56,985,351</td>
<td>$120,865,280</td>
</tr>
<tr>
<td>2022</td>
<td>$21,398,135</td>
<td>$0</td>
<td>$623,346</td>
<td>$16,981,250</td>
<td>$10,443,998</td>
<td>$(2,718,134)</td>
<td>$51,322,610</td>
<td>$64,088,705</td>
</tr>
<tr>
<td>2021</td>
<td>$21,509,985</td>
<td>$2,442,235</td>
<td>$680,872</td>
<td>$14,966,000</td>
<td>$3,627,520</td>
<td>$17,758,456</td>
<td>$49,536,518</td>
<td>$75,705,116</td>
</tr>
<tr>
<td>2020</td>
<td>$23,708,629</td>
<td>$5,883,932</td>
<td>$660,302</td>
<td>$13,587,500</td>
<td>$4,409,485</td>
<td>$(7,739,531)</td>
<td>$49,686,370</td>
<td>$51,253,831</td>
</tr>
</tbody>
</table>

3 In calculating the ‘compensation actually paid’ amounts reflected in these columns, the fair value or change in fair value, as applicable, of the equity award adjustments included in such calculations was computed in accordance with FASB ASC Topic 718. The assumptions used to calculate the fair values did not materially differ from what was used at the time of grant.
The Non-PEO NEO Summary Compensation Table (SCT) to compensation actually paid reconciliation is summarized in the following table, including the shift in pension from change in pension value to pension service cost, and the summary compensation table equity amount to the change in value for equity:

<table>
<thead>
<tr>
<th>Year</th>
<th>Average SCT Total Compensation for Non-PEO NEOs</th>
<th>Average SCT Change in Pension Value</th>
<th>Average Pension Service Cost</th>
<th>Average SCT Equity Value</th>
<th>Average Change in Value: Equity Granted in Current Year</th>
<th>Average Change in Value: Unvested Equity</th>
<th>Average Final Value: Vested Equity</th>
<th>Average Compensation Actually Paid to Non-PEO NEOs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>$7,836,611</td>
<td>$455,154</td>
<td>$159,626</td>
<td>$4,387,275</td>
<td>$5,693,252</td>
<td>$9,514,261</td>
<td>$8,888,576</td>
<td>$27,249,897</td>
</tr>
<tr>
<td>2022</td>
<td>$5,769,810</td>
<td>$93,171</td>
<td>$185,293</td>
<td>$3,553,000</td>
<td>$2,494,818</td>
<td>$1,188,603</td>
<td>$7,900,916</td>
<td>$13,893,269</td>
</tr>
<tr>
<td>2021</td>
<td>$4,730,690</td>
<td>$159,911</td>
<td>$135,445</td>
<td>$3,115,360</td>
<td>$1,276,786</td>
<td>$861,413</td>
<td>$834,482</td>
<td>$4,563,545</td>
</tr>
</tbody>
</table>

The company’s TSR and the company’s peer group TSR reflected in these columns for each applicable fiscal year is calculated based on a fixed investment of $100 at the applicable measurement point on the same cumulative basis as is used in Item 201(e) of Regulation S-K. The peer group used for calculating Peer Group Total Shareholder Return for each applicable fiscal year is the same peer group that was used by the company for benchmarking compensation, setting the growth goals for the performance award and for determining relative total shareholder return performance for the relative value award for the 2023 fiscal year.

For pay versus performance analysis, adjusted non-GAAP EPS is consistent with the adjusted non-GAAP EPS values for performance awards in Appendix A, “Summary of Adjustments Related to the Annual Cash Bonus and Performance Award.”

The average CAP for 2023 comprised compensation for Ms. Ashkenazi, Dr. Skovronsky, Ms. Hakim and Mr. Van Naarden.

The average CAP for 2022 comprised compensation for Ms. Ashkenazi, Dr. Skovronsky, Ms. Hakim and Mr. Jonsson.

The average CAP for 2021 comprised compensation for Ms. Ashkenazi, Dr. Skovronsky, Mr. Van Naarden, Mr. Rau, and Mr. Smiley. Ms. Ashkenazi succeeded Mr. Smiley as CFO on February 9, 2021 when Mr. Smiley resigned his position.

The average CAP for 2020 comprised compensation for Mr. Smiley, Dr. Skovronsky, Ms. Hakim and Mr. Zulueta.

Pay versus Performance: Most Important Measures
The measures most important in determining pay during 2023 were those most heavily weighted in our long-term incentive and annual bonus programs.

### Most Important Performance Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted non-GAAP EPS</td>
<td>$7,088,331</td>
<td>$8,888,576</td>
<td>$9,514,261</td>
<td>$5,693,252</td>
</tr>
<tr>
<td>Total Shareholder Return</td>
<td>$10,732,708</td>
<td>$4,563,545</td>
<td>$4,563,545</td>
<td>$4,387,275</td>
</tr>
<tr>
<td>Revenue</td>
<td>$2,289,092</td>
<td>$(505,850)</td>
<td>$1,188,603</td>
<td>$2,494,818</td>
</tr>
</tbody>
</table>

Pay versus Performance: Total Shareholder Return
Over the immediately preceding four-year period, the company’s total shareholder return (TSR) significantly exceeded the peer group’s TSR. The company’s chosen peer group is the same as the group used for benchmarking compensation, setting growth goals for the performance award and for determining relative TSR performance for the relative value award.

Lilly’s relative TSR outperformance was substantially attributable to strong developments in our product pipeline and launches of new products and indications. As reflected in the chart below, this outperformance was a significant contributor to the PEO and non-PEOs’ compensation over the four-year period. While the PEO CAP grew with each successive year of TSR outperformance, the highest growth occurred during 2023 when Lilly’s TSR was 61 percent compared to -1 percent for the peer group. Non-PEO average CAP was impacted by the shifting of non-PEO membership and the cancellation of compensation for the company’s former CFO, who departed during the 2021 reporting year.
Pay versus Performance: Net Income

Lilly does not currently utilize GAAP or non-GAAP net income as a metric in any of its incentive programs. Generally, CAP is not heavily correlated with GAAP net income because GAAP net income includes certain items that the Talent and Compensation Committee believes are not reflective of the underlying performance of the business. By excluding the impact of (i) amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties, (ii) net losses or gains on investments in equity securities, and (iii) other specified items that are not reflective of underlying business performance, the Talent and Compensation Committee believes non-GAAP net income better represents the operating performance of the company. For comparison purposes, the graph below reflects both GAAP net income and non-GAAP net income against PEO and average NEO CAP. The 2023 GAAP and non-GAAP net income results include significantly higher acquired IPR&D charges compared to prior years. While immediately expensed for accounting purposes, the company views investments in acquired IPR&D as important contributions to its pipeline of product candidates which is a key driver of the company’s future performance. For additional information on non-GAAP financial metrics, see Appendix A, “Summary of Adjustments Related to the Annual Cash Bonus and Performance Award.”
GAAP net income and non-GAAP net income are discrete outcomes. GAAP Net Income and non-GAAP Net Income figures shown in the graphic above both include acquired IPR&D charges, net of taxes, as follows: $680.3 million in 2020, $785.5 million in 2021, $813.2 million in 2022, and $3.70 billion in 2023.

**Pay versus Performance: Adjusted Non-GAAP EPS**

Lilly has chosen adjusted non-GAAP EPS as its most important CSM. Lilly leverages annual non-GAAP EPS derived from the board-approved business plan to set targets for the Lilly bonus. Additionally, Lilly uses a non-GAAP EPS derived from the median external analyst anticipated two-year non-GAAP EPS growth for our peer group to set our growth goal for our performance award. While these two approaches differ in performance period duration and source of performance comparison, significant sustained profitability growth can contribute to higher total CAP as seen in the graphic below. For additional information on non-GAAP financial metrics, see Appendix A, “Summary of Adjustments Related to the Annual Cash Bonus and Performance Award.”

![Pay vs. Performance: Adjusted non-GAAP EPS](image)

* Adjusted non-GAAP EPS data points are discrete outcomes.

**Pay versus Performance: Revenue**

Lilly strives to make breakthrough medicines available to patients around the globe. Given a growing portfolio of new medicines, we motivate our entire workforce to reach as many patients as possible. The combination of a strong product portfolio and effective patient delivery yields higher sales volume and, generally, higher total revenue. A decline in product portfolio quality or effective launch execution reduces revenue. As such, revenue is one of our most important measures to ensure we are consistently growing the number of patients we serve. Our revenue curve over the preceding four-year period aligns with the growth in PEO and average non-PEO CAP.
Revenue data points are discrete outcomes.

Pay versus Performance: Conclusions

The Talent and Compensation Committee believes in pay for performance and has structured the Lilly compensation programs to reward leaders when the company is delivering strong results. Lilly has had strong cumulative TSR, EPS and revenue growth over the immediately preceding four-year period. As a result of this strong performance, shareholders have been rewarded with significant total stock returns and leadership has been rewarded with above target payouts from their incentive compensation programs.

Audit Matters

Item 3. Ratification of the Appointment of the Independent Auditor

Audit Committee Oversight of the Independent Auditor

The Audit Committee is responsible for the appointment, compensation, retention, and oversight of the independent auditor and oversees the process for reviewing and evaluating the lead audit partner. Further information regarding the Audit Committee’s oversight of the independent auditor can be found in the Audit Committee charter, available online at lilly.com/leadership/governance.

Evaluation Process: In connection with the decision regarding whether to reappoint the independent auditor each year (subject to shareholder ratification), the Audit Committee assesses the independent auditor’s performance. This assessment includes:

1. the independent auditor’s qualifications and experience;
2. the communication and interactions with the auditor over the course of the year;
3. the auditor’s independence, objectivity, and professional skepticism; and
4. the independent auditor’s tenure.

These criteria are assessed against an internal and an external scorecard and are discussed with management during a private session as well as in executive session.
Based on the Audit Committee’s assessment of Ernst & Young LLP’s (EY) performance during 2023, the Audit Committee believes that the continued retention of EY to serve as the company’s independent auditor is in the best interests of the company and its shareholders and has therefore reappointed EY as the company’s independent auditor for 2024.

**Benefits of Longer Tenure:** EY has served as the independent auditor for the company since 1940. There are several benefits of retaining a longer-tenured independent auditor, including:

- **Qualifications and experience** - institutional knowledge and expertise regarding the company’s global operations, accounting policies and practices, and internal controls over financial reporting.

- **Competitive fees** - audit and other fees are competitive with peer companies because of familiarity with the company and its operations.

**Independence Controls**

- **EY’s internal independence assessment** - EY conducts periodic internal reviews of its audit and other work, assesses the adequacy of partners and other personnel working on the Company’s account and rotates the lead assurance engagement partner, the global coordinating partner, and other partners on the engagement consistent with independence requirements.

- **Limits on non-audit services** - The Audit Committee pre-approves audit and permissible non-audit services provided by EY in accordance with its pre-approval policy (described below).

**Audit Committee Oversight:** Oversight includes regular private sessions with EY, discussions on the scope of audit, an annual evaluation (described above) when determining whether to reengage EY and rotation of lead assurance engagement partner and global coordinating partner.

Representatives of EY are expected to participate in the Annual Meeting and will be available to respond to questions. Those representatives will have the opportunity to make a statement if they wish to do so.

The board recommends that you vote **FOR** ratifying the appointment of EY as the independent auditor for 2024.

**Audit Committee Report**

The Audit Committee reviews the company’s financial reporting process on behalf of the board. Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls and disclosure controls. In this context, the Audit Committee has met and held discussions with management and the independent auditor. Management represented to the Audit Committee that the company’s consolidated financial statements for the year ended December 31, 2023, were prepared in accordance with GAAP, and the Audit Committee has reviewed and discussed the audited financial statements and related disclosures with management and the independent auditor, including a review of the significant management judgments underlying the financial statements and disclosures.

The independent auditor reports directly to the Audit Committee, which has sole authority to appoint and to replace the independent auditor (subject to shareholder ratification).

The Audit Committee has discussed with the independent auditor the matters required to be discussed with the Audit Committee by the standards of the Public Company Accounting Oversight Board (PCAOB), the SEC, and the NYSE, including the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, and the clarity of the disclosures in the financial statements. In addition, the Audit Committee has received the written disclosures and the letter from the independent auditor required by applicable PCAOB rules regarding communications with the Audit Committee concerning independence and has discussed with the independent auditor the auditor’s independence from the company and its management. In concluding that the auditor is independent, the Audit Committee determined, among other things, that the non-audit services provided by EY (as described below) were compatible with its independence. Consistent with the requirements of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), the Audit Committee has adopted policies to ensure
the independence of the independent auditor, such as prior committee approval of non-audit services and required audit partner rotation.

The Audit Committee discussed with the company’s internal and independent auditors the overall scope and plans for their respective audits, including internal control testing under Section 404 of the Sarbanes-Oxley Act. The Audit Committee periodically meets with the internal and independent auditors, with and without management present, and in private sessions with members of senior management (such as the chief financial officer and the chief accounting officer) to discuss the results of their examinations, their evaluations of the company’s internal controls, and the overall quality of the company’s financial reporting. The Audit Committee also periodically meets in executive session.

In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the board (and the board subsequently approved the recommendation) that the audited consolidated financial statements be included in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, for filing with the SEC. The Audit Committee has also appointed EY as the company’s independent auditor, subject to shareholder ratification, for 2024.

Audit Committee
Jamere Jackson, Chair
Ralph Alvarez
Gabrielle Sulzberger
Karen Walker

Services Performed by the Independent Auditor

The Audit Committee pre-approves all services performed by the independent auditor, in part to assess whether the provision of such services might impair the auditor’s independence. The Audit Committee’s policy and procedures are as follows:

- **Audit services:** The Audit Committee approves the annual audit services engagement and, if necessary, any changes in terms, conditions, and fees resulting from changes in audit scope, company structure, or other matters. Audit services include internal controls attestation work under Section 404 of the Sarbanes-Oxley Act. The Audit Committee may also pre-approve other audit services, which are those services that only the independent auditor reasonably can provide.

- **Audit-related services:** Audit-related services are assurance and related services that are reasonably related to the performance of the audit or reviews of the financial statements, and that are traditionally performed by the independent auditor. The Audit Committee believes that the provision of these services does not impair the independence of the auditor.

- **Tax services:** The Audit Committee believes that, in appropriate cases, the independent auditor can provide tax compliance services, tax planning, and tax advice without impairing the auditor’s independence.

- **Other services:** The Audit Committee may approve other services to be provided by the independent auditor if (i) the services are permissible under SEC and PCAOB rules, (ii) the Audit Committee believes the provision of the services would not impair the independence of the auditor, and (iii) management believes that the auditor is the best choice to provide the services.

**Pre-approval process:** At the beginning of each audit year, management requests pre-approval from the Audit Committee of the annual audit, statutory audits, and quarterly reviews for the upcoming audit year as well as any other services known at that time. Management will also present at that time an estimate of all fees for the upcoming audit year and known services. As specific engagements are identified thereafter that were not initially approved, they are brought forward to the Audit Committee for approval. To the extent approvals are required between regularly scheduled Audit Committee meetings, pre-approval authority is delegated to the committee chair.

For each engagement, management provides the Audit Committee with information about the services and fees, sufficiently detailed to allow the committee to make an informed judgment about the nature and scope of the services and the potential for the services to impair the independence of the auditor.
After the end of the audit year, management provides the committee with a summary of the actual fees incurred for the completed audit year.

**Independent Auditor Fees**

The following table shows the fees incurred for services rendered on a worldwide basis by EY in 2023 and 2022. All such services were pre-approved by the Audit Committee in accordance with the pre-approval policy.

<table>
<thead>
<tr>
<th>Service Description</th>
<th>2023 ($ millions)*</th>
<th>2022 ($ millions)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Audit Fees</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual audit of consolidated and subsidiary financial statements, including</td>
<td>$15.2</td>
<td>$13.9</td>
</tr>
<tr>
<td>Sarbanes-Oxley 404 attestation, reviews of quarterly financial statements</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Audit-Related Fees</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primarily related to assurance and related services reasonably related to the</td>
<td>$1.1</td>
<td>$0.7</td>
</tr>
<tr>
<td>performance of the audit or reviews of the financial statements primarily related</td>
<td></td>
<td></td>
</tr>
<tr>
<td>to employee benefit plan and other ancillary audits, and due diligence services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>on potential acquisitions</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tax Fees</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tax compliance services, tax planning, tax advice</td>
<td>$1.0</td>
<td>$1.6</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advisory services related to regulatory and contractual matters</td>
<td>$0.2</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$17.4</td>
<td>$16.2</td>
</tr>
</tbody>
</table>

* Numbers may not add due to rounding

**Management Proposals**

**Item 4. Proposal to Amend the Company’s Articles of Incorporation to Eliminate the Classified Board Structure**

The company’s articles of incorporation provide that the board is divided into three classes, with each class elected every three years. The board, after review by its Directors and Corporate Governance Committee, has approved, and recommends that the shareholders approve, amendments to eliminate the classified board structure in order to provide for the annual election of all directors (the Declassification Amendments). From 2010 through 2012 and again from 2018 through 2023, the board submitted this management proposal to shareholders seeking approval to eliminate the company’s classified board structure; however, under the company’s articles of incorporation the proposal requires the vote of 80 percent of the outstanding shares to be approved and on each prior occasion failed to receive the required vote.

If approved, the Declassification Amendments would become effective following the Annual Meeting upon the company making the required filings of the Declassification Amendments with the Secretary of State of Indiana. Directors elected prior to the effectiveness of the Declassification Amendments would serve the remainder of their respective three-year terms and each director elected after the Annual Meeting would serve a one-year term, ending at the next annual meeting of shareholders. Thereafter, the company’s classified board structure would be fully eliminated starting with the 2027 annual meeting of shareholders. In the case of any vacancy on the board occurring after the Annual Meeting created by an increase in the number of directors, the vacancy would be filled through an appointment by the board, with the new director to serve a term ending at the next annual meeting of shareholders. Vacancies created by resignation, removal or death would be filled by appointment by the board of a new director to serve until the end of the term of the director being replaced. This proposal would not change the present number of directors or the board’s authority to change that number and to fill any vacancies or newly created directorships.

**Background of Proposal**

As part of its ongoing review of corporate governance matters, the board, taking into account the input of the Directors and Corporate Governance Committee, considered the advantages and disadvantages of maintaining the classified board structure. The board considered the view of certain shareholders who believe that classified boards have the effect of reducing the accountability of directors to shareholders because shareholders are unable to evaluate and consider all directors for election on an annual basis. The board gave considerable weight to the favorable votes of a strong majority of the outstanding shares for management’s proposals in prior years.
The board also considered the benefits of retaining the classified board structure. A classified structure may promote shareholder value by providing continuity and stability in the management of the business and affairs of the company, as a majority of the board always has prior experience as directors of the company. In addition, under certain circumstances, classified boards may protect shareholder value by forcing an entity seeking control of the company to initiate discussions at arm’s-length with the board of the company, because the entity cannot replace the majority of the board in a single election. The board also considered that even without a classified board (and without the supermajority voting requirements, which the board also recommends eliminating), the company would have appropriate safeguards to protect the interests of all shareholders and discourage a would-be acquirer from proceeding with a proposal that undervalues the company or is opportunistic. These include other provisions of the company’s articles of incorporation and bylaws, as well as certain provisions of Indiana corporation law.

After balancing these interests, the board has decided to resubmit this proposal to eliminate the classified board structure. The affirmative vote of at least 80 percent of the outstanding shares of common stock is needed to approve this proposal. Unless such vote is received, the present classification of the board will continue.

Text of the Amendments

Article 9(b) of the company’s articles of incorporation contains the provisions that will be affected if this proposal is adopted. This article, set forth in Appendix B to this proxy statement, shows the proposed changes, with deletions indicated by strikeouts and additions indicated by underlining. The board has also adopted conforming amendments to the company’s bylaws, to be effective immediately upon, and subject to, the effectiveness of the amendments to the articles of incorporation.

RECOMMENDATION FOR

The board recommends that you vote FOR amending the company’s articles of incorporation to eliminate the classified board structure.

Item 5. Proposal to Amend the Company’s Articles of Incorporation to Eliminate Supermajority Voting Provisions

The company’s articles of incorporation provide that nearly all matters submitted to a vote of shareholders can be adopted by a majority of the votes cast. However, the company’s articles of incorporation require certain fundamental corporate actions to be approved by the holders of 80 percent of the outstanding shares of common stock. Those actions are:

- amending certain provisions of the articles of incorporation that relate to the number and terms of office of directors:
  - the company’s classified board structure (as described under Item 4)
  - a provision that the number of directors shall be specified solely by resolution of the board
- removing directors prior to the end of their elected term
- entering into mergers, consolidations, recapitalizations, or certain other business combinations with a “related person”—a party who has acquired at least five percent of the company’s stock (other than the Endowment or a company benefit plan) — without the prior approval of such action or transaction by the directors not affiliated with such shareholder
- modifying or eliminating any of the above supermajority voting requirements.

The board, after review by the Directors and Corporate Governance Committee, has approved, and recommends that the shareholders approve, amendments to eliminate the supermajority voting requirements (the Supermajority Voting Amendments). From 2010 through 2012 and again from 2018 through 2023, the board submitted this management proposal to shareholders seeking approval to eliminate these supermajority voting requirements; however, under the company’s articles of incorporation the proposal requires the vote of 80 percent of the outstanding shares to be approved and on each prior occasion failed to receive the required vote.
Background of Proposal

As part of its ongoing review of corporate governance matters, the board, taking into account the input of the Directors and Corporate Governance Committee, considered the advantages and disadvantages of maintaining the supermajority voting requirements. The board considered the potential adverse consequences of maintaining the supermajority voting requirements. The board believes it is important to maintain shareholder confidence by demonstrating that the board is responsive and accountable to shareholders and committed to strong corporate governance. This requires the board to carefully balance sometimes competing interests. In this regard, the board gave considerable weight to the favorable votes of a strong majority of the outstanding shares for management’s proposal in the previous four years. Many shareholders believe that supermajority voting requirements impede accountability to shareholders and contribute to board and management entrenchment. The board also considered that, even without the supermajority vote (and without the classified board, which the board also recommends eliminating), the company has appropriate safeguards to protect the interests of all shareholders and to discourage a would-be acquirer from proceeding with a proposal that undervalues the company or is opportunistic and to assist the board in responding to such proposals. These include other provisions of the company’s articles of incorporation and bylaws as well as certain provisions of Indiana corporation law.

The board also considered that under certain circumstances, supermajority voting requirements can provide benefits to the company and all its shareholders by making it more difficult for one or a few large shareholders to facilitate a takeover of the company or implement certain significant changes to the company without more widespread shareholder support.

After balancing these interests, the board has decided to resubmit this proposal to eliminate the supermajority voting requirements. The affirmative vote of at least 80 percent of the outstanding shares of common stock is needed to approve this proposal. Unless such vote is received, the supermajority voting requirements will continue to be in effect.

Text of Amendments

Articles 9(c), 9(d), and 13 of the company’s articles of incorporation contain the provisions that will be affected if this proposal is adopted. These articles, set forth in Appendix B to this proxy statement, show the proposed changes with deletions indicated by strikeouts and additions indicated by underlining. The board has also adopted conforming amendments to the company’s bylaws, to be effective immediately upon, and subject to, the effectiveness of the amendments to the articles of incorporation.

RECOMMENDATION FOR

The board recommends that you vote FOR amending the company’s articles of incorporation to eliminate supermajority voting requirements.

Shareholder Proposals

Item 6. Proposal to Publish an Annual Report Disclosing Lobbying Activities

The Service Employees International Union Pension Plans Master Trust (SEIU), 1800 Massachusetts Ave. NW, Suite 301, Washington, D.C. 20036-1202, a beneficial owner of shares of our common stock having a market value in excess of $2,000, has submitted the following proposal:

Resolved, the shareholders of Lilly request the preparation of a report, updated annually, disclosing:

1. Company policy and procedures governing lobbying, both direct and indirect, and grassroots lobbying communications.

2. Payments by Lilly used for (a) direct or indirect lobbying or (b) grassroots lobbying communications, in each case including the amount of the payment and the recipient.
3. Lilly’s membership in and payments to any tax-exempt organization that writes and endorses model legislation.

4. Description of management’s and the Board’s decision-making process and oversight for making payments described in sections 2 and 3 above.

For purposes of this proposal, a “grassroots lobbying communication” is a communication directed to the general public that (a) refers to specific legislation or regulation, (b) reflects a view on the legislation or regulation and (c) encourages the recipient of the communication to take action with respect to the legislation or regulation. “Indirect lobbying” is lobbying engaged in by a trade association or other organization of which Lilly is a member.

Both “direct and indirect lobbying” and “grassroots lobbying communications” include efforts at the local, territorial, state and federal levels.

The report shall be presented to the Directors and Corporate Governance Committee and posted on Lilly’s website.

Supporting Statement

Full disclosure of Lilly’s lobbying activities and expenditures is needed to assess whether Lilly’s lobbying is consistent with its expressed goals and shareholder interests. Lilly spent $103,363,850 from 2010 – 2022 on federal lobbying. This figure does not include state lobbying, where Lilly lobbied in all 50 states in 2022. Lilly also lobbies abroad, spending between €900,000–999,000 on lobbying in Europe for 2022.

Companies can give unlimited amounts to third party groups that spend millions on lobbying and undisclosed grassroots activity.¹ Unlike many of its peers, Lilly fails to disclose its third-party payments to trade associations and social welfare groups (SWGs), or the amounts used for lobbying, to shareholders. Lilly belongs to the Chamber of Commerce, Business Roundtable, National Association of Manufacturers and Pharmaceutical Research and Manufacturers of America (PhRMA), which together have spent over $2.9 billion on federal lobbying since 1998, and supports SWGs that lobby, like the Alliance for Patient Access (AfPA).²

Lilly’s lack of disclosure presents reputational risk when its lobbying contradicts company public positions. For example, Lilly states it supports more affordable medicines, yet funds PhRMA and AfPA’s opposition to lower prescription drug prices.³ Lilly believes in addressing climate change, yet the BRT lobbied against the Inflation Reduction Act⁴ and the Chamber reportedly has been a “central actor” in dissuading climate legislation over a two-decade period.⁵ Lilly opposed Indiana voter restrictions, yet groups have asked Lilly to cut ties with the American Legislative Exchange Council (ALEC) “because of its voter restriction efforts.”⁶ Lilly is also represented at ALEC by its trade associations, as the Chamber and PhRMA each sit on its Private Enterprise Advisory Council.⁷

Lilly should expand its lobbying disclosure.

---

Lilly’s Opposing Statement

The board, after review by its Directors and Corporate Governance Committee, recommends a vote AGAINST this proposal.

As discussed in more detail below, the report requested by the proposal is unnecessary because:

- Lilly already publicly discloses information regarding the company’s policies and procedures governing direct and indirect lobbying activities;
- Lilly already publicly discloses information regarding our direct and indirect lobbying expenditures;
- Lilly already publicly discloses information regarding our membership in, and payments to, tax-exempt organizations that write and endorse model legislation;
- Lilly already publicly discloses information regarding its decision-making process and the board’s oversight over direct and indirect lobbying activities; and
- Requiring Lilly to prepare a separate report with this information would place an undue administrative burden on the company and would not provide meaningful additional information to shareholders.

Contrary to the proposal’s assertions, Lilly does not fund opposition to lowering prescription drug prices. Lilly does, however, oppose legislative policies that would hinder medical discovery for patients. For example, while Lilly actively supported portions of the Inflation Reduction Act of 2022 (the IRA) that we believe will benefit patients and innovation, such as the $35 out of pocket cap on insulin costs for Medicare beneficiaries and the elimination of the coverage gap in Medicare Part D plans, we opposed the aspects of the IRA that we believe have negative consequences to drug discovery without directly helping patients—such as Medicare price setting under the guise of negotiation.

Our political expenditures, in fact, cover the political spectrum and reflect our approach to engaging stakeholders on various complex issues to help preserve incentives and ensure an environment conducive to finding new treatments. As explained in further detail below, the company already publicly discloses this information, which provides shareholders with the information necessary to assess the consistency of the company’s lobbying activities with its expressed goals.

Lilly already publicly discloses the information requested by the proposal regarding the company’s policies and procedures governing direct and indirect lobbying activities.

In this proxy statement, the political participation page of Lilly’s website (Political Participation Website), and Lilly’s corporate governance guidelines, the company discloses its extensive policies and procedures governing direct and indirect lobbying activities. For example, the Political Participation Website discloses:

- Lilly’s commitment, through public policy engagement, to provide a way for all our locations globally to offer Lilly’s perspective on the political environment in a manner that supports access to innovative medicines, as well as to look for ways to engage on issues specific to local business environments;
- that Lilly employees must comply with our global policies, core values and legal obligations, which are outlined in our written code of business conduct;
- that when engaging in lobbying activities, Lilly complies with the laws that govern such activities, and that Lilly’s senior vice president, global government affairs is responsible for overseeing these activities and the company’s general counsel and chief financial officer, or their designees, also approve all corporate political contributions before they are made; and
- that, where permitted, Lilly makes lawful political contributions in the United States to political candidate committees, political parties, political action committees, ballot measure committees, associations and other political organizations operating under section 527 of the Internal Revenue Code.

Lilly already publicly discloses the information requested by the proposal regarding our direct and indirect lobbying expenditures.

Lilly makes extensive disclosures regarding its direct and indirect lobbying expenditures in its Political Participation Website, environmental, social and governance report, and other public disclosures regarding its political activities. The trade associations through which Lilly conducts its indirect lobbying activities (which are
evaluated annually by the company’s U.S. government affairs leaders) also publicly disclose their lobbying expenditures. In recent years, following feedback from shareholders, Lilly substantially enhanced its disclosures related to its direct and indirect lobbying activities, including lobbying expenditures. Lilly voluntarily discloses its corporate political contributions and expenditures on an annual basis on the Political Participation Website. The proposal also requests we disclose our grassroots lobbying communications, however, Lilly does not engage in grassroots lobbying communications to the general public. Additional details regarding the company’s corporate contributions, LillyPAC’s contributions (which are also voluntarily disclosed on a bi-annual basis), contribution data, and the company’s direct lobbying expenses are also already made available to the public from numerous public sources.

Lilly already publicly discloses the information requested by the proposal regarding our membership in, and payments to, any tax-exempt organization that writes and endorses model legislation.

As noted above, Lilly’s Political Participation Website also contains information regarding the company’s U.S. trade association memberships for which the company pays annual dues of $50,000 or more and information regarding the percentage of dues collected by such trade associations utilized for federal and state lobbying and political expenditures. In the Political Participation Website, Lilly already discloses Lilly’s memberships in organizations that report lobbying activity to the U.S. federal government, including the Pharmaceutical Research and Manufacturers of America, the National Association of Manufacturers, the Biotechnology Innovation Organization, the U.S. Chamber of Commerce, and the Business Roundtable.

Lilly already publicly discloses the information requested by the proposal regarding its decision-making process and the board’s oversight over direct and indirect lobbying activities.

In this proxy statement and the Political Participation Website, Lilly already discloses its decision-making process and the board’s oversight over the company’s political expenditures and direct and indirect lobbying activities to ensure the company fulfills its commitment to stewardship of corporate funds and minimizes risk with respect to such activities.

For example, the board receives regular updates from management, and communications regarding public policy issues and the company’s direct and indirect lobbying activities and receives semi-annual updates on direct and indirect lobbying activities and trade association memberships. See “Governance—How We Operate an Effective Board—Key Areas of Oversight by the Board and Its Committees—Political Activities” for additional information.

Requiring Lilly to prepare a separate report with this information would place an undue administrative burden on the company and would not provide meaningful additional information to shareholders.

We do not believe that publishing the standalone report requested by the proposal would provide meaningful additional information to shareholders to merit the resources required to provide the requested report. For these reasons, we believe the proposal is not in the best interests of the company and its shareholders.

**RECOMMENDATION AGAINST**

The board recommends that you vote **AGAINST** this proposal.

---

**Item 7. Proposal to Report on Effectiveness of the Company’s Diversity, Equity, and Inclusion Efforts**

As You Sow, on behalf of Marguerite Casey Foundation, each a beneficial owner of shares of our common stock having a market value in excess of $2,000, has submitted the following proposal:

**Resolved:** Shareholders request that Eli Lilly & Co. (Eli Lilly) report to shareholders on the effectiveness of the Company’s diversity, equity, and inclusion efforts. The report should be done at reasonable expense, exclude proprietary information, and provide transparency on outcomes, using quantitative metrics for workforce diversity, hiring, promotion, and retention of employees, including data by gender, race, and ethnicity.

**Supporting Statement:** Quantitative data is sought so that investors can assess and compare the effectiveness of companies’ diversity, equity, and inclusion programs.
It is advised that this content be provided through Eli Lilly’s existing sustainability reporting infrastructure. An independent report specific to this topic is not requested.

WHEREAS: Companies that release, or have committed to release, more inclusion data than Eli Lilly include:
Baxter International, Biogen, CVS Health, Gilead Sciences, Pfizer, and UnitedHealth Group.

As You Sow and Whistle Stop Capital released research in November 2023 that reviewed over 4,500 EEO-1 reports, which show corporate workforce diversity.\(^1\) The data shows a positive correlation between manager diversity and corporate performance. Within the healthcare sector, statistically significant positive correlations were found between manager diversity and free cash flow per share, income after tax, long-term growth, and ten-year growth rate.

As of the date of the filing of this proposal, Eli Lilly had not yet shared sufficient hiring, retention, or promotion data to allow investors to determine the effectiveness of its diversity and inclusion programs.

As detailed below, inclusion indicators are also important in assessing Eli Lilly’s workplace equity efforts and if the Company will be able to successfully build, utilize, and retain a diverse management team.

Hiring: Studies conducted by economists at the University of Chicago and UC Berkeley found that “discriminating companies tend to be less profitable,” stating “it is costly for firms to discriminate against productive workers.”\(^2\)

Promotion: Without equitable promotional practices, companies will be unable to build the necessary employee pipelines for diverse management. Women and employees of color experience “a broken rung” in their careers; for every 100 men who are promoted, only 87 women are. Whereas women of color comprise 18 percent of the entry-level workforce and only 6 percent of executives.\(^3\)

Retention: Retention rates indicate if employees believe a company represents their best opportunity. Morgan Stanley has found that employee retention above industry average can indicate a competitive advantage and higher levels of future profitability.\(^4\)

Investors have reason to be concerned about Eli Lilly’s workplace culture given allegations of age discrimination\(^5\) and sexual harassment at the Company,\(^6\) as well as the loss of an executive team member as a result of an “inappropriate personal relationship.”\(^7\)

---

5. https://www.fiercepharma.com/pharma/lilly-forks-over-24m-settle-federal-agencys-age-discrimination-lawsuit#:~:text=Eli%20Lilly%20will%20pay%20out%20%28PDF%29%20242.4%20million.prioritize%20recruitment%20of%20more%20millenials%20to%20its%20workforce
Lilly’s Opposing Statement

The board, after review by its Directors and Corporate Governance Committee, recommends a vote AGAINST this proposal.

As discussed in more detail below, the action requested by the proposal is unnecessary because:

- Lilly already publicly discloses extensive information on its diversity, equity, and inclusion efforts;
- Lilly already provides multi-year metrics on women and minority group member representation in management and its workforce (see p. 40);
- Lilly is transparent about its data and has posted its consolidated EEO-1 reports;
- Lilly continues to be recognized by others for its diversity, equity, and inclusion practices, programs and outcomes; and
- The additional granularity of disclosure would place an undue administrative burden on the company and would not provide meaningful additional information to shareholders.

Lilly takes a data-driven approach to diversity, equity, and inclusion.

At Lilly, we believe in the power of diversity, equity, and inclusion to fulfill our purpose of creating medicines that make life better for people around the world. At our core, we believe that by leveraging the varied backgrounds of our more than 43,000 employees—and by driving actionable and measurable strategies to improve inclusivity, including within our clinical trials—we can better deliver scientific breakthroughs. We take a data-driven approach so that our business and employee base better reflect the world around us and the patients we serve.

Lilly’s commitment to inclusion includes, among other things, high-level oversight, purposeful corporate culture and ongoing data analyses to inform our approach. Our CEO and Executive Committee (EC) consistently set expectations for inclusive leadership and hold leaders accountable for building diverse, inclusive and high-functioning teams. The EC is dedicated to promoting an inclusive corporate culture, as highlighted in our proxy statement and other public disclosures. The EC receives regular updates on Lilly’s aspirational goals, metrics and outcomes, and employee survey data. Lilly is committed to data-driven results, and metrics are used to develop annual plans, track our performance and implement Lilly’s strategies, which are reviewed at least annually by the board.

Our executive leadership team purposefully integrates inclusion within our human resources talent management organization. Lilly’s executive vice president for human resources and diversity, a member of the EC, reports directly to our chair and CEO and is ultimately accountable for diversity, equity, and inclusion at Lilly. Our chief diversity, equity, and inclusion officer is a senior vice president reporting to the executive vice president for human resources and diversity and is also responsible for leading our talent management functions. Our people strategy, which is developed and maintained by the talent management organization, includes programming focused on fairness and creating equity and inclusive career development opportunities for all employees.

Lilly already provides extensive information on its workforce diversity efforts and has posted its consolidated EEO-1 reports.

We already disclose Lilly’s workforce inclusion efforts, including the information provided above, in this proxy statement and in other public disclosures along with quantitative diversity data, including the gender and ethnicity breakdown of both Lilly’s workforce and management. As one can see from that information, over the past five years, Lilly has seen gender parity in its U.S. and global workforce. Furthermore, the number of women and minority group members in management positions has also steadily increased. In addition, the company has published its annual EEO-1 report on its website since 2021, which provides additional transparency and accountability with respect to Lilly’s workforce diversity data.

Lilly continues to be recognized for its inclusivity efforts.

Finally, Lilly has been recognized externally several times for its inclusivity efforts. Lilly is and has been ranked in the Top 5 Companies for Diversity by Fair360 for the past five years and in the Top 50 the past 13 years running. Fair360 has a systematic process that reviews companies’ data across six categories: Leadership Accountability, Talent Programs, Human Capital Metrics, Workplace Practices, Supplier Fairness and Philanthropy.
Additionally, Lilly has been recognized by a variety of organizations as set out in our Environmental, Social, and Governance Report, including Forbes, America’s Best Large Employers list; DisabilityIN, Disability Equality Index Best Places to Work – Perfect Score; Human Rights Campaign Foundation, Corporate Equality Index – Perfect Score to name a few.

The additional granularity of disclosure would place an undue administrative burden on the company and would not provide meaningful additional information to shareholders.

We believe our existing disclosures provide meaningful information that allows shareholders to determine the effectiveness of our policies related to workplace inclusivity efforts. We do not believe the additional levels of granularity of reporting requested by the proposal would provide meaningful additional information to shareholders to merit the resources required to provide the disclosure. For these reasons, we believe the proposal is not in the best interests of the company and its shareholders.

**RECOMMENDATION AGAINST**

The board recommends that you vote **AGAINST** this proposal.

---


Trinity Health, as lead filer, with multiple additional cofilers, each a beneficial owner of shares of our common stock having a market value in excess of $2,000, has submitted the following proposal:

RESOLVED, that shareholders of Eli Lilly & Co. (“Lilly”) ask the Board of Directors to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. Secondary and tertiary patents are patents applied for after the main active ingredient/molecule patent(s) and which relate to the product. The report on the process should be prepared at reasonable cost, omitting confidential and proprietary information, and be published on Lilly’s website.

SUPPORTING STATEMENT: According to a 2021 Congressional Research Service report, “Intellectual property rights play an important role in the development and pricing of prescription drugs and biologics.”\(^1\) When patent protection on a drug ends, generic manufacturers can enter the market, reducing prices. According to the report, branded drug manufacturers may try to delay generic competition and impact access by extending their exclusivity periods.

In part because of this behavior, access to medicines is the subject of consistent and widespread public debate in the U.S. A 2021 Rand Corporation analysis concluded that U.S. prices for branded drugs were nearly 3.5 times higher than prices in 32 OECD member countries.\(^2\) The Kaiser Family Foundation has “consistently found prescription drug costs to be an important health policy area of public interest and public concern.”\(^3\)

This high level of concern has driven policy responses. The Inflation Reduction Act (“IRA”) empowers the federal government to negotiate some drug prices, and in fact some have argued it enacts significant patent reform, specifically around the issue this proposal addresses. The IRA provision stating that the only drugs that can be considered for price negotiations are those with no generic competition has the effect of discouraging extended patent exclusivities. One law firm asserts that “prevailing in a patent infringement lawsuit against a forthcoming competitor may no longer be as valuable for a branded drug company because high-expenditure single-source

---

\(^1\) [https://crsreports.congress.gov/product/pdf/R/R46679](https://crsreports.congress.gov/product/pdf/R/R46679)


\(^3\) [https://www.kff.org/health-costs/poll--finding/public-opinion-on-prescription-drugs-and-their-prices/](https://www.kff.org/health-costs/poll--finding/public-opinion-on-prescription-drugs-and-their-prices/)
drugs are at risk of being selected for price negotiation if there is no generic or biosimilar competitor on the market.\textsuperscript{4}

Additionally, five bipartisan bills aimed at providing speedier access to generics have been introduced in the Senate:

- Ensuring Timely Access to Generics Act of 2023 (S. 1067)
- Expanding Access to Low-Cost Generics Act of 2023 (S. 1114)
- Increasing Transparency in Generic Drug Applications Act of 2023 (S. 775)
- Preserve Access to Affordable Generics and Biosimilars Act of 2023 (S. 142)
- Stop STALLING Act of 2023 (S. 148)

In our view, a process that considers the impact of extended exclusivity periods on patient access would ensure that Lilly considers not only whether it can apply for secondary and tertiary patents but also whether it should do so. Such a process could, we believe, bolster Lilly's reputation and help avoid regulatory blowback resulting from high drug prices and perceptions regarding abusive patenting practices.

**Lilly’s Opposing Statement**

The board, after review by its Directors and Corporate Governance Committee, recommends a vote AGAINST this proposal.

As discussed in more detail below, the report requested by the proposal is unnecessary because:

- Lilly already provides information about its guiding principles related to its intellectual property protection strategies;
- Patent strategy involves complicated decisions at the core of the company’s business model, and is key to the company’s ability to invest in future innovation;
- Lilly already provides information about its goals and approach to access to medicine; and
- Requiring Lilly to prepare a separate report with this information would place an undue administrative burden on the company and would not provide meaningful additional information to shareholders.

**Lilly already provides information about its guiding principles related to its intellectual property protection strategies.**

Lilly believes that patients benefit most from a biopharmaceutical innovation ecosystem that both (a) incentivizes discovery and development of a sustainable pipeline of innovative drugs and (b) leads to reliable entry of lower-cost biosimilar and generic drugs.

As described in our Environmental, Social, and Governance Report, intellectual property protection improves patient access by incentivizing investment and innovation. Consistent with our commitment to promote access to our medicines so that our breakthroughs can transform more people’s lives, Lilly supports the removal of regulatory or pricing, reimbursement and access restrictions for generics and biosimilars when intellectual property protections expire. In addition, Lilly has a long-standing practice of not seeking or enforcing patents for medicines in countries designated by the United Nations as the “least developed”.

In 2021, Lilly publicly announced its participation in the IP Principles for Advancing Cures and Therapies (the IP PACT), which serves as a framework for guiding the company’s commitment to innovation while keeping patients at the heart of its efforts. The IP PACT framework includes the following principles, among others:

- Patient and societal benefit will guide Lilly’s approach to IP.
- Lilly will support initiatives to ensure patent quality, which help advance biopharmaceutical innovation.

• Lilly will use IP rights to facilitate collaboration and enable partnerships that advance global health.

• Lilly believes that accessible patent information promotes scientific progress and helps improve the procurement of medicines, and we support voluntary initiatives that advance these goals.

• Lilly will act responsibility and professionally in the Company’s patent proceedings, and seek timely resolutions to enhance certainty for all stakeholders.

• Lilly believes that generic and biosimilar medicines are important for sustainable health systems, and that certain activities related to seeking regulatory approval should be exempt from patent infringement.

• Lilly believes that advancing public health depends on robust IP, rights as well as collaboration among stakeholders, and may call for tailored uses of our IP where these add value for patients.

• Lilly will approach IP in the world’s poorest countries in ways that considers their unique socio-economic challenges.

As part of our process for determining whether to apply for patent protection for new innovation, we conduct a fact-specific and complicated analysis in connection with patent applications for potential products or uses, including for secondary and tertiary patents. Once filed, those patent applications are examined by patent offices around the world to ensure any patent granted meets stringent legal requirements for patentability, including that the invention is appropriately described, new, and not obvious. The statutory text underlying the patent examination standards makes no distinction between the patentability requirements for applications directed to different technologies or for different application types. The IP PACT principles help guide our patent decisions and ensure that we consider product access as part of our evaluation.

Patent strategy involves complicated decisions at the core of the company’s business model, and is key to the company’s ability to invest in future innovation.

We are proud of the work we do to increase access to medicines around the world. Intellectual property protection through patents is critical to Lilly’s ability to achieve this work, successfully commercialize our innovations and invest in the search for new medicines and indications. Like other companies in our industry, Lilly could not invest or operate to research, discover, develop, test, manufacture or deliver existing and new medicines for patients without an effective patent application strategy. Given the nature of our business, without obtaining patent protections, we could not make the significant investments necessary to develop new medicines or further develop already-approved products. There is a high rate of failure inherent in new drug discovery. To bring a drug from the discovery phase to market can take over a decade and can often cost in excess of $2 billion. Failure can occur at any point in the process, including in later stages after substantial investment. As a result, most funds invested in research programs will not generate financial returns. The decisions of when to incur technical risk, time, effort, and significant expense to seek to develop a new product or develop new indications or new medicine delivery options (the typical innovation sources for so-called “secondary” patents), and when to permit copying of an already-approved product are complicated decisions at the core of the company’s business model. Lilly’s process for patent prosecution is thoughtful and overseen by legal experts focused on compliance with applicable laws. Subjecting this process to additional cumbersome procedures and shareholder oversight would interfere with Lilly’s operations and management’s ability to run the business.

There have been many misleading assertions that have been publicized regarding basic facts and inaccurate data about the pharmaceutical industry’s patent practices.\(^5\) The misleading and factually inaccurate information reveals a misunderstanding of the critical role of patents in sustaining and incentivizing an ecosystem that is fundamental for patient access to innovative drugs and that leads to the reliable entry of lower-cost biosimilar and generic drugs. Such misunderstanding, combined with the misleading data presented around patents is in fact ultimately antithetical to patient access to innovative and lower-cost biosimilar and generic drugs. Due to the importance of and complexities involved in patent strategy, Lilly uses a framework (described above) to guide the internal experts who have the factual details to make patent strategy decisions on behalf of the company. In

\(^5\) See, e.g., Adam Mossoff, Unreliable Data Have Infected the Policy Debates Over Drug Patents (Jan. 2022); Letter from Sen. Thom Tillis to Dr. Janet Woodcock and Mr. Drew Hirshfeld (Jan. 31, 2022); Letter from Sen. Thom Tillis to Dr. Robert Califf and Mr. Drew Hirshfeld (Apr. 1, 2022); Erika Lietzan & Kristina Acri née Lybecker, Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations, 33 Fordham Intell. Prop., Media & Ent. L.J., at 1 (forthcoming). As noted by Mossoff, the data underlying sources for the proponent’s statement include “reported numbers of issued patents, patent applications, and exclusivity periods for drugs are infected with serious questions of reliability and accuracy...[with]repeated and vast discrepancies” from official, publicly available government sources like the FDA’s Orange Book. This data relied upon “has wrongfully inflated the purported number of patents covering biopharmaceutical products and has extended their predictions of loss of exclusivity dates beyond reality...”
addition, and as explained above, Lilly has already provided public disclosure concerning its patent application process that is responsive to the proposal’s request.

Lilly provides information on its goals and approach to access to medicine.

As further discussed in this proxy statement, on our website, in our Environmental, Social, and Governance Report, and in other public materials, Lilly provides extensive disclosure regarding goals and initiatives related to access and affordability of our medicines. For example, our global access program—30x30—is our strategy to invest in pipeline and efforts to increase access to 30 million people in resource limited settings by 2030. In the U.S., Lilly has taken many steps to increase access and affordability through price reductions and through LillyDirect, which offers disease management resources for certain diseases, including access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.6

Requiring Lilly to prepare a separate report with the information requested by the proposal would place an undue administrative burden on the company and would not provide meaningful additional information to shareholders.

We do not believe the separate report requested by the proposal would provide meaningful additional information to shareholders to merit the resources required to provide the report. For all of these reasons, we believe the proposal is not in the best interests of the company and its shareholders.

RECOMMENDATION AGAINST

The board recommends that you vote AGAINST this proposal.

Item 9. Proposal to Adopt a Comprehensive Human Rights Policy

CommonSpirit Health, 444 West Lake Street, Chicago, IL 60606, as lead filer, along with several co-filers, each a beneficial owner of shares of our common stock having a market value in excess of $2,000, has submitted the following proposal:

RESOLVED, that shareholders of Eli Lilly and Company (“Lilly” or the “Company”) urge the board of directors to adopt a comprehensive human rights policy, referencing internationally recognized human rights standards, that applies to both its own operations and its suppliers that includes the right to health and establishes a process to identify, prevent, mitigate, and remedy adverse human rights impacts, above and beyond supplier audits.

Supporting Statement:

Lilly currently has a code of conduct (the “Code”) applicable to its suppliers, which refers to nondiscrimination and “uphold[ing] the human and employment rights of workers” and includes Lilly’s expectation that suppliers will “abstain from procuring materials from all conflict areas or sources including the Democratic Republic of Congo.”1 Similarly, the Pharmaceutical Supply Chain Initiative (“PSCI”) Principles,2 a link to which appears on Lilly’s website, includes an expectation that suppliers respect workplace human rights. Neither the Code nor PSCI Principles references any internationally recognized human rights standards, nor do they apply to Lilly’s own business and operations, just those of its suppliers.

Although the human rights of workers mentioned in the Code and PSCI Principles are important, we believe that a global pharmaceutical firm like Lilly must also commit to respect the human right to health. The Universal Declaration of Human Rights (“UDHR”) states, “Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, including . . . medical care.”3 Article 12.1 of the International

---

6 See Lilly news releases Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month (Mar. 1, 2023); Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch “Tap the Cap” (Jun. 20,2023); Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ (Jan. 4, 2024).

1 https://assets.ctfassets.net/srys4ukjcerm/1Y51D0izDLx03DFP1mlZps/eea5bbbc50251e48ff3a020f0e81e6a5/Lilly_SCoBC_2021_EN.pdf

2 https://pscinitiative.org/principles

Covenant on Economic, Social, and Cultural Rights ("ICESCR") “recognize[s] the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.”

Target 3.8 of Sustainable Development Goal 3 assesses progress toward “access to safe, effective, quality and affordable essential medicines and vaccines for all.” Insulin has been on the World Health Organization’s essential medicines list since 1977. The UN Special Rapporteur on the Right to Health has made clear that responsibility for increasing access to medicines is shared between states and pharmaceutical firms and recommends that firms “should adopt a human rights policy statement which expressly recognises the importance of human rights generally, and the right to the highest attainable standard of health in particular.” Novartis has done so, adopting a human rights commitment statement that incorporates the right to health, including access to medicine, and references the UDHR and ICRSCR.

A process to identify, prevent, mitigate, and remedy adverse human rights impacts—“human rights due diligence”—is a key part of a comprehensive human rights policy. The Code makes no mention of how Lilly evaluates and enforces suppliers’ compliance with the Code’s vague expectations, aside from a reporting hotline. The PSCI Principles contemplate supplier audits, whose effectiveness has been questioned. Including a human rights due diligence process in its human rights policy, as Novartis has done, would enable Lilly to identify potential impacts before they occur, track its human rights performance, and embed human rights in its operations.

Lilly’s Opposing Statement

The board, after review by its Directors and Corporate Governance Committee, recommends a vote AGAINST this proposal.

As discussed in more detail below, the action requested by the proposal is unnecessary because:

- Lilly signed on to the United Nations Global Compact (UNGC) in 2009 and is committed to the UNGC’s Ten Principles on respecting internationally proclaimed human rights, labor, environment and anti-corruption.
- Lilly’s human rights commitments and efforts with respect to its own operations and its suppliers, including Lilly’s commitment related to global access and health, are already reported in our Environmental, Social, and Governance Report; and
- A standalone policy is redundant and unnecessary.

Lilly has disclosed its human rights commitments and efforts, including a commitment to global access and health and to the United Nations Global Compact (UNGC).

One of our long-established core values – respect for people – guides us to maintain and uphold an environment built on mutual respect, openness and individual integrity. Our purpose of making life better guides our commitment to ensure employees, partners and suppliers uphold our values and respect human rights as we work together to improve lives.

Lilly is a 15 year signatory to the United Nations Global Compact and is committed to its Ten Principles on respecting internationally proclaimed human rights, labor, environment and anti-corruption. We provide an index in our Environmental, Social, and Governance Report that maps each of the UNGC principles to the location of disclosure about efforts related to that principle. We also expect our suppliers to uphold Lilly values and standards as outlined in our Supplier Code of Conduct. In 2011, we revised our global standards and procedures to include specific language about human rights, including our expectation that our vendors abide by Lilly’s human rights standards.
Our Environmental, Social, and Governance Report outlines our commitments and efforts on human rights topics, including that:

- Lilly adheres to human rights and labor laws, complies with anti-corruption practices, and endeavors for a diverse supplier base;

- Lilly has adopted a supplier code of business conduct, which applies to all suppliers, and includes such topics as ethical business practices, upholding human and employment rights of workers, treating workers with dignity and respect, prohibition against forced labor, rejection of child labor, freedom from exposure to improper conduct (discrimination, retaliation, harassment), responsible sourcing of raw materials, maintaining safe and healthful working conditions, and compliance with wage laws;

- In addition to Lilly’s process for evaluating potential new contract manufacturers and routinely conducted formal assessments for existing contract manufacturers, Lilly has also taken steps to educate and engage its suppliers directly on health, safety and environmental issues and to help them build expertise around these topics;

- Lilly supports human rights in its own operations by (i) offering fair and competitive employment practices, including wages and benefits; (ii) promoting a safe and healthy workplace; (iii) fostering a more diverse, equitable and inclusive work environment; (iv) cultivating diverse talent through the recruitment process, learning and development, and the advancement and retention of people with wide-ranging backgrounds and experiences; (v) complying with local minimum age laws and requirements and not employing child labor, or forced or compulsory labor; and (vi) respecting freedom of association in the workplace;

- Lilly develops and administers our research and development efforts and clinical trials in ways that support our commitment to human rights, such as bioethics and clinical trial diversity;

- Lilly has adopted a code of business conduct, policies, compliance management systems, HR performance and promotion systems, training programs and communications initiatives designed to work together to reinforce a culture of integrity and ethical behavior; and

- Lilly encourage employees and suppliers to share concerns openly and honestly – including on issues of human rights.

In addition, also as described in our Environmental, Social, and Governance Report, we are committed to equitable and affordable access to our medicines and to expanding our impact on society by addressing complex global health challenges, with a focus on people living in communities with limited resources. We contribute to the global drive for universal health coverage as part of the UN Sustainable Development Goals through our continued investment in developing medicines to address unmet medical needs around the world, our efforts to extend the reach of our existing medicines to more people who need them, and our efforts to strengthen health systems and policies.

Lilly’s “30x30” program strives to improve access to quality health care for 30 million people living in settings with limited resources annually by 2030. We are working to develop high-impact, scalable solutions for people living in communities with limited resources through our pipeline, programming and relationships with that strengthen health systems and increase access to medicines. See the “Proxy Statement Summary” for specific examples of some of our efforts in global access and affordability.

In support of its request that Lilly adopt a human rights policy, this proposal states: “Insulin has been on the World Health Organization’s essential medicines list since 1977.” Lilly takes its role as a leading diabetes company seriously, and we believe that includes ensuring people have affordable access to insulin therapies. As described in more detail in the “Proxy Statement Summary”, Lilly has taken many actions over the years to increase insulin access and affordability around the world. Today, anyone in the United States is eligible to obtain a monthly prescription of Lilly insulin for $35 or less — regardless of the number of vials or pens — whether they are uninsured or use commercial insurance, Medicaid or a participating Medicare Part D plan. In addition, Lilly has entered into collaborations around the world to increase access to affordable insulin.

**A separate human rights policy is redundant and unnecessary.**

We believe that human rights is an important issue that is not static. We will continue to monitor human rights issues that are relevant to our operations around the globe and, when appropriate, will make changes to our commitments, policies and practices in order to maintain our continued commitment to human rights. We will
continue to use our supplier code of business conduct, corporate code of business conduct, and our stated human rights commitments as frameworks to guide our constructive engagement on human rights issues.

Our human rights commitments, efforts and progress are already disclosed in our Environmental, Social, and Governance Report. We do not believe a separate policy is necessary.

**RECOMMENDATION AGAINST**

The board recommends that you vote **AGAINST** this proposal.

---

**Other Information**

**Meeting and Voting Logistics**

**Quorum**

A majority of the outstanding shares entitled to vote, present or represented by proxy, constitutes a quorum for the Annual Meeting. As of February 28, 2024, 950,766,100 shares of company common stock were issued and outstanding.

**Who Can Vote**

Shareholders as of the close of business on February 28, 2024 (the record date) may vote or have their shares voted at the Annual Meeting. You have one vote for each share of common stock you held on the record date, including shares:

- held directly in your name as the shareholder of record;
- held for you in an account with a broker, bank, or other nominee; and
- attributed to your account in the company's 401(k) Plan.

**Why You May Receive Multiple Notices, Proxy Materials, or Emails**

If you received more than one notice, full set of proxy materials, or email related to proxy materials, you hold shares in more than one account. You will need to cast a vote for each notice, full set of proxy materials, or email you receive. If you do not receive a proxy card, you may have elected to receive your proxy statement electronically, in which case you should have received an email with directions on how to access this proxy statement and how to vote your shares. If you wish to request a paper copy of these materials and a proxy card, please call 1-800-579-1639 on or before April 22, 2024, to facilitate timely delivery.
## Voting Choices

<table>
<thead>
<tr>
<th>Voting Matter</th>
<th>Required Vote</th>
<th>Voting Options</th>
<th>Effect of Abstentions</th>
<th>Broker Discretionary Voting Allowed?</th>
<th>Effect of Broker Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Election of directors</td>
<td>Majority of votes cast</td>
<td>FOR, AGAINST or ABSTAIN (for each director nominee)</td>
<td>No effect - not counted as a &quot;vote cast&quot;</td>
<td>No</td>
<td>No effect</td>
</tr>
<tr>
<td>Advisory vote on compensation paid to named executive officers</td>
<td>Majority of votes cast</td>
<td>FOR, AGAINST or ABSTAIN</td>
<td>No effect - not counted as a &quot;vote cast&quot;</td>
<td>No</td>
<td>No effect</td>
</tr>
<tr>
<td>Ratification of the appointment of the independent auditor</td>
<td>Majority of votes cast</td>
<td>FOR, AGAINST or ABSTAIN</td>
<td>No effect - not counted as a &quot;vote cast&quot;</td>
<td>Yes</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Proposal to amend the company’s articles of incorporation to eliminate the classified board structure</td>
<td>80% of outstanding shares</td>
<td>FOR, AGAINST or ABSTAIN</td>
<td>Treated as a vote AGAINST the proposal</td>
<td>No</td>
<td>Treated as a vote AGAINST the proposal</td>
</tr>
<tr>
<td>Proposal to amend the company’s articles of incorporation to eliminate supermajority voting provisions</td>
<td>80% of outstanding shares</td>
<td>FOR, AGAINST or ABSTAIN</td>
<td>Treated as a vote AGAINST the proposal</td>
<td>No</td>
<td>Treated as a vote AGAINST the proposal</td>
</tr>
<tr>
<td>Shareholder Proposals</td>
<td>Majority of votes cast</td>
<td>FOR, AGAINST or ABSTAIN (for each shareholder proposal)</td>
<td>No effect - not counted as a &quot;vote cast&quot;</td>
<td>No</td>
<td>No effect</td>
</tr>
</tbody>
</table>

### Additional Items of Business

We do not expect any items of business to be submitted to shareholders at the Annual Meeting other than the proposals referred to in this proxy statement. Nonetheless, if necessary, the persons named on the proxy have discretionary authority to vote the shares represented thereby with respect to any other matters that might be brought before the meeting. Those persons intend to vote on any such matters in accordance with their best judgment.

### Vote Tabulation

Votes are tabulated by an independent inspector of election, Broadridge Financial Solutions, Inc.

### List of Shareholders of Record

A list of the names of shareholders entitled to vote at the Annual Meeting will be available to shareholders for five business days prior to the Annual Meeting for any purpose germane to the Annual Meeting. Please contact us at shareholderproposals@lilly.com if you wish to examine the list prior to the Annual Meeting. The shareholder list will also be available during the virtual Annual Meeting for examination by shareholders who access the Annual Meeting using their 16-digit control number at virtualshareholdermeeting.com/LLY2024.

### The 2025 Annual Meeting

The company’s 2025 annual meeting of shareholders is currently scheduled for May 5, 2025.
# How to Vote

You may vote by any one of the following methods:

<table>
<thead>
<tr>
<th>Shareholders of Record</th>
<th>Shares Held by a Broker</th>
<th>Shares Held in the Company 401(k) Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Online</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vote online at <a href="https://www.proxyvote.com">ProxyVote.com</a></td>
<td>The broker will ask you how you want your shares to be voted. You may instruct your broker or other nominee to vote your shares by following instructions that the broker or nominee provides to you. Most brokers offer voting by mail, by telephone, and online. You may submit new voting instructions by contacting your broker or other nominee or, if your broker provides you with a 16-digit control number found on the voting instruction form for <a href="https://www.proxyvote.com">ProxyVote.com</a>, by signing in with your 16-digit control number and voting at the Annual Meeting.</td>
<td>Vote online at <a href="https://www.proxyvote.com">ProxyVote.com</a>.</td>
</tr>
<tr>
<td><strong>Telephone</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Call 1-800-690-6903 using a touch-tone phone and follow the instructions provided.</td>
<td>Call 1-800-690-6903 using a touch-tone phone and follow the instructions provided.</td>
<td>Call 1-800-690-6903 using a touch-tone phone and follow the instructions provided.</td>
</tr>
<tr>
<td><strong>Mail</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sign, date, and return each proxy card you received in the prepaid envelope.</td>
<td>Sign, date, and return the voting instruction form you received in the prepaid envelope.</td>
<td>Plan shares cannot be voted at the meeting. The Trustee must receive your instructions by one of the methods above by May 1, 2024.</td>
</tr>
<tr>
<td><strong>At the Meeting</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow the instructions at <a href="https://virtualshareholdermeeting.com/LLY2024">virtualshareholdermeeting.com/LLY2024</a> to vote during the meeting</td>
<td>Please refer to the information provided by your broker, bank or other nominee.</td>
<td>11:59 p.m. EDT on May 1, 2024.</td>
</tr>
</tbody>
</table>

**Voting Deadline:** 11:59 p.m. EDT on May 5, 2024, unless you are voting at the meeting.

We encourage you to vote by mail, by telephone, or online even if you plan to attend the Annual Meeting.

**General:** Follow the instructions on your proxy card, voting instruction form or notice. If you received these materials electronically, follow the instructions in the email message that notified you of their availability.

**Signing your proxy card or voting instruction form:** Sign your name exactly as it appears. If you are signing in a representative capacity (for example, as an attorney-in-fact, executor, administrator, guardian, trustee, or the officer or agent of a corporation or partnership), please indicate your name and your title or capacity. If the stock is held in custody for a minor (for example, under the Uniform Transfers to Minors Act), the custodian should sign, not the minor. If the stock is held in joint ownership, one owner may sign on behalf of all owners. If you return your signed proxy but do not indicate your voting preferences, the proxy holder will vote on your behalf based upon the board’s recommendations.

**Voting Deadlines:**

- Shareholders of record may vote their shares prior to the Annual Meeting until 11:59 p.m. EDT on May 5, 2024, by mail, online, or by telephone. If you are voting by mail, your marked, signed, and dated proxy card must be received by May 5, 2024. You have the right to change your vote or revoke your proxy before it is voted at the Annual Meeting by (i) timely notifying the General Counsel and Secretary in writing, (ii) timely delivering a later-dated proxy by mail, (iii) timely casting a new vote online or by telephone, or (iv) voting at the Annual Meeting.

- Shareholders who hold their shares in the 401(k) Plan must vote by 11:59 p.m. EDT on May 1, 2024 (mailed ballots must be received by the trustee by this time), so the plan trustee can vote the shares accordingly.

- Shareholders whose shares are held by a broker should follow the instructions and deadlines on your proxy card, voter instruction form or notice. If you received these materials electronically, follow the
instructions in the email message that notified you of their availability. You may submit new voting instructions by contacting your broker or other nominee or by voting at the Annual Meeting.

**Broker Non-Votes:** If your shares are held through a broker and you give the broker instructions, your shares will be voted as you direct. If you do not provide voting instructions, your shares will not be voted on any proposal on which the broker does not have discretionary authority to vote. This is called a “broker non-vote.” In these cases, the broker can register your shares as being present at the Annual Meeting for purposes of determining the presence of a quorum and will be able to use their discretionary voting authority under NYSE rules to vote your shares on the ratification of EY as the independent auditor for 2024. However, the broker will not be able to vote on those matters for which specific authorization is required under NYSE rules, such as to vote on the election of directors, the advisory approval of executive compensation, or the shareholder or management proposals without instructions from you, in which case a broker non-vote will occur, and your shares will not be voted on these matters.

**Additional Voting Information for shares held in the company 401(k) Plan:** If you hold shares in the company 401(k) Plan, unless you decline, your vote will apply to a proportionate number of other shares held by participants in the 401(k) Plan for which voting directions are not received (except for a small number of shares from a prior stock ownership plan, which can be voted only on the directions of the participants to whose accounts the shares are credited).

All participants are named fiduciaries under the terms of the 401(k) Plan and under the Employee Retirement Income Security Act (ERISA) for the limited purpose of voting shares credited to their accounts and the portion of undirected shares to which their vote applies. Under ERISA, fiduciaries are required to act prudently in making voting decisions.

If you do not want to have your vote applied to the undirected shares, you must so indicate when you vote. Otherwise, the trustee will automatically apply your voting preferences to the undirected shares proportionally with all other participants who elected to have their votes applied in this manner.

If you do not vote by the deadline, your shares will be voted in accordance with instructions received from other plan participants who have elected to have their voting preferences applied proportionally to all shares for which voting instructions are not otherwise received.

**Attending the Annual Meeting**

**Who:** All shareholders as of close of business on February 28, 2024 are entitled to participate.

**When:** Monday, May 6, 2024, starting at 8:30 a.m. EDT and ending at or before 9:15 a.m. EDT. Following the formal meeting and after agenda items are addressed there will be an opportunity for shareholder questions.

**Where:** The live webcast of the Annual Meeting can be accessed by shareholders on the day of the meeting at virtualshareholdermeeting.com/LLY2024. To attend the Annual Meeting, you will need to log in to virtualshareholdermeeting.com/LLY2024 using the 16-digit control number found on the proxy card, voting instruction form, or notice you previously received. This website can be accessed on a computer, tablet, or phone with internet connection. Online access to the webcast will open 15 minutes prior to the start of the Annual Meeting to allow time to log in and test your device’s audio system. We encourage you to access the meeting in advance of the designated start time.

Although you will not be able to attend the Annual Meeting at a physical location, we have designed the Annual Meeting live webcast to provide shareholders the opportunity to participate virtually to facilitate shareholder attendance and provide a consistent experience to all shareholders, regardless of location.

**Asking Questions:** To submit questions in advance of the Annual Meeting, visit ProxyVote.com before May 6, 2024, and enter your 16-digit control number. During the meeting, if you wish to submit a question, log into the virtual meeting website at virtualshareholdermeeting.com/LLY2024, click on “Q&A,” type your question into the “Submit a Question” field, and click “Submit.” In order to provide an opportunity to as many shareholders as possible who wish to ask a question, each shareholder will be limited to one question. Shareholders may ask a second question if all other shareholders have had an opportunity to ask a question and if time allows. We will endeavor to answer as many questions submitted by shareholders as time permits. We reserve the right to edit
profanity or other inappropriate language, to simplify language and to exclude questions regarding topics that are not pertinent to meeting matters or company business. If we receive substantially similar questions, we may group such questions together and provide a single response to avoid repetition. As appropriate, responses to questions relevant to meeting matters that we do not have time to respond to by the 9:15 a.m. EDT end time will be posted to our website following the meeting. Questions regarding topics that are not pertinent to meeting matters or company business will not be answered.

**Technical Assistance:** Support staff will be available on the meeting day should you experience any technical difficulties in accessing the virtual meeting. Instructions for requesting technical assistance will be available at virtualshareholdermeeting.com/LLY2024.

**Other Matters**

**Notice and Access**

We distribute proxy materials to many shareholders via the internet under the SEC’s “Notice and Access” rules to reduce production and mailing costs and to help preserve environmental resources. Using this method of distribution, on or about March 22, 2024, we mailed the Notice Regarding the Availability of Proxy Materials that contains basic information about the Annual Meeting and instructions on how to view all proxy materials and vote. If you receive the notice and prefer to receive proxy materials by regular mail or email, follow the instructions in the notice for making this request, and the materials will be sent promptly to you via the preferred method. If you prefer to vote by phone rather than online, the website listed on the notice (ProxyVote.com) has instructions for voting by phone.

**Householding**

We have adopted a procedure approved by the SEC called “householding.” Under the householding procedure, certain shareholders, whether they own registered shares or shares in street name, who have the same address and who receive either notices or paper copies of the proxy materials in the mail will receive only one copy of our proxy materials, or a single notice, for all shareholders at that address, unless one or more of the shareholders at that address has previously notified us that they want to receive separate copies. Each 401(k) Plan participant will continue to receive a copy of all of the proxy materials. Regardless of how you own your shares, if you received a single set of proxy materials as a result of householding, and one or more shareholders at your address would like to have separate copies of these materials with respect to the Annual Meeting or in the future, or if you would like to request that only a single set of proxy materials be sent to the household, please contact Broadridge Financial Solutions, Inc., at 1-866-540-7095 or 51 Mercedes Way, Edgewood, NY 11717.

**Other Information Regarding the Company’s Proxy Solicitation**

The board is soliciting proxies for the Annual Meeting. We will pay all expenses in connection with our solicitation of proxies. We will pay brokers, nominees, fiduciaries, or other custodians their reasonable expenses for sending proxy material to and obtaining instructions from persons for whom they hold stock of the company. We expect to solicit proxies primarily by mail and email, but directors, officers, and other employees of the company may also solicit in person or by telephone, fax, or email. We have retained Georgeson LLC to assist in the distribution and solicitation of proxies. Georgeson may solicit proxies by personal interview, telephone, fax, mail, and email. We expect that the fee for those services will not exceed approximately $17,500 plus reimbursement of customary out-of-pocket expenses.

**Corporate Governance Materials**

The company’s main corporate website address is lilly.com. We also make available through our investor relations website, free of charge, our company filings with the SEC as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents. The website link to our SEC filings is investor.lilly.com/sec.cfm. This proxy statement and the annual report to shareholders are also available at ProxyVote.com as well as on our website at lilly.com/policies-reports/annual-report, and the articles of incorporation, bylaws, and all committee charters are available online at lilly.com/leadership/governance. Certain documents and information referenced in this proxy statement are available on our website. However, except as otherwise expressly provided in this proxy statement, we are not including the information contained on our website, or any information that may
be accessed by links on our website, as part of, or incorporating it by reference into, this proxy statement.

By order of the Board of Directors,

**Anat Hakim**  
Executive Vice President, General Counsel and Secretary  
March 22, 2024

---

**Electronic Delivery of Proxy Materials**

**Help Us Help the Environment**

We encourage shareholders to voluntarily elect to receive future proxy materials and annual reports electronically to help contribute to our sustainability efforts.

The benefits include:

- you receive immediate and convenient access to the materials,
- you can help reduce our impact on the environment, and
- you can help reduce our printing and mailing costs.

### How to Enroll

<table>
<thead>
<tr>
<th>Shareholders of Record</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Internet</strong></td>
<td><a href="http://www.proxyvote.com">www.proxyvote.com</a> under the “Delivery Settings” tab</td>
</tr>
<tr>
<td><strong>Telephone</strong></td>
<td>1-800-690-6903 and follow the instructions provided</td>
</tr>
</tbody>
</table>

**Shares Held by Broker**

<table>
<thead>
<tr>
<th>Contact</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Email</strong></td>
<td>Send a blank email with your control number in the subject line to: <a href="mailto:sendmaterial@proxyvote.com">sendmaterial@proxyvote.com</a></td>
</tr>
<tr>
<td><strong>Contact</strong></td>
<td>Contact your bank, broker or other nominee</td>
</tr>
</tbody>
</table>
Appendix A - Summary of Adjustments Related to the Annual Cash Bonus and Performance Award

Consistent with past practice, the Talent and Compensation Committee adjusted the reported financial results on which the 2023 annual cash bonus and the 2022-2024 performance awards were determined to eliminate the distorting effect of certain unusual items on incentive compensation performance measures. The adjustments were intended to:

- align award payments with the underlying performance of the core business
- avoid volatile, artificial inflation or deflation of awards due to unusual items during any year in the performance period, and, where relevant, the previous (comparator) year
- eliminate certain counterproductive short-term incentives—for example, incentives to refrain from acquiring new technologies, to defer disposing of underutilized assets, or to defer settling legacy legal proceedings to protect current bonus payments
- facilitate comparisons with peer companies

To ensure the integrity of the adjustments, the Talent and Compensation Committee reviews and approves adjustment guidelines at least annually. These guidelines are generally consistent with the company guidelines for reporting non-GAAP financial measures to the investment community, which are reviewed by the Audit Committee. The adjustments apply equally to income and expense items. The Talent and Compensation Committee reviews all adjustments and retains downward discretion (i.e., discretion to reduce compensation below the amounts that are yielded by the adjustment guidelines).

Adjustments for 2023 Bonus Plan

For 2023 bonus calculations, the Talent and Compensation Committee made the following adjustments to reported EPS consistent with our external reporting of non-GAAP financial measures:

- Eliminated the impact of amortization of intangible assets
- Eliminated the impact of asset impairments, restructuring, and other special charges
- Eliminated the impact of net gains and losses on investments in equity securities

In addition to the adjustments consistent with our reporting of non-GAAP financial measures, the Talent and Compensation Committee made the following adjustments:

- Eliminated the impact of acquired in-process research and development (IPR&D) charges
- Eliminated the revenue and EPS impacts of business development transactions to divest certain products, including the divestitures of the olanzapine portfolio and Baqsimi, which were not in the company’s 2023 bonus targets for revenue and EPS.

A reconciliation of adjustments to our reported revenue is below:

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue as reported</td>
<td>$34,124.1</td>
</tr>
<tr>
<td>Divestitures of products</td>
<td>(1,672.1)</td>
</tr>
<tr>
<td>Adjusted revenue</td>
<td>$32,452.0</td>
</tr>
</tbody>
</table>
A reconciliation of adjustments to our reported EPS is below:

<table>
<thead>
<tr>
<th>2023</th>
<th></th>
<th>(%) Change</th>
<th>2023 vs. 2021</th>
<th>2022 vs. 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS as reported</td>
<td>$5.80</td>
<td>$6.90</td>
<td>(15.9)%</td>
<td>$6.12</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>0.45</td>
<td>0.50</td>
<td>(15.9)%</td>
<td>0.53</td>
</tr>
<tr>
<td>Asset impairments, restructuring, and other special charges</td>
<td>0.06</td>
<td>0.21</td>
<td>(71.4)%</td>
<td>0.28</td>
</tr>
<tr>
<td>Net losses (gains) on investments in equity securities</td>
<td>0.02</td>
<td>0.33</td>
<td>(94.1)%</td>
<td>(0.31)</td>
</tr>
<tr>
<td>Charge related to repurchase of debt</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.35</td>
</tr>
<tr>
<td>COVID-19 antibodies inventory charges</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.25</td>
</tr>
<tr>
<td>Non-GAAP EPS</td>
<td>6.32</td>
<td>7.94</td>
<td>7.39</td>
<td></td>
</tr>
<tr>
<td>Acquired IPR&amp;D charges</td>
<td>4.10</td>
<td>0.90</td>
<td>0.86</td>
<td></td>
</tr>
<tr>
<td>Adjusted Non-GAAP EPS for purposes of performance awards</td>
<td>$10.42</td>
<td>$8.84</td>
<td>17.9%</td>
<td>$8.25</td>
</tr>
</tbody>
</table>

*Numbers may not add due to rounding

Adjustments for 2022-2024 Performance Award

For the 2022-2024 performance award payout calculations, the Talent and Compensation Committee made the following adjustments to reported EPS consistent with our reporting of non-GAAP financial measures:

- 2023, 2022, and 2021: Eliminated the impact of amortization of intangible assets
- 2023, 2022, and 2021: Eliminated the impact of asset impairments, restructuring, and other special charges
- 2023, 2022, and 2021: Eliminated the impact of net gains and losses on investments in equity securities
- 2021: Eliminated the impact of charge related to the repurchase of debt
- 2021: Eliminated the impact of COVID-19 antibodies inventory charges that were recognized primarily due to changes in forecasted demand from U.S. and international governments

In addition to the adjustments consistent with our reporting of non-GAAP financial measures, the Talent and Compensation Committee made the following adjustment:

- 2023, 2022, and 2021: Eliminated the impact of charges recognized for acquired IPR&D

A reconciliation of adjustments to our reported EPS is below:

*Numbers may not add due to rounding
Appendix B - Proposed Amendments to the Company’s Articles of Incorporation

Proposed changes to the company’s articles of incorporation are shown below related to Items 4 and 5. The changes shown to Article 9(b) will be effective if Item 4, “Proposal to Amend the Company’s Articles of Incorporation to Eliminate the Classified Board Structure,” receives the vote of at least 80 percent of the outstanding shares. The changes to Articles 9(c), 9(d), and 13 will be effective if Item 5, “Proposal to Amend the Company’s Articles of Incorporation to Eliminate Supermajority Voting Provisions,” receives the vote of at least 80 percent of the outstanding shares. Additions are indicated by underlining and deletions are indicated by strikeouts. The full text of the company’s Articles of Incorporation can be found on our website at lilly.com/leadership/governance.

9. The following provisions are inserted for the management of the business and for the conduct of the affairs of the Corporation, and it is expressly provided that the same are intended to be in furtherance and not in limitation or exclusion of the powers conferred by statute:

(a) The number of directors of the Corporation, exclusive of directors who may be elected by the holders of any one or more series of Preferred Stock pursuant to Article 7(b) (the “Preferred Stock Directors”), shall not be less than nine, the exact number to be fixed from time to time solely by resolution of the Board of Directors, acting by not less than a majority of the directors then in office.

(b) Prior to the 2025 annual meeting of directors, the Board of Directors (exclusive of Preferred Stock Directors) shall be divided into three classes, with the term of office of one class expiring each year. At the annual meeting of shareholders in 1985, five directors of the first class shall be elected to hold office for a term expiring at the 1986 annual meeting, five directors of the second class shall be elected to hold office for a term expiring at the 1987 annual meeting, and six directors of the third class shall be elected to hold office for a term expiring at the 1988 annual meeting. Commencing with the annual meeting of shareholders in 1986, each class of directors whose term shall then expire shall be elected to hold office for a three-year term expiring at the next annual meeting of shareholders. In the case of any vacancy on the Board of Directors, including a vacancy created by an increase in the number of directors, the vacancy shall be filled by election of the Board of Directors with the director so elected to serve for the remainder of the term of the director being replaced or, in the case of an additional director, for the remainder of the term of the class to which the director has been assigned until the next annual meeting of shareholders. All directors shall continue in office until the election and qualification of their respective successors in office. When the number of directors is changed, any newly created directorships or any decrease in directorships shall be so assigned among the classes by a majority of the directors then in office, though less than a quorum, as to make all classes as nearly equal in number as possible. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Election of directors need not be by written ballot unless the By-laws so provide.

(c) Any director or directors (exclusive of Preferred Stock Directors) may be removed from office at any time, but only for cause and only by the affirmative vote of at least 80% of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock (as defined in Article 13 hereof), voting together as a single class.

(d) Notwithstanding any other provision of these Amended Articles of Incorporation or of law, which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class of Voting Stock required by law or these Amended Articles of Incorporation, the affirmative vote of at least 80% of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock, voting together as a single class, shall be required to alter, amend or repeal this Article 9.

13. In addition to all other requirements imposed by law and these Amended Articles and except as otherwise expressly provided in paragraph (c) of this Article 13, none of the actions or transactions listed below shall be effected by the Corporation, or approved by the Corporation as a shareholder of any majority-owned subsidiary of the Corporation if, as of the record date for the determination of the shareholders entitled to vote thereon, any Related Person (as hereinafter defined) exists, unless the applicable requirements of paragraphs (b), (c), (d), (e), and (f) of this Article 13 are satisfied.
(a) The actions or transactions within the scope of this Article 13 are as follows:

(i) any merger or consolidation of the Corporation or any of its subsidiaries into or with such Related Person;

(ii) any sale, lease, exchange, or other disposition of all or any substantial part of the assets of the Corporation or any of its majority-owned subsidiaries to or with such Related Person;

(iii) the issuance or delivery of any Voting Stock (as hereinafter defined) or of voting securities of any of the Corporation's majority-owned subsidiaries to such Related Person in exchange for cash, other assets or securities, or a combination thereof;

(iv) any voluntary dissolution or liquidation of the Corporation;

(v) any reclassification of securities (including any reverse stock split), or recapitalization of the Corporation, or any merger or consolidation of the Corporation with any of its subsidiaries, or any other transaction (whether or not with or otherwise involving a Related Person) that has the effect, directly or indirectly, of increasing the proportionate share of any class or series of capital stock of the Corporation, or any securities convertible into capital stock of the Corporation or into equity securities of any subsidiary, that is beneficially owned by any Related Person; or

(vi) any agreement, contract, or other arrangement providing for any one or more of the actions specified in the foregoing clauses (i) through (iv).

(b) The actions and transactions described in paragraph (a) of this Article 13 shall have been authorized by the affirmative vote of at least 80% of all holders of Voting Stock, voting together as a single class.

(c) Notwithstanding paragraph (b) of this Article 13, the 80% voting special shareholder approval requirement set forth in paragraph (b) shall not be applicable if any action or transaction specified in paragraph (a) is approved by the Corporation's Board of Directors and by a majority of the Continuing Directors (as hereinafter defined).

(d) Unless approved by a majority of the Continuing Directors, after becoming a Related Person and prior to consummation of such action or transaction:

(i) the Related Person shall not have acquired from the Corporation or any of its subsidiaries any newly issued or treasury shares of capital stock or any newly issued securities convertible into capital stock of the Corporation or any of its majority-owned subsidiaries, directly or indirectly (except upon conversion of convertible securities acquired by it prior to becoming a Related Person or as a result of a pro rata stock dividend or stock split or other distribution of stock to all shareholders pro rata);

(ii) such Related Person shall not have received the benefit, directly or indirectly (except proportionately as a shareholder), of any loans, advances, guarantees, pledges, or other financial assistance or tax credits provided by the Corporation or any of its majority-owned subsidiaries, or made any major changes in the Corporation's or any of its majority-owned subsidiaries' businesses or capital structures or reduced the current rate of dividends payable on the Corporation's capital stock below the rate in effect immediately prior to the time such Related Person became a Related Person; and

(iii) such Related Person shall have taken all required actions within its power to ensure that the Corporation's Board of Directors included representation by Continuing Directors at least proportionate to the voting power of the shareholdings of Voting Stock of the Corporation's Remaining Public Shareholders (as hereinafter defined), with a Continuing Director to occupy an additional Board position if a fractional right to a director results and, in any event, with at least one Continuing Director to serve on the Board so long as there are any Remaining Public Shareholders.

(e) A proxy statement responsive to the requirements of the Securities Exchange Act of 1934, as amended, whether or not the Corporation is then subject to such requirements, shall be mailed
to the shareholders of the Corporation for the purpose of soliciting shareholder approval of such action or
transaction and shall contain at the front thereof, in a prominent place, any recommendations as to the
advisability or inadvisability of the action or transaction which the Continuing Directors may choose to
state and, if deemed advisable by a majority of the Continuing Directors, the opinion of an investment
banking firm selected by a majority of the Continuing Directors as to the fairness (or not) of the terms of
the action or transaction from a financial point of view to the Remaining Public Shareholders, such
investment banking firm to be paid a reasonable fee for its services by the Corporation. The requirements
of this paragraph (e) shall not apply to any such action or transaction which is approved by a majority of
the Continuing Directors.

(f) For the purpose of this Article 13:

(i) the term "Related Person" shall mean any other corporation, person, or entity
which beneficially owns or controls, directly or indirectly, 5% or more of the outstanding shares of
Voting Stock, and any Affiliate or Associate (as those terms are defined in the General Rules and
Regulations under the Securities Exchange Act of 1934) of a Related Person; provided, however,
that the term Related Person shall not include (a) the Corporation or any of its subsidiaries, (b)
any profit-sharing, employee stock ownership or other employee benefit plan of the Corporation
or any subsidiary of the Corporation or any trustee of or fiduciary with respect to any such plan
when acting in such capacity, or (c) Lilly Endowment, Inc.; and further provided, that no
corporation, person, or entity shall be deemed to be a Related Person solely by reason of being
an Affiliate or Associate of Lilly Endowment, Inc.;

(ii) a Related Person shall be deemed to own or control, directly or indirectly, any
outstanding shares of Voting Stock owned by it or any Affiliate or Associate of record or
beneficially, including, without limitation, shares

a. which it has the right to acquire pursuant to any agreement, or upon
exercise of conversion rights, warrants, or options, or otherwise; or

b. which are beneficially owned, directly or indirectly (including shares
deemed owned through application of clause a. above), by any other corporation, person,
or other entity with which it or its Affiliate or Associate has any agreement, arrangement,
or understanding for the purpose of acquiring, holding, voting, or disposing of Voting
Stock, or which is its Affiliate (other than the Corporation) or Associate (other than the
Corporation);

(iii) the term "Voting Stock" shall mean all shares of any class of capital stock of the
Corporation which are entitled to vote generally in the election of directors;

(iv) the term "Continuing Director" shall mean a director who is not an Affiliate or
Associate or representative of a Related Person and who was a member of the Board of
Directors of the Corporation immediately prior to the time that any Related Person involved in the
proposed action or transaction became a Related Person or a director who is not an Affiliate or
Associate or representative of a Related Person and who was nominated by a majority of the
remaining Continuing Directors; and

(v) the term "Remaining Public Shareholders" shall mean the holders of the
Corporation’s capital stock other than the Related Person.

(g) A majority of the Continuing Directors of the Corporation shall have the power and duty to
determine for the purposes of this Article 13, on the basis of information then known to the Continuing
Directors, whether (i) any Related Person exists or is an Affiliate or an Associate of another and (ii) any
proposed sale, lease, exchange, or other disposition of part of the assets of the Corporation or any
majority-owned subsidiary involves a substantial part of the assets of the Corporation or any of its
subsidiaries. Any such determination by the Continuing Directors shall be conclusive and binding for all
purposes.

(h) Nothing contained in this Article 13 shall be construed to relieve any Related Person or
any Affiliate or Associate of any Related Person from any fiduciary obligation imposed by law.

(i) The fact that any action or transaction complies with the provisions of this Article 13 shall
not be construed to waive or satisfy any other requirement of law or these Amended Articles of Incorporation or to impose any fiduciary duty, obligation, or responsibility on the Board of Directors or any member thereof, to approve such action or transaction or recommend its adoption or approval to the shareholders of the Corporation, nor shall such compliance limit, prohibit, or otherwise restrict in any manner the Board of Directors, or any member thereof, with respect to evaluations of or actions and responses taken with respect to such action or transaction. The Board of Directors of the Corporation, when evaluating any actions or transactions described in paragraph (a) of this Article 13, shall, in connection with the exercise of its judgment in determining what is in the best interests of the Corporation and its shareholders, give due consideration to all relevant factors, including, without limitation, the social and economic effects on the employees, customers, suppliers, and other constituents of the Corporation and its subsidiaries and on the communities in which the Corporation and its subsidiaries operate or are located.

(j) Notwithstanding any other provision of these Amended Articles of Incorporation or of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class of Voting Stock required by law or these Amended Articles of Incorporation, the affirmative vote of the holders of at least 80% of the votes entitled to be cast by holders of all the outstanding shares of Voting Stock, voting together as a single class, shall be required to alter, amend, or repeal this Article 13.